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ABSTRACT 
 
Tissue engineering offers a significant potential alternative to conventional methods for 
rectifying tissue defects by evoking natural regeneration process via interactions between cells 
and 3D porous scaffolds. Imparting adequate mechanical properties to biodegradable scaffolds 
for bone tissue engineering is an important challenge and extends from molecular to macroscale. 
This work focuses on the use of sodium montmorillonite (Na-MMT) to design polymer 
composite scaffolds having enhanced mechanical properties along with multiple interdependent 
properties.  
Materials design beginning at the molecular level was used in which Na-MMT clay was 
modified with three different unnatural amino acids and further characterized using Fourier 
Transform Infrared (FTIR) spectroscopy, X-ray diffraction (XRD). Based on improved 
bicompatibility with human osteoblasts (bone cells) and intermediate increase in d-spacing of 
MMT clay (shown by XRD), 5-aminovaleric acid modified clay was further used to prepare 
biopolymer (chitosan-polygalacturonic acid complex) scaffolds. Osteoblast proliferation in 
biopolymer scaffolds containing 5-aminovaleric acid modified clay was similar to biopolymer 
scaffolds containing hydroxyapatite (HAP).  
A novel process based on biomineralization in bone was designed to prepare 5-
aminovaleric acid modified clay capable of imparting multiple properties to the scaffolds. Bone-
like apatite was mineralized in modified clay and a novel nanoclay-HAP hybrid (in situ 
HAPclay) was obtained. FTIR spectroscopy indicated a molecular level organic-inorganic 
association between the intercalated 5-aminovaleric acid and mineralized HAP. Osteoblasts 
formed clusters on biopolymer composite films prepared with different weight percent 
compositions of in situ HAPclay. Human MSCs formed mineralized nodules on composite films 
iv 
 
and mineralized extracellular matrix (ECM) in composite scaffolds without the use of osteogenic 
supplements.  
Polycaprolactone (PCL), a synthetic polymer, was used for preparing composites (films 
and scaffolds) containing in situ HAPclay. Composite films showed significantly improved 
nanomechanical properties. Human MSCs formed mineralized ECM on films in absence of 
osteogenic supplements and were able to infiltrate the scaffolds. Atomic force microscopy 
imaging of mineralized ECM formed on composite films showed similarities in dimensions, 
arrangement of collagen and apatite with their natural bone counterparts.  
This work indicates the potential of in situ HAPclay to impart polymeric scaffolds with 
osteoinductive, osteoconductive abilities and improve their mechanical properties besides 
emphasizing nanoclays as cell-instructive materials.  
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CHAPTER 1. INTRODUCTION1 
 
This chapter presents an introduction to tissue engineering and discusses significant 
factors responsible for the use of 3D scaffolds in tissue engineering studies. It also describes 
different materials and methods used for fabricating tissue engineering scaffolds. Further, this 
chapter presents a discussion about cells used for bone tissue engineering and gives a review of 
mesenchymal stem cells (MSCs). Also, it discusses the potential of polymer clay 
nanocomposites (PCNs) in bone tissue engineering and choice of materials used for this doctoral 
research. The contents of this chapter (sections 1.3. & 1.4. including figures) have been 
published in book chapter by Kalpana S. Katti, Dinesh R. Katti, Avinash H. Ambre, 
Nanocomposites for Bone Tissue Engineering, Nanomaterials for Life Sciences Vol.8: 
Nanocomposites, Edited by Challa S.S.R. Kumar, Wiley-VCH Verlag GmbH & Co., 2010. 
Contents of sections 1.5.1., 1.5.2. and 1.5.3. have been published in book chapter by Kalpana S. 
Katti, Avinash H. Ambre, Dinesh R. Katti, Mesenchymal Stem Cells in Tissue Regeneration, 
Integrated Biomaterials in Tissue Engineering, Edited by M. Ramalingam, Z. Haidar, S. 
Ramakrishna, H. Kobayashi, Y. Haikel, Wiley, Scrivener, 2012.  These contents have been 
modified to accommodate additional information wherever required for presentation in this 
dissertation.      
1.1. Tissue Engineering 
Tissue engineering, a continuously evolving interdisciplinary field, gained momentum in 
the early 1990s when Langer and Vacanti [1] perspicuously described it as an alternative 
approach having advantages over conventional methods to treat tissue defects and involving 
                                                          
1 The contents of this chapter [sections 1.3., 1. 4., 1.5.1, 1.5.2., 1.5.3.] were co-authored by 
Avinash Ambre and Drs. Kalpana Katti and Dinesh Katti. Avinash Ambre conducted literature 
search, review for these sections and also wrote, revised these sections. Drs. Kalpana Katti and 
Dinesh Katti assisted in discussion, compilation and proofreading of these sections.    
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combined use of cells, scaffolds and growth factors for tissue regeneration. There have been 
reports related to experiments based on concepts similar to tissue engineering from the early 
1930s. In one of these early experiments murine tumor cells enclosed in a polymer membrane 
showed survival after being implanted in the abdominal cavity of chick embryos [2]. Another 
study involved culture of murine pancreatic beta cells on synthetic polymer (silicone 
polycarbonate) capillaries to study their sensitivity to glucose and insulin release behavior [3]. 
Following these studies “artificial skin” made of collagen and chondroitin 6 sulfate serving as 
host for migrated fibroblast cells was used to treat skin burn injuries [4]. Extensive research 
focused on the regeneration of different types of tissues started after Langer and Vacanti [1] 
described the potential benefits of tissue engineering for tissue regeneration.  Tissue engineering 
research has shown rapid progress, expansion due to the realization of its potential over the years 
for other therapeutic applications and as a platform for studying different diseases.  
Conventional treatment methods to repair tissue defects such as autografts, allografts, 
xenografts and metallic implants are considered to have limitations. Autograft transplant 
procedures involving procurement of tissue from a patient’s own own body have limitations 
related to availability of such tissue grafts and injury to the site from where the tissue was 
obtained. It becomes extremely difficult to use autografts in cases where larger volumes of tissue 
are required for rectifying the defect. Allograft transplant procedures that involve obtaining 
tissue from other healthy donor for a patient have risks associated with immune rejection, 
pathogen transfer and immune rejection. Xenograft transplantations involving use of tissue from 
an animal donor are limited by immune rejection and pathogen transfer. Metallic implants have 
been associated with problems such as stress shielding that weakens the surrounding bone, 
corrosion and their limited functional life (10-15 years). Ceramic implants being brittle may fail 
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suddenly and polymeric implants may weaken over time due to degradation. Tissue engineering 
has significant potential to overcome these limitations since it makes use of cell-scaffold 
interactions to stimulate new tissue formation via natural regeneration process. Besides this, 
there is a good possibility that the new tissue generated using tissue engineering approach has 
structural and functional characteristics similar to a natural, healthy tissue.  
Scaffolds, cells and growth factors are the key components of tissue engineering (Figure 
1.1). Each of these components has been the genesis of several interesting research problems 
encompassing different science and engineering disciplines. Scaffolds and cells have been the 
major focus of numerous studies over the course of evolution of tissue engineering since the 
early 1990s and these studies have laid the foundation for expansion of tissue engineering 
concepts beyond tissue regeneration. The studies presented in this dissertation deal with the 
design of polymer composite scaffolds for bone tissue engineering. Experimental investigations 
related to interactions of human osteoblasts (bone cells), human mesenchymal stem cells 
(hMSCs) with these scaffolds or scaffold materials also forms a part of these studies.    
 
Figure 1.1. Schematic depicting the concept of tissue (e.g. bone) engineering  
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Tissues are composed of cells and extracellular matrix (ECM). Proteins and 
polysaccharides constituting the ECM show remarkable diversity and are arranged as a non-
woven mesh in close association with the cells that produce them. Differences in the relative 
amounts of these ECM macromolecules and also in their arrangement give rise to diverse 
structural forms. Each of these structural forms suit the tissue-specific functional requirements. 
ECM is considered to be a dynamic, hierarchically organized (molecular scale to macroscale) 
nanocomposite that provides mechanical support to the cells [5]. It also presents a highly 
interactive environment to the cells in addition to performing an important role in cellular 
functions such as adhesion, migration, proliferation, differentiation and morphogenesis. Protein 
fibers (including both structural and functional) present in the ECM have nanoscale dimensions 
(10 to several hundred nanometers). An environment consisting of components having nanoscale 
dimensions is thus thought to be highly conducive to influence cell behavior. Protrusive cellular 
structures (filopodia and lamellipodia) having nanoscale dimensions are considered to 
complement such environmental components with nanoscale dimensions [6]. This leads to 
increase in sensitivity of cells to nanodimensional components or nanoscale features in their 
surrounding environment. Cells are also responsive to the mechanical and chemical cues from 
their surrounding environment. Therefore one of the major focus areas in tissue engineering is 
the development of three dimensional porous scaffolds that have structural and functional traits 
similar to those of the ECM present in a certain tissue.  
Bone is considered a complex nanocomposite having a hierarchical structure extending 
from nanoscale to macroscale [7]. Besides performing important functions such as protection of 
vital internal organs, storage of calcium and phosphate based minerals and facilitating 
movement, bone also provides structural support. The mechanical properties of bone have been 
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attributed to its hierarchical structure. A major challenge in bone tissue engineering is designing 
scaffolds with mechanical properties adequate to support biomechanical loads at defect site for 
restoring mechanical function while the new tissue forms, matures in the scaffolds. Scaffolds 
need to provide appropriate microenvironment to the cells for tissue formation and also need to 
satisfy requirements related to porosity, pore size, biodegradability that further enhances the 
difficulty of designing scaffolds for bone tissue engineering. Among the multiple cues from their 
surrounding microenvironment cells are known to respond to mechanical cues by converting 
them in to biochemical signals [8].The mechanical properties required at macroscale to support 
the biomechanical loads can be different from those required at the sub-micron/molecular scale 
to influence cell behavior. Mechanical properties of bone tissue engineering scaffolds should be 
thus enough to provide appropriate mechanical cues to the cells for bone tissue formation and 
supporting biomechanical loads at the defect site in vivo or the regenerating bone (in case of in 
vitro bone regeneration). Thus the challenge related to mechanical properties of scaffolds seems 
to extend from molecular to macroscale.  
The following sections in this chapter give a brief overview of the significant reasons for 
using 3D scaffolds also presents reasons for using 2D substrates (films) for tissue engineering. A 
description of different materials and methods used for fabricating tissue engineering scaffolds is 
also presented in these sections.  Polymer clay nanocomposites (PCNs) and their potential for 
bone tissue engineering applications along with major reasons for the choice/selection of 
materials used for this doctoral research are also presented in the following sections. Further, this 
chapter discusses cells used for bone tissue engineering and presents a review of mesenchymal 
stem cells (MSCs). 
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1.2. Scaffolds: Significance in Tissue Engineering 
Scaffolds for tissue engineering are expected to provide a microenvironment to the cells 
similar to the one cells experience in the extracellular matrix (ECM) under in vivo conditions. 
Designing scaffolds with a microenvironment similar to the ECM existing in a natural, healthy 
tissue in vivo can assist in providing cells with appropriate cues useful for regenerating (or 
engineering) the desired tissue. Compared to two-dimensional (2D) substrates, scaffolds used for 
tissue engineering studies are considered to provide a more physiological environment to the 
cells. Recently, fundamental characteristics of three-dimensional (3D) scaffolds apart from their 
dimensionality factor that make these scaffolds capable of presenting a more physiological 
environment have been identified and discussed extensively [9]. Cells exhibit relatively different 
morphology, organization (polarity) when cultured in 3D environment that can directly affect 
cellular functions. Effect of cell spreading, cell geometry on cellular functions has been well-
studied in case of 2D substrates but have been proposed to have dissimilarities with those 
observed under 3D environment. These dissimilarities arise due to the steric constraints in 3D 
environment that cells need to overcome for spreading/extension, migration unlike on 2D 
substrates which are relatively unrestricted. Moreover, local mechanical properties and 
topography are likely to influence the adhesion between the cells and the surrounding matrix 
under 3D environment. This may further be responsible for the variations in cell-matrix 
adhesions under 3D environment.  The ways in which the force in transmitted to the cells in 3D 
environment can differ compared to 2D substrates since cells in 3D environment experience 
physical constraints during deformation and have different morphology and organization. Cells 
cultured in a 3D environment are also more likely to experience diffusion dependent gradients of 
soluble factors in media and oxygen. 3D environment of scaffolds can also provide opportunities 
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for storage of soluble factors and synchronizing the timing of their release with their spatial 
presentation to the cells [9]. Although studies performed using 3D scaffolds are more significant 
in tissue engineering, use of 2D substrates have constituted an important part of several tissue 
engineering studies. Limitations and difficulties related to currently available experimental 
techniques (e.g. imaging of non-planar samples) to study specific cell-matrix interactions (e.g., 
cell adhesions, migration) in 3D environment have contributed to the use of 2D substrates. 
Besides this, fabrication methods having a control over surface morphology (at subcellular scale 
to nanoscale) of 3D scaffolds are still in the developmental stage [9] and this has contributed to 
the limited use of 3D scaffolds for studies related to understanding of specific factors affecting 
cell behavior. In tissue engineering studies involving materials design, 2D substrates are used to 
understand the effect of the designed material on cell behavior (e.g., biocompatibility, tissue 
formation ability) rather than the complex effects of 3D environment. Besides this, materials 
characterization in case of 2D substrates also involves relatively lesser experimental difficulties.   
Design of tissue engineering scaffolds having the required properties is dependent on 
factors such as materials used for scaffold preparation and the processing routes used for scaffold 
fabrication. The following sections will thus elaborate on materials and processing routes used 
for fabricating scaffolds. 
1.3. Materials for Scaffold Fabrication 
Various organic and inorganic materials are used in the design of bone tissue engineering 
scaffolds. The organic materials that can be used for developing composite scaffolds are natural 
or synthetic polymers whereas commonly used inorganic materials are nanohydroxyapatite, 
silicates and carbon nanotubes. The success of these materials is dependent on whether they are 
able to mimic the nuances of the natural extracellular matrix. 
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1.3.1. Hydroxyapatites 
Hydroxyapatite (HAP) is the major component of inorganic phase of bone and its natural 
or synthetic forms are known to be bioactive, osteoconductive, non-toxic, non-immunogenic 
with a crystal structure that is similar to the HAP present in bone tissue. It has been found that 
HAP at the nanoscale (nano-HAP) is functionally more effective as compared to HAP at the 
microscale that can be due to its improved surface properties such as higher surface roughness, 
lower contact angles and reduced pore size. These characteristics of nano-HAP are known to 
improve cell adhesion, differentiation and growth by increased adsorption of specific proteins [7, 
10]. Nano-HAP is more active in influencing the unfolding of adhesive proteins to a greater 
extent and increase the number of available arginine-glycine-aspartic (RGD) acid sequences 
present in adhesive proteins for the cell surface receptors [10]. Many methods that have been 
used for synthesizing nano-HAP are solid-state, wet-chemical, hydrothermal, mechanochemical, 
pH shockwave and microwave techniques. Nano-HAP has been used in various studies for 
preparing nanocomposites for bone tissue engineering. In some of the recent studies, nano-HAP 
has been incorporated in polymers such as chitosan [11-13], poly-2-hydroxyethylmethacrylate-
polycaprolactone (PHEMA/PCL) [14], poly (lactic acid) [15],  poly(3-hydroxybutyrate-co-3-
hydroxyvalerate) [16], polycaprolactone [17], and poly(propylene fumarate) [18]. All these 
studies demonstrate the utility of nano-HAP for developing nanocomposites for bone tissue 
engineering.  
1.3.2. Silicates 
Very few studies involving cell-material interactions [12, 19-23] have been conducted 
regarding the use of silicates, such as montmorillonite (MMT) clays, for the purpose of bone 
tissue engineering. MMT clays have been used for the purpose of preparing nanocomposites with 
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improved mechanical properties, decreased gas permeability and flammability and improved 
biodegradability [24]. The development of scaffolds with adequate mechanical properties that 
can withstand the rigors of the in-vivo environment after implantation, without adversely 
affecting the functions of the surrounding tissue, represents one of the major challenges of bone 
tissue engineering. The potential of MMT clays to improve the mechanical properties of the 
composites can be exploited in the case of scaffolds used for bone tissue engineering. Studies 
have suggested that MMT clays possess medicinal properties [25-28] and over the past few years 
have shown the potential of MMT clays to improve the mechanical properties of composites 
used in bone tissue engineering applications [12, 29-31].  
1.3.3. Carbon Nanotubes 
Carbon nanotubes (CNTs), which are members of the fullerene family of carbon 
allotropes, have mechanical properties in the gigapascal range, possess high surface area and are 
also known to be internalized by the cells. Functionalized carbon nanotubes have been used for 
studies related to cancer treatment [32], scaffolds for neurite growth [33], antiseptic bandages 
[34] and as biosensors for insulin detection [35]. The exceptional mechanical properties and 
surface area of CNTs can prove to be useful for bone tissue engineering applications and several 
studies have been conducted in this respect. For example, Shi et al. [36] prepared nanocomposite 
scaffolds using functionalized and non-functionalized ultra-short single walled carbon nanotubes 
(SWCNTs) and poly(propylene fumarate) (PPF). The functionalized ultra-short carbon 
nanotubes were found to be more effective in increasing the compressive properties of the 
scaffolds, on which rat bone mesenchymal stem cells (MSCs) were able to attach and proliferate. 
In another study, injectable nanocomposites of poly(propylene fumarate)  and single walled 
carbon nanotubes were fabricated that not only had improved compressive and flexural 
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properties but also showed that the dispersion of CNTs was affected by their concentration in the 
nanocomposites [37]. Similar type of nanocomposites were prepared by Sitharam et al. [38], 
using PPF, SWCNTs and ultra-short SWCNTs. Notably, the rheological properties of the 
nanocomposites that affect their injectability was dependent on the size of the CNTs whereas the 
mechanical properties were dependent on the surface area of the CNTs. In another study, 
Sitharam et al. [39] assessed the in vivo biocompatibility of scaffolds made up of ultra-short 
CNTs and PPF/propylene fumarate diacrylate. It was found that bone growth was relatively 
faster on PPF/propylene fumarate diacrylate/CNT scaffolds than on scaffolds not containing 
carbon nanotubes. This suggested that composite scaffolds containing CNTs were 
osteoconductive and promoted osteogenesis. There have also been several other studies 
involving the use of CNTs based on composite systems such as chitosan/multi-walled CNTs [40] 
HAP/CNTs [41, 42], poly(carbonate)urethane/multi-walled CNTs [43] and poly(L-
lactide)/magnetic multiwalled CNTs [44] and these studies have emphasized CNTs as useful 
bone tissue engineering materials.  
1.3.4. Bioactive Glass 
Bioactive glass, as an inorganic material can be used in the preparation of 
nanocomposites for bone tissue engineering applications. These glasses are characterized by 
rapid formation of hydroxycarbonate apatite layer on their surface that promotes their adhesion 
to the bone apatite. Apatite layer formation on bioactive glasses is observed when they are in 
contact with fluids identical or similar to human plasma [45]. In addition, they have a faster 
bonding rate with bone and stimulate osteogenic cells upon dissolution due to release of Si, Ca, P 
and Na ions. Notably, bioactive glasses prepared using the sol-gel method are nanostructured as 
opposed to those prepared by melt method [46, 47]. Bioactive glasses prepared by using sol-gel 
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method are more bioactive as compared to -those prepared by melt-method [48-50]. There was 
an emergence of interest a few years ago in using bioactive glass nanoparticles for preparing 
composites useful for bone tissue engineering. For example, Hong et al. [51] showed how 
bioactive glass ceramic nanoparticles can be prepared by combining sol-gel and coprecipitation 
method. The bioactivity of these nanoparticles was confirmed by formation of hydroxyapatite on 
these particles through FTIR and XRD experiments. In another study, Hong et al. [52] prepared 
nanocomposites scaffolds by incorporating bioactive glass nanoparticles in poly(L-lactic acid) 
that exhibited an increase in compressive strength, compressive modulus with an increase in the 
bioactive glass nanoparticle content. These scaffolds were bioactive and in vitro degradation rate 
of the scaffolds in PBS was more as compared to scaffolds without the bioactive glass 
nanoparticles due to the hydrophilic nature of bioactive glass. Liu et al. [53] modified the 
bioactive glass nanoparticles with low molecular weight poly(L-lactide) and further used these 
modified nanoparticles for preparing poly(L-lactide) composite scaffolds that showed an 
improvement in tensile strength up to 6 wt % loading. Biocompatibility studies using marrow 
stromal cells from rabbit on these scaffolds showed that the composites with unmodified 
bioactive glass nanoparticles had better initial cell adhesion and proliferation as compared to 
scaffolds with the modified particles but the trends were reversed after 7 days. Couto et al. [54] 
developed hydrogel composites using chitosan and bioactive glass nanoparticles with an aim to 
prepare injectable nanocomposites useful for tissue engineering. Rheological and in-vitro studies 
to determine the bioactivity of these hydrogel composites showed that they could prove useful 
for bone tissue regeneration. Mansur et al. [55] prepared nanocomposite scaffolds based on poly 
(vinyl alcohol) and bioactive glass that had interconnected macroporous structure with pores in 
the 10-500 m range along and a mesoporous structure in the nanometer range. The compressive 
12 
 
properties of these scaffolds were found to be affected by the poly (vinyl alcohol) content and its 
degree of hydrolysis. 
1.3.5. Polymers 
Bone is considered to be a nanocomposite with the inorganic phase as its major 
component and hence it may be argued that in order to develop nanocomposites with appropriate 
mechanical properties mimicking those of bone, the inorganic phase would be relatively 
significant while designing nanocomposites in bone tissue engineering. But it is important to 
consider that the mechanical properties of bone are due to its hierarchical structure. It is very 
difficult to mimic this structural hierarchy during the preparation of nanocomposites in bone 
tissue engineering. Therefore proper selection of the organic phase becomes equally important 
for preparing nanocomposites in bone tissue engineering. Besides being able to mimic the 
features of the extracellular matrix (ECM), the organic phase is expected to have appropriate 
biodegradation rate that leads to successful tissue regeneration. In addition, the organic phase 
may have biodegradation products that cause changes in local pH but should be excreted from 
the body without affecting the pH dependent enzymatic reactions simultaneously taking place 
within the cells and their environment. It should also possess adequate mechanical properties to 
support the growing tissue in the dynamic in vivo environment without triggering an immune 
response. Natural and synthetic polymers can constitute the organic phase of composite scaffolds 
used for bone regeneration.  
Natural polymers are obtained from natural sources such as animals and plants. These 
type of polymers possess biomolecules or sequences of biomolecules that are favorable for cell 
attachment and differentiation [56]. These polymers can be degraded by enzymes or by 
hydrolysis, are similar to biological macromolecules and may not trigger an immune response 
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due to their similarity with the extracellular matrix [57]. But some of their key disadvantages are 
uncontrolled biodegradation rate, variation in mechanical properties from batch to batch, scale up 
difficulties [56], possibility of infections in case of polymers derived from animal source such as 
collagen. Moreover, it is difficult to predict or estimate the in vivo biodegradation rate in these 
polymers because of different extent of enzymatic activity in different individuals. In case of 
synthetic polymers, it is possible to control their biodegradation rate properties by introducing 
appropriate functional groups in the polymeric chain by grafting or by choosing appropriate 
monomers while preparing these polymers. The mechanical properties of synthetic polymers are 
dependent on their molecular weight and can be controlled by using the proper polymer synthesis 
method such as addition polymerization, condensation polymerization and ring opening 
polymerization. But these polymers pose problems such as chronic inflammation, lack of desired 
cell response since they do not have the natural biomolecule sequences that promote cell 
attachment and uncertainties involved in complete removal of solvents during the processing of 
some synthetic polymers that can have an effect on the cell response. The following sections will 
discuss the natural and synthetic polymers that are used for bone tissue engineering. 
1.3.5.1. Natural Polymers 
Collagen is present in most connective tissues (bone, cartilage, tendon, cornea, blood 
vessels and skin) and known to be deposited by fibroblasts or by connective tissue cells in the 
extracellular matrix. Collagen is an important component of extracellular matrix (ECM) and is 
responsible for maintaining its structural integrity besides performing biological functions. The 
collagen superfamily is known to consist of 28 members/types. Types I, II, III and V considered 
to be main types of collagen are present in bone, cartilage, skin and muscle respectively [58]. 
Collagen (type I) is known to be extensively used for tissue engineering applications and can be 
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extracted/isolated from animal or human tissues such as skin, tendons and ligaments. It exhibits 
good biocompatibility, low immune response, good mechanical strength and can be crosslinked, 
hence helping control its mechanical and degradation properties [57]. Kikuchi et al [59] used 
glutaraldehyde for preparing crosslinked collagen/hydroxyapatite nanocomposites and found that 
the mechanical strength of these composites improved with glutaraldehyde content. In vivo 
studies involving the implantation of these crosslinked nanocomposites in to rabbit tibia 
indicated that the osteoclastic resorption of these composites decreased with the increasing 
glutaraldehyde content without any adverse reactions. Kim et al. [60] developed microspheres of 
collagen-apatite nanocomposites and studied the in vitro response of rat bone marrow stem cells 
on these microspheres. The in vitro studies showed that the rat bone marrow stem cells were able 
to attach and grow on these nanocomposite microspheres, which indicated that they can be used 
for bone tissue regeneration. There have also been several other studies involving use of collagen 
that emphasize its importance in bone tissue engineering [61-65].  
Chitosan is another important biopolymer and is an incompletely deacetylated form of 
chitin that has been studied extensively for bone tissue engineering applications. It is known to 
be biocompatible, shows antimicrobial activity, is capable of activating macrophages and 
promotes the proliferation of fibroblasts [66]. There has been a sustained interest in chitosan 
based nanocomposites for bone tissue engineering. Thein-Han et al. prepared biomimetic 
chitosan-nanohydroxyapatite scaffolds that showed that the mechanical properties and the 
response of pre-osteoblasts improved and the degradation rate decreased by addition of nano-
hydroxyapatite [11]. Their studies also suggested that the mechanical properties of the scaffolds 
were affected by the molecular weight and degree of deacetylation of chitosan. Zhang et al. 
studied nanofibrous scaffolds made up of chitosan and hydroxyapatite with attributes similar to 
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the extracellular matrix and found that these scaffolds favored the formation of bone tissue [67]. 
Kong et al. used chitosan for preparing chitosan/nanohydroxyapatite scaffolds and found that the 
biocompatibility and bioactivity of chitosan was further enhanced by adding nano-
hydroxyapatite [68]. Li et al. prepared hybrid scaffolds of chtosan-alginate that had improved 
Young’s modulus, improved shape retention in solutions of wide pH range, better cell 
proliferation as compared to pure chitosan scaffolds [69]. In one of the recent studies, Cai et al. 
developed nanocomposites based on chitosan, polylactic acid and hydroxyapatite with highly 
improved elastic modulus and compressive strength that were dependent on polylactic acid 
content [70]. The polylactic acid used in these composites was responsible for the rod-like shape 
of hydroxyapatite in these nanocomposites. Although there have been many studies based on 
chitosan for bone tissue engineering applications, it still remains the major component of most 
present studies because of presence of amino groups and its tunable degree of deacetylation that 
can have an effect on its ability to form complexes with other polyelectrolyte molecules and its 
mechanical properties. The amino groups of chitosan are protonated in acidic media and can 
form complexes with other polymeric molecules having functional groups with a complementary 
charge on them. This has increased the chances of developing novel nanocomposite systems 
involving the use of chitosan. For example, Verma et al. developed nanosfibrous polyelectrolyte 
scaffolds based on chitosan, polygalacturonic acid and hydroxyapatite that had better osteoblast 
cell adhesion compared to the scaffolds without hydroxyapatite [71].  
Cellulose is a natural polymer that is found in plants such as cotton, wood, straw and 
produced by microbes such as acetobacter xylinum. It is convertible into different derivative 
forms such as carboxymethylcellulose, cellulose nitrate, cellulose acetate and cellulose xanthate 
and can be moulded or processed into fibers. It cannot be degraded enzymatically which is one 
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of its disadvantages but can be made degradable by altering its higher order structure [57]. 
Bacterial cellulose is superior to plant cellulose in aspects such as mechanical properties (tensile 
strength and modulus), surface area, water holding capacity and crystallinity [72]. Wan et al. 
studied the prospects of cellulose as a useful bone tissue engineering material by preparing 
nanocomposites based on hydroxyapatite and bacterial cellulose [72]. The prepared 
nanocomposites had 3-dimensional network structure with formation of carbonated 
hydroxyapatite after soaking in simulated body fluid. Li et al. oxidized bacterial cellulose with 
sodium periodate to obtain 2,3-dilaldehyde bacterial cellulose which is a biodegradable and 
biocompatible form of bacterial cellulose [73]. Although these studies did not involve the 
preparation of composites, it was interesting to note that the 2, 3-dilaldehyde bacterial cellulose 
scaffolds were able to degrade both in SBF and PBS and were able to form a microporous 
structure that was in a range useful for cell growth. Jiang et al. found that the microstructure, 
mechanical properties, degradation and bioactivity of nano- hydroxyapatite 
/chitosan/carboxymethyl cellulose scaffolds was suitable for bone tissue engineering applications 
[74]. Studies by Muller et al. [75] and Svensson et al. [76] have also shown that cellulose can be 
a useful material for tissue engineering applications. 
Starch is a natural polymer found in plants such as corn, rice, potato, wheat and capable 
of being crosslinked, acetylated, converted into thermoplastic and blended with synthetic 
polymers to improve its mechanical properties [57]. Salgado et al. developed scaffolds based on 
starch/cellulose acetate blends and found that these scaffolds showed compressive properties that 
were adequate for bone tissue engineering [77]. Moreover, these scaffolds favored cell 
proliferation, formation of extracellular matrix and mineralization that suggested the utility of 
starch based materials in bone tissue engineering. Marques et al. studied composites of 
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hydroxyapatite and corn starch blended with polymers such as ethylene vinyl alcohol, cellulose 
acetate and polycaprolactone [78]. Their studies demonstrated the suitability of starch for bone 
tissue engineering and also explained that the importance of surface roughness, miscibility of the 
blend systems used and hydroxyapatite on osteoblast cell behavior. There have been few other 
studies [79-81] that imply that starch can be a useful bone tissue engineering material. 
Hyaluronic acid is a natural polymer that consists of disaccharide units of α-1,4-D-glucoronic 
acid and β-1,3-N-acetyl-D-glucosamine that is found in connective tissues such as umbilical 
cord, synovial fluid and vitreous [82] It is also known to be present in the extracellular matrix 
and participates in maintaining the structure of the extracellular matrix, morphogenesis, wound 
repair and metastasis [83]. Hyaluronic acid has been used in studies related to bone tissue 
engineering. Lisignoli et al. used esterified hyaluronic acid based scaffolds having non-woven, 
micron-sized fibrous structures to study the differentiation and mineralization of rat bone marrow 
stromal cells in the presence and absence of basic fibroblast growth factor (bFGF) [84]. It was 
found that bFGF enhanced the mineralization rate and expression of differentiation markers such 
as osteocalcin and osteopontin. Their studies concluded that the hyaluronic acid based scaffolds 
were capable of supporting bone growth before implanatation. As an extension of these in vitro 
studies, Lisignoli et al. further implanted the hyaluronic acid based scaffolds cultured with rat 
bone marrow stromal cells in rats with defects in their forearm bones and found that these 
scaffolds showed bone growth trends that were similar to those found in their in vitro studies 
[85]. Ji et al. prepared hyaluronic acid based scaffolds by electrospinning and found them 
suitable for cell attachment and spreading [82]. Kim et al. used hyaluronic acid based scaffolds 
seeded with human mesenchymal stem cells for curing bone defects in rats that supported 
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formation of new bone tissue that was more enhanced in the presence of bone morphogenic 
protein (BMP-2) [83]. 
Silk fibroin polymers obtained from animal sources such as spiders (e.g. Nephila 
clavipes) and worms (e.g. Bombyx mori) that consist of secondary β-sheet structures formed due 
to the specific arrangement of hydrophobic and hydrophilic domains composed of specific amino 
acid sequences have also been investigated for nanocomposites design. The hydrophobic 
domains form the β-sheet structure (ordered) and their combination with the less ordered 
hydrophilic structures is responsible for the mechanical properties of silk. Silk fibroin obtained 
from B. Mori consists of light and heavy protein chains that are linked by disulfide bonds and 
coated with sericins. It is biocompatible, enzymatically degradable, has good mechanical 
properties with an advantage that its properties can be altered according to the requirements by 
using different processing routes. 
1.3.5.2. Synthetic Polymers 
Aliphatic polyesters such as poly (glycolic acid) (PGA), poly (lactic acid) (PLA), poly 
(lactic-co-glycolic acid) (PLGA) and polycaprolactone (PCL) are a class of synthetic polymers 
that can be used for bone tissue engineering applications. The differences in the properties of the 
polymers that fall under this category depend upon their monomer units.  
PGA is characterized by moderate crystallinity, high melting point, low solubility in 
organic solvents and ability to undergo hydrolytic degradation. It has been suggested that PGA 
can be used in situations in which an initially faster degradation rate is needed, although the 
possibility of local pH variations due to its degradation products necessitates the consideration of 
its use in regions that have a buffering capacity or a mechanism for rapid removal of the 
degradation wastes.  
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PLA can be prepared either as D or L isomeric forms, denoted as PLLA or PDLA 
respectively. Since the degradation product of PLLA (i.e. is L-lactic acid) is found in the human 
metabolic, its use may be preferable. The higher solubility of PLA as compared to PGA in 
organic solvents can prove to be advantageous for electrospinning. The properties of PLGA can 
be controlled by adjusting the lactic acid/glycolic acid ratio.  
PCL is semicrystalline, has good solubility in organic solvents and low melting point 
with a degradation rate lower than PGA and PLGA. Aliphatic polyesters have been used in 
numerous studies related to bone tissue engineering. Lee et al. [86]  prepared PLLA/MMT 
scaffolds with improved mechanical properties and porosity that was suitable for bone tissue 
engineering. Liu et al. [87] showed that the extent of decrease in pH due to degradation of PLGA 
can be decreased by incorporating titania nanaoparticles in PLGA. The titania nanoparticles 
acted as a buffer to control the reduction in pH that further enhanced the significance of these 
nanocomposites [88] in relation to the behavior of osteoblasts on PLGA/titania nanocomposites. 
Nejati et al. [89] prepared PLLA/HAP nanocomposites with microstructure and compressive 
strength that was close to that of cancellous bone. Serrano et al. [90] studied the biocompatibility 
of PCL using murine fibroblasts. Their studies showed that PCL served as a good substrate for 
fibroblast adhesion and also increased the mitochondrial activity of the fibroblasts. Shor et al. 
[91] developed PCL/HAP scaffolds with a controlled microstructure (by using an extrusion 
technique) that showed an ability for mineralization upon seeding with fetal bovine osteoblasts. 
Erisken et al. [92] prepared graded nanocomposites scaffolds using PCL and β-tricalcium 
phosphate with spatial variation in structure and composition and ability to form extracellular 
mineralized extracellular matrix (ECM). There have also been several other studies [15, 93-98] 
illustrating aliphatic polyesters as a useful bone tissue engineering material.  
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Polyphosphazene is a synthetic polymer with a backbone of alternating phosphorous and 
nitrogen atoms with each phosphorous atom linked to two organic side groups. The degradation 
of polyphosphazene can be modulated by making changes in the side groups. This gives 
polyphosphazene an advantage over aliphatic polyesters that require changes in their backbone 
structure for controlling their degradation rate [99, 100]. The incorporation of side groups such 
as imidazolyl, amino acid esters, glycolate esters and lactate esters causes polyphosphazene to 
become sensitive to hydrolysis and release non-toxic products. Bhattacharya et al. [101] prepared 
polyphosphazene-nanohydroxyapatite composite nanofibers as a potential material system for 
bone tissue engineering application. Nukavarapu et al. [102] synthesized prepared three different 
types of polyphosphazene with different side groups and further used phenylalanine ethyl ester 
substituted polyphosphazene having glass transition temperature higher than 37ºC (physiological 
temperature) for developing scaffolds with nanohydroxyapatite. These scaffolds showed 
compressive strength close to human cancellous bone and also proved favorable for osteoblast 
cell adhesion and proliferation.  
Poly (propylenefumarate) (PPF) is an unsaturated linear polyester capable of being 
crosslinked by using crosslinking agents such as methyl methacrylate, N-vinyl pyrrolidinone and 
PPF-diacrylate and poly (ethylene glycol)-diacrylate [18, 103]. Degradation products of poly 
(propylenefumarate) are non-toxic that makes it useful from tissue engineering perspective. 
Horch et al. [104] used alumoxane nanoparticles for making PPF composites with improved 
flexural properties for bone tissue engineering applications. Lee et al. [18] found that PPF/HAP 
nanocomposite system was suitable for attachment and proliferation of  murine pre-osteoblast 
cells and could serve as suitable system for bone tissue engineering. Several other studies [105-
108] have also reported the suitability of PPF for bone tissue engineering applications. One of 
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these studies demonstrated an interesting possibility of developing injectable nanocomposites 
made up of PPF and single-walled carbon nanotubes (SWCNTs) [106]. It was found that 
functionalization of the carbon nanotubes (CNTs) played an important role in the rheological 
behavior and degree of crosslinking in these nanocomposites that are important in case of 
developing injectable nanocomposites. Studies related to injectable nanocomposites are 
important for tissue engineering because these composites provide us with an option of 
minimizing complex surgical procedures, developing scaffolds for curing defects having unusual 
shapes and delivering cells, bioactive molecules to the defect sites along with the nanocomposite 
solution.  
A wide variety of synthetic polymers can be developed and used for designing 
nanocomposites useful for tissue engineering applications. The improvement in the 
understanding of the polymerization mechanisms over the years has increased the possibilities of 
developing synthetic polymer systems according to the requirements of bone tissue engineering. 
Other than some of the synthetic polymers discussed in the preceding paragraphs, the synthetic 
polymer systems that have been developed and studied for bone tissue engineering are poly(ester 
urethane) [109], poly(urethane) [110-112] and poly(vinyl alcohol) [113, 114].  
1.4. Methods of Scaffold Fabrication 
The fact that nanoscale features have an important effect on cell behavior emphasizes the 
importance of nanocomposites in bone tissue engineering. In order to obtain appropriate 
nanoscale features or nanostructure in the final nanocomposite, it is necessary to use appropriate 
processing methods. There are some challenges associated with the preparation of these 
nanocomposites. One of them is the need to conserve the intrinsic properties of the materials 
used for preparation of the nanocomposites. The processing method used might affect the 
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conformation of the polymer chains in case of polymers or the distribution of the nanosized 
inorganic materials in the form of particles while preparing the nanocomposites. The changes in 
conformation of polymer chains in case of natural polymers may affect the available biomolecule 
sequences and cell behavior. In addition to this, the properties of polymeric materials such as 
melting point, glass transition temperature, viscosity and their resistance to solvents used during 
processing may also limit the number of routes by which they can be processed. For bone 
regeneration it is necessary to develop nanocomposites with structural features that mimic or at 
least resemble the structural features of the extracellular matrix (ECM). In this context, at present 
there are a number of processing routes used for developing nanocomposites for bone tissue 
engineering and these are discussed in the following sections.  
1.4.1. Electrospinning 
Electrospinning is a simple technique that can be used to produce fibers having diameter 
in the nanometer range. This makes it useful for mimicking the structure of the extracellular 
matrix proteins. Besides this, the fibers produced by electrospinning have high surface area to 
mass ratio (40 to 100 m2/g), superior stiffness and tensile strength [115, 116]. Also, the 
possibilities of spinning fibers at room temperature from a variety of polymers, producing 
aligned nanofibers, and spinning fibers simultaneously from separate solutions to generate 
layered scaffold structures emphasize its attractiveness in bone tissue engineering [115, 117]. 
Electrospinning apparatus consists of a high voltage supply, a capillary tube containing a 
polymer solution connected to a needle or a pipette and a grounded metallic collector. A 
schematic of this process is shown in Figure 1.2. The needle and the metallic collector act as two 
electrodes between which a high voltage (several tens of KV) is applied. Application of a high 
voltage supply generates an electric field between the two electrodes that produces electrostatic 
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forces (generated by electrostatic repulsion between the surface charges on the droplet and 
Columbic force exerted by the external electric field) in the spherical droplet liquid (polymer 
solution) at the needle tip and opposes the surface tension forces in the liquid droplet. This 
results in the deformation of the spherical droplet to a conical shape known as “Taylor cone.” 
When the electric field surpasses a critical value the electrostatic force overcomes the surface 
tension forces that results in the ejection of an electrically charged jet from the tip of the Taylor 
cone. The electrically charged jet interacts with the externally applied electric field that makes it 
unstable, causes it to bend as it moves towards the grounded collector and thus produce long 
ultrafine fibers (produced by the splitting of the jet due to repulsive forces) in the form of a non-
woven structure [118]. The evaporation of the solvent from the charged jet takes place as it 
moves towards the collector. Different types of collectors such as plate-type, cylinder-type, disc-
type and frame-type can be used to control the alignment of the electrospun fibers [119]. The 
electrospinning process and thus the dimensions of the electrospun fibers are affected by a 
number of factors such as viscosity, conductivity, surface tension, the magnitude of the applied 
voltage, the distance between the needle and the collector, solution flow rate and solution 
temperature. There are also some limitations associated with the electrospinning process such as 
use of organic solvents and difficulty in generation of controlled, three-dimensional pore 
structure. In case of natural polymers that are categorized as proteins, the electrospinning process 
may alter the structure of such polymers that can further affect the cell behavior on the scaffolds. 
Also, chemical crosslinking may be necessary for some electrospun polymers to prevent them 
from dissolving in aqueous media [5]. In relation to bone tissue engineering, electrospinning 
process has been used in a number of studies for developing polymer or polymer nanocomposite 
scaffolds. Some examples of polymer and polymer nanocomposite systems in the form of 
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Figure 1.2. Schematic of electrospinning process 
eletrospun scaffolds that have been investigated for bone tissue regeneration applications are 
polycaprolactone/nanohydroxyapatite/collagen [120], polyphosphazene/nanohydroxyapatite 
[101], carboxymethyl chitin/poly(vinyl alcohol) [121], poly(D,L-lactide-co-glycolide)/nano-
hydroxyapatite [122], silk fibroin/bone morphogenetic/nanohydroxyapatite [123], poly(lactide-
co-glycolide/amorphous tricalcium phosphate [124], and thiolated hyaluronic acid derivative 
[82].  
1.4.2. Phase Separation 
Phase separation is a thermodynamic process that is used for preparing interwoven, nano-
fibrous scaffolds in bone tissue engineering. The thermally induced phase separation method is 
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the common method for phase separation but it is also possible to use a non-solvent to the 
polymer for inducing phase separation. A schematic showing this process is shown in Figure 1.3. 
Thermally induced phase separation is of two types; viz., solid-liquid phase separation 
and liquid-liquid phase separation depending on the crystallization temperature (freezing point) 
of the solvent used. In case of solid-liquid phase separation, the crystallization temperature of the 
solvent used is higher than the liquid-liquid phase separation temperature that makes the solvent 
to crystallize and the polymer to separate when the temperature of the polymer solution is 
lowered. The crystallized solvent is further removed by freeze-drying (sublimation) that leaves 
behind pores having morphology similar to the solvent crystallites. Thus, it is possible to control 
the pore structure and the type of phase separation by using solvents having different 
crystallization (freezing) properties.  
For liquid-liquid phase separation to take place, the crystallization temperature of the solvent 
used is lower than the liquid-liquid phase separation temperature that makes the polymer to 
separate in to polymer-rich and polymer-lean phase. This type of phase separation is affected by 
the upper or a lower critical solution temperature of the polymers involved and is posited to take 
place either due to spinodal liquid-liquid phase separation or nucleation and growth mechanism. 
Phase separation by nucleation and growth mechanism is supposed to take place in the 
metastable region of the temperature-composition phase diagram where the solution is stable 
with respect to the small fluctuations in composition. The polymer concentration under the 
metastable region controls the structure of the polymer solid that is obtained after the removal of 
the solvent with low polymer concentration resulting in a powder like polymer solid and high 
concentration resulting in a closed pore structure of the polymer solid. The spinodal region is 
unstable and small variations in polymer concentration cause a decrease in free energy that 
26 
 
 
Figure 1.3. Schematic of phase separation process 
results in a wave of concentration fluctuations in the polymer solution. These further result in the 
formation of interconnected polymer-rich and polymer-lean (mostly solvent) phases to give a 
scaffold having a continuous pore network after the removal of the polymer-lean phase. It is also 
possible to induce phase separation at room temperature by adding a non-solvent to the polymer 
solution to obtain a gel from which the solvent is then extracted by using water. The gel is 
further cooled below the glass transition temperature of the polymer and freeze dried to get a 
nanofibrous scaffold.   
One of the advantages of the phase separation technique is that the morphology of the 
scaffold can be controlled by changing the parameters such as polymer type and concentration, 
polymer type, freezing temperature and using different types of porogens. Further, this technique 
can also be useful for preparing scaffolds of different shapes according to the requirement and 
maintaining batch-to-batch consistency. In spite of being a simple technique, phase separation 
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remains a laboratory scale technique limited to a few polymers. Phase separation technique has 
been used in preparing scaffolds based on polymer systems such as PEG/PLLA[125], 
polylactide-dextran blend [126], PLLA [127], PLGA [128], hydroxyapatite/poly 
(hydroxyabutyrate-co-hydroxyvalerate) [129], and hydroxyapatite/chitosan-gelatin [130].  
1.4.3. Freeze Drying 
Freeze drying technique is used for the removal of the solvent after phase separation of 
the polymer solution by lowering the temperature or by adding a non-solvent to the polymer. 
During freeze-drying, the temperature is maintained low enough so that remixing of the phase 
separated polymer solution is prevented. A schematic showing the freeze drying methodology is 
shown in Figure 1.4. It has been used in several studies related to bone tissue regeneration for 
developing scaffolds based on polymers such as PLLA  [131], chitosan [71, 132], gelatin [133], 
carboxymethyl cellulose [134], poly(ether ester) [135], silk fibroin/hyaluronan [136, 137]. There 
have also been studies involving the use of nanocomposite scaffolds prepared by using the phase 
separation technique for bone tissue engineering applications. Few examples of polymer 
nanocomposite scaffolds that have been fabricated by using the freeze drying technique are poly 
(L-lactic acid)/nanohydroxyapatite [138], collagen/hydroxyapatite [139], 
chitosan/hydroxyapatite [11, 140], gelatin/hydroxyapatite [141, 142], PDLLA/PLGA/bioglass 
[143]. Also, polyelectrolyte complex (PEC) fibrous scaffolds for tissue engineering have been 
synthesized and scaffolds are fabricated using the freeze drying methodology [71]. The design 
parameters that are typically optimized are temperature ranges, and time as well as the 
concentrations of the polymer solutions. 
 
 
28 
 
1.4.4. Particulate Leaching 
The particulate leaching technique is a relatively simple technique used to prepare porous 
scaffolds by using porogens that are soluble in water or non-toxic solvents. Porogens such as 
sugar, sodium chloride and saccharose are used to generate the pores. A polymer solution with 
the porogens dispersed in it is cast in to a mold followed by removal of the solvent by 
evaporation and subsequent leaching of the porogen to produce a porous scaffold. A schematic 
showing this process is shown in Figure 1.5. Effective control of pore size and porosity by 
varying the size and amount of porogens is the main advantage of this technique. Incomplete 
removal of solvents from the polymer solution by evaporation, lack of interconnectivity and open 
pore structure in scaffolds requiring low porosity due to decrease in the number of contact points 
between the porogens due to reduction in the number of porogens and suitability of this 
technique to mostly thin scaffolds are the limitations of this technique. This technique has been 
used in combination with other techniques but lack of complete interconnectivity is still its one 
of the major limitations. Liu et al. [144] prepared gelatin/apatite nanofibrous scaffolds by 
combining thermally induced phase separation and particulate (porogen) leaching technique. 
 
Figure 1.4. Schematic of freeze drying process 
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Figure 1.5. Schematic of particulate leaching process 
 
They employed preheating of the mold to develop interconnectivity in between the particulates 
and thus between the pores of the scaffold. The interconnected pores in the scaffold were helpful 
in distribution of the cells throughout the scaffold. Several studies related to bone tissue 
generation have been carried out using scaffolds prepared by using the particulate leaching 
technique and the recent trend has been to further improve this technique [126, 145-149].  
1.5. Cells for Bone Tissue Engineering 
Cells have a key role in tissue engineering, especially in case of critical size tissue defects 
where the size of the defect presents difficulties related to the number of cells required. In 
addition to this, the cells used for tissue engineering also need to satisfy other requirements. 
Cells must be capable of differentiating into desired phenotype [150] upon being stimulated by 
appropriate signals (chemical, mechanical and electrical). They must be capable of organization 
through structural support from the surrounding environment (e.g. scaffolds) and also producing 
a properly organized extracellular matrix (ECM) [150, 151]. Cells also need to produce the 
required cytokines (or cell signaling molecules) [151], show mechanical and structural 
confirmity with the surrounding native cells and integrate with the surrounding cells to minimize 
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the risks of immune rejection [150]. Cells for tissue engineering can be obtained from autologous 
(patient’s own) sources, allogenic (from human donor excluding the patient) and xenogenic 
(from animal donor) sources that have limitations. Autologous cells are considered the most 
appropriate for use due to low possibilities of immune rejection but have limitations in case of 
critical size tissue defects due to difficulties in obtaining sufficient cell numbers without 
affecting the donor site. Allogenic and xenogenic cells are associated with risks of immune 
rejection and pathogen transfer. Primary (mature) cells obtained from tissue explants have 
limited proliferation, tissue formation abilities and may show improper phenotype expression 
[151]. In case of bone tissue engineering, cell-related factors such as osteogenic and 
vasculogenic potential of cells, ability to control differentiation into osteogenic lineage, stable 
expression of osteogenic phenotype to avoid “non-specific” tissue formation [152] are 
considered important for bone formation. Extensive and emerging research over the past few 
years has shown that mesenchymal stem cells (MSCs), embryonic stem cells and induced 
pluripotent stem cells are promising alternatives to conventional cell types. This research work 
involves the use of osteoblasts (from bone tissue) and human mesenchymal stem cells (hMSCs). 
Since relevant characteristics of mature cells obtained from tissues having been already 
mentioned, the following sections will discuss mesenchymal stem cells (MSCs) in detail 
considering them as one of the major cell source for bone tissue engineering applications.  
1.5.1. Mesenchymal Stem Cells 
The term “mesenchymal” in mesenchymal stem cells is related to the embryological germ 
layer known as “mesoderm” or “mesenchyme.” This germ layer is supposed to be capable of 
differentiating into different types of tissues such as bone, cartilage, blood, cartilage, vascular, 
tendons and ligaments. However, the term “mesenchymal stem cells” is mostly used to describe 
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cells that are known to give rise to connective tissue cells except the blood. Hematopoietic stem 
cells are known to be responsible for giving rise to blood cells. A proper definition for the 
“mesenchymal stem cells” seems to be in an emerging state. Many studies describe 
mesenchymal stem cells as a concept that developed on the basis of work carried out by 
Friedenstein and his co-workers. They noticed adherent colony forming units (CFUs) of 
fibroblastic nature during the culture of bone marrow cells [153, 154] and through further studies 
demonstrated that these cells were capable of differentiating into osteogenic and chondrogenic 
lineage [154]. Similar observations were made in subsequent studies carried out by other groups 
[155, 156]. MSCs can be distinguished from hematopoietic stem cells by their ability to rapidly 
adhere to tissue culture plastic and the fibroblastic appearance of their progeny. The International 
Society for Cellular Therapy has set up criteria for the identification of MSCs and these are as 
follows [157]:  
a. MSCs must adhere to plastic during cell culture 
b. MSCs must express specific surface antigens. Greater than 95 percent of the MSC 
population should express surface antigens such as CD73, CD90 and CD105. Also, the 
percentage of cells expressing antigens such as CD34, CD45 should be less than 2 
percent. 
c. MSCs must show ability to differentiate into osteogenic, chondrogenic and adipogenic 
lineages. The ability to differentiate into different lineages can be demonstrated by 
accepted staining methods.  
Despite the criteria set up by the International Society for Cellular Therapy, studies 
suggest that these may be subjected to change due to the constantly evolving understanding of 
mesenchymal stem cells. MSCs are being scrutinized with respect to their self-renewal ability, 
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heterogeneity, in vitro and in vivo identity, differentiation potential and similarities or 
differences between the MSCs derived from different types of tissues. These points of scrutiny 
related to MSCs would be briefly discussed in the following sections.  
1.5.1.1. Self-renewal of MSCs 
Self-renewal is one of the important characteristics of MSCs and can take place through 
symmetric and asymmetric cell divisions[158]. The self-renewal ability of MSCs has been under 
question in several studies. Present understanding of the MSCs has been through extensive 
experiments related to their ex vivo culture. Adequate evidence regarding the self-renewal ability 
of the MSCs in the in vivo environment is still lacking that makes it difficult to validate the 
definition of MSCs. There may be a possibility that the self-renewal ability of MSCs seen during 
culture may be an effect of the culture conditions and not their inherent nature. Lack of evidence 
regarding the self-renewal ability of MSCs has been attributed to the difficulty in identifying a 
specific phenotype marker for MSCs in vivo [159]. Very few studies have attempted to address 
this problem. Simmons et al [160] developed an antibody known as STRO1 to identify the cell 
surface antigens present in MSCs from bone marrow. STRO1 is capable for identifying a 
population of bone marrow cells that are clonogenic, have ability to form colony forming unit 
(CFU) fibroblasts and differentiate into specialized cell types. In order to further improve the 
process of identifying MSC rich population, it was proposed that markers such as VCAM/CD106 
can be used along with STRO1. But the binding ability of STRO1 to erythrocyte progenitor cells 
can limit its use [161]. In a recent study, markers such as SSEA-1 and SSEA-4 have been 
reported for identifying the mesenchymal stem cells in vivo [162]. Despite this, there seems to be 
a need for extensively characterizing the MSCs in vivo like the hematopoietic stem cells. The 
issue of finding a specific marker for the MSCs in vivo is complicated further due to the loss of 
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the in vivo markers during the in vitro cell culture that creates difficulties during interpretation of 
results [161]. Besides the lack of adequate evidence for specific markers in MSCs for in vivo 
characterization, the mode of cell division (symmetric or asymmetric) utilized by the MSCs for 
self-renewal is uncertain [157, 158]. The concept of self-renewal related with the MSCs seems to 
drift towards uncertainty due to the accumulation of mutations during each round of DNA 
replication during cell division. Thus, there would be some differences between the parent cell 
and the daughter cell and this has been often ignored for practical reasons [163].  
1.5.1.2. Heterogeneity of MSCs 
The heterogeneity of MSC population has been reported widely in literature. MSC 
populations cultured both ex vivo and in vivo have been reported for their heterogeneity on the 
basis of MSC colonies having differences in growth rates, cell morphology, multipotentiality and 
phenotype [164].  The difference in multipotentiality of the stem cells in a MSC population is 
linked to the question regarding the true stem cell nature of the MSCs. There is a possibility that 
the “clonal expansion” of MSCs can be interpreted as self-renewal but in reality MSCs can be 
said to have true stem cell nature if they also are able to show the same multipotentiality as their 
parent cells during their expansion [157]. This has further given rise to the methods that can be 
used for assaying the true stem cell nature of the MSCs. For the purpose of assaying the true 
stem cell nature of the MSCs, researchers have proposed the development of in vivo assays at the 
single cell level [159, 165]. Assaying self-renewal ability and multipotentiality at the single cell 
level in vivo would be a more accurate way of examining the true stem cell nature of the MSCs. 
These types of assays have been already well-established for the hematopoietic stem cells. The 
low frequency of MSCs and their requirement in large numbers further adds to the difficulty of 
developing methods to assess their true stem cell nature in vivo [165].  
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1.5.1.3. MSCs from Different Types of Tissues 
There have been reports that MSCs are also present in different types of tissues such as 
adipose, umbilical cord blood, pancreas and synovial tissue. For the purpose of tissue 
regeneration there is a requirement for a considerable number of MSCs. Presence of MSCs in 
other tissues in addition to the bone marrow seems encouraging with respect to the prospect of 
tissue regeneration. The low frequency of MSCs in the bone marrow also makes it important to 
study the other tissues consisting MSCs. Comparative studies between the MSCs found in bone 
marrow and other tissues would be helpful in finding whether MSCs from different sources can 
fall under the same category. This is a difficult task since no definite phenotypic markers for 
identifying MSCs in vivo have been established. Despite this, there have been studies suggesting 
that there may be differences in the differentiation capacity of the MSCs from different tissues 
under the same culture conditions [166]. Studies have also found that the MSCs from different 
tissues have same morphology and phenotype but were different with respect to the ease of 
isolation, proliferation and differentiation capacity [159].  
1.5.1.4. MSCs, Progenitor Cells and Precursor Cells 
The difficulties in the identification of MSCs appear to be further increased due to the 
similarities between the MSCs and the supporting cells in their environment [167]. For example, 
there are similarities in the morphology and phenotype between the MSCs and the adventitial 
reticular cells in the bone marrow. Also, similarities exist between the MSCs and the pericytes 
(cells in close proximity to the endothelial cells in blood vessels) related to their differentiation 
potential and the capacity to preserve their multipotentiality after several cell culture passages. 
The pericytes and also the bone lining cells express the same surface markers as the MSCs. 
Another facet of confusion related to MSCs is the presence of progenitor and precursor cells in 
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different types of tissues containing MSCs. These cells are representative of different levels of 
differentiation. The progenitors have less differentiation compared to the MSCs and the 
precursors have the least differentiation potential since they represent a stage just before a 
complete differentiation. Progenitors and precursors have also been categorized as the “transit 
amplifying cells.” The transit amplifying cells are known to arise from the stem cells and 
undergo limited number of cell divisions before they lose their self-renewal ability and then 
differentiate terminally [168].  
1.5.1.5. Differentiation Potential of MSCs 
The supposed ability of the MSCs to differentiate into different lineages has contributed 
immensely to their importance in tissue regeneration applications. Studies focused on studying 
the differentiation potential of MSCs have shown that they are able to differentiate into cells of 
mesodermal origin such as the osteoblasts, chondrocytes and the adipocytes and also into non-
mesodermal cell lineages such as the neurons, skin cells and hepatocytes [157, 169]. Some of 
these studies involved in vitro experiments whereas in some studies also involved in vivo 
experiments. In addition to this, there are also reports related to the differentiation of MSCs into 
more cell types of mesodermal origin such as the endothelial cells, muscle cells and cardiac cells. 
In one of the studies, it was shown that the MSCs show pluripotent behavior both in vitro and in 
vivo [170]. This has raised questions whether the MSCs can be known as pluripotent cells and 
also whether the term “mesenchymal” associated with the MSCs is appropriate [169]. Therefore, 
there seems to be a need for assessing the MSCs for pluripotency and the repeatability of the 
pluripotent behavior by stringent assays. The differentiation of the MSCs can be affected by 
using growth factors and cytokines such as fibroblast growth factor, transforming growth factor-
β, bone morphogenetic protein (BMP-2), harmones such as dexamethasone, vitamins such as 
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ascorbic acid and also chemicals such as β-glycerophosphate. Besides this, signaling pathways 
such as Wnt, Notch and regulation of factors such as runt homology domain transcription factor 
(Runx)2 are involved in the process of MSC differentiation [166, 169]. For the purpose of 
studying the differentiation potential of the MSCs, cell assays involving nonclonal cell strains are 
used. Such assays involve stains such as alizarin red (for osteogenesis), oil red O (for 
adipogenesis), alcian blue (for chondrogeneis). Although these assays have been used 
extensively for studying the differentiation of MSCs, there are difficulties in comparing these in 
vitro assays with the in vivo assays. The use of nonclonal cell strains in these assays gives results 
that are not a precise measure of the multipotentiality of the MSCs. 
1.5.1.6. Dedifferentiation and Transdifferentiation of MSCs 
The MSCs also show ability to dedifferentiate and transdifferentiate in addition to their 
ability to differentiate into different lineages. Dedifferentiation is a process in which completely 
differentiated cells are able to reverse their developmental process and convert into a less 
differentiated state (precursor or progenitor cells) [171, 172]. During this process, reversal is 
observed in the cells at the “genetic level”, “protein level”, in terms of morphology and at the 
“functional level” [172]. Reversal at the genetic level can be identified by the changes in gene 
expression profile and reversal at the protein level can be identified by increase in protein 
production related to a less differentiated state of the cell. At the morphological level, the 
dedifferentiated cells appear to be smaller in size than the completely differentiated cells, possess 
less cell organelles and higher “karyoplasmic ratio”. Also, at the “functional level” the 
differentiated cells get back their ability to proliferate. In case of transdifferentiation, 
differentiated cells change into cells of a completely different phenotype. It can also be said to 
switching of a cell committed to a specific lineage to a cell committed to a different lineage and 
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can be a result of reprogramming at the genetic level [173]. Transdifferentiation may involve two 
stages. During the first stage, the differentiated cells are converted back to a cell having stem cell 
or progenitor cell phenotype. In the second stage, the cells resulting from the conversion of the 
differentiated cells redifferentiate into new, differentiated cells. This suggests that 
dedifferentiation may be a part of transdifferentiation. Studies have shown that completely 
differentiated osteoblasts obtained from MSCs dedifferentiated into a less differentiated state 
resembling a stem cell like stage. These cells derived from the differentiated osteoblasts then 
differentiated into chondrocytes and adipocytes [173]. In a similar manner, differentiated 
adipocytes and chondrocytes were also able to transdifferentiate into other cell types of 
mesenchymal origin. In some of the other studies, it has been shown that MSCs were able to 
transdifferentiate into cardiomyocytes and epithelial cells [174]. The dedifferentiation capacity 
of the MSCs has increased the difficulty in understanding their direct role in tissue repair. It may 
be possible that during tissue repair, the already existing differentiated cells derived from the 
MSCs may dedifferentiate into a less differentiated state, get back their stem cell like properties 
and then differentiate into a specific lineage. It is thus possible that not only the MSCs but also 
the new differentiated cells obtained by transdifferentiation of the already existing differentiated 
cells may play a role in tissue repair [161]. Transdifferentiation of MSCs can be advantageous 
for tissue engineering where a considerable number of cells are required for tissue regeneration. 
In order to extend the use of cells obtained by transdifferentiation, extensive studies are required 
to assess their long-term stability.  
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1.5.2. Understanding the Mesenchymal Stem Cells (MSCs) 
Development in the understanding of factors at different length and time scales that affect 
the behavior of the MSCs can provide the impetus for regenerating tissues ready for clinical 
applications. But this seems to be a difficult task and depends on the present understanding of the 
mesenchymal stem cell (MSC) components, molecules involved in adhesion of MSCs, niche (in 
vivo microenvironment of the MSCs), migration ability of MSCs, immunomodulatory effect of 
MSCs and stimuli necessary for MSC differentiation. The following sections of the chapter 
would make an attempt to discuss these topics briefly. Also, the present cell culture methods, 
differentiation assays and characterization methods related to MSCs would also be discussed in 
the remaining part of this chapter. Besides this, the present and the potential use of MSCs for 
bone tissue engineering applications would be discussed.  
1.5.2.1. Integrins and Their Role in Mesenchymal Stem Cells (MSCs) 
For tissue engineering applications, the cells seeded on the porous scaffolds need to 
adhere to the scaffold substrate and also migrate to the interior parts of the scaffold. Adhesion 
and migration have an effect on different cellular processes involved in tissue formation. 
Integrins and focal adhesions play an important role in the adhesion and migration of the cells. 
Integrins constitute a large family of receptors and are known to take part in cell-extracellular 
matrix adhesion and cell-cell adhesion. In tissue engineering, the scaffold is designed so that it 
provides an environment similar to the extracellular matrix and therefore integrins become 
important for cell-scaffold adhesion.  
Integrins are known as “heterodimeric” receptors since they consist of non-covalently 
bonded α and β subunits[159]. These subunits are type 1 transmembrane glycoproteins and each 
of them has a comparatively long extracellular domain and a short cytoplasmic domain. There 
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are 18 α and 8 β subunits in case of mammalian integrins and these subunits combine together in 
different ways to create 24 different types of heterodimeric integrins. These integrins can bind to 
a range of ligands on the cell surface and the extracellular matrix [159]. The extracellular 
domains bind to the extracellular proteins and the cytoplasmic domains bind to the intracellular 
domains. The intracellular domain and ligand link serves as a connection between the receptor, 
the signaling pathways and the cytoskeletal system. The binding of the receptors to the 
extracellular and intracellular domains gives the receptors an ability to transmit signals from the 
inside to the outside of the cell and vice versa. Important events such as cell morphology, cell 
migration, cell proliferation, cell differentiation and cell death are dependent on the interactive 
signaling between the cells and the extracellular matrix. Fibronectin, laminin, collagens, 
tenascin, vitronectin, osteopontin and bone sialoprotein are some of the ligands for the integrins 
that are present in the extracellular matrix. Adhesion between the cells is supposed to take place 
by binding of the integrins to the cell membrane receptors. Counter receptors such as vascular 
cell adhesion molecule (VCAM-1), inter-cellular cell adhesion molecules ICAM-1 and ICAM-2 
are involved in these types of intercellular adhesions. Additionally, the integrins promote the 
adhesion between the cells through soluble, multivalent molecules. The binding of the 
extracellular domain of the integrins with the extracellular matrix ligands is followed by binding 
of the cytoplasmic domain to the anchor proteins inside the cell such as catenin, talin and actinin. 
These anchor proteins connect the integrins to the actin filaments that constitute a part of the 
cytoskeleton. The link formed between the integrins and the actin filaments by the anchor 
proteins can cause clustering of integrins under favorable conditions. These integrins clusters are 
known as the focal adhesion between the cell and the extracellular matrix [175]. Focal adhesions 
are also important for cell polarization, cell migration, cell growth and cell survival [176]. 
40 
 
Integrins through their involvement in the focal adhesions affect cell morphology and control 
cell migration. Studies seem to suggest that integrins indirectly control cell migration by their 
participation in the signaling related to the matrix metalloproteinases (MMPs) expression [159]. 
MMPs are proteolytic enzymes that degrade the extracellular matrix proteins at specific sites and 
thus help in cell migration. Regulation of some of the proteins from the cyclin family by 
integrins is suggestive of their role in cell proliferation.  
Components of integrins such as α1, α2, α3, α5, α6, β1, β3, β4 for human mesenchymal 
stem cells (MSCs) have been identified by fluorescence activated cell sorting method. 
Additionally, integrins such as ICAM-1, ICAM-2, VCAM-1, CD72 and LFA3 have also been 
identified for MSCs [177]. Integrins are also known to play a role in the differentiation of MSCs 
and keeping in mind their use for bone tissue engineering applications, an overview of their role 
in osteogenic differentiation would be given in the following paragraph. Studies have shown that 
the integrin β1 significantly affects the adhesion, proliferation and the differentiation of the 
MSCs [159, 177-179]. It has also been found that integrins such as α11, α2 and integrin linked 
kinase (ILK) are upregulated during osteogenic differentiation. Increase in glycoprotein levels 
such as tenascin during osteogenic differentiation has been linked to the hypothesis of reduction 
in MSC motility during osteogenic differentiation. Also, binding between the upregulated 
integrin α2β1 with type I collagen has been identified as one of the events involved in regulation 
of osteogenic differentiation. Phosphorylation of focal adhesion kinase (FAK) in MSCs has also 
been suggested as one of the possible reasons for the increase in osteogenic gene expression 
during osteogenic differentiation.  
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1.5.2.2. Mesenchymal Stem Cell (MSC) Niche 
In addition to insufficient information on the in vivo behavior of the MSCs, the specific 
location of the MSCs in vivo also seems to be characterized insufficiently. Recent studies seem 
to support the concept of “niche” put forth in the 1970s [180]. The niche is supposed to be 
composed of “microenvironmental cells” that support the stem cells and also help the stem cells 
to maintain tissue homeostasis [181]. The supporting cells can be non-stem cells. These along 
with the extracellular matrix and soluble molecules are the niche components. Niche helps in 
maintaining the stem cells in an undifferentiated state and provides them a protective 
environment from different types of stimuli to maintain this undifferentiated state. Besides this, 
niche protects the stem cells from uncontrolled cell division and occasionally allows 
differentiation of stem cells through certain cues on requirement. The microenvironment of the 
niche is dynamic and it has been proposed that the concept of niche can be also applicable to 
MSCs in the bone marrow [157]. Studies have indicated that the MSCs are located in a 
perivascular niche in the adult tissues [157, 182]. MSCs have been found lining the blood vessels 
and have also been hypothesized to be pericytes. The MSCs and pericytes have been found to 
express surface markers representative of both cell types and also show similar multipotentiality. 
The location of the MSCs in the perivascular niche is implicative that the MSCs can migrate to 
distant tissues in response to injuries or disease.  
1.5.2.3. Immunomodulatory Effect of MSCs 
MSCs have been reported for their ability to avoid allogenic rejection in humans and 
animals [166]. Specific reasons for this ability of MSCs have yet not been clearly understood, 
but one of the possible reasons suggested is the lack of major histocompatibility complex 
(MHC)-II in MSCs. Mechanisms similar to those involved in avoiding the rejection of a foetal 
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allograft by the maternal immune system have also been suggested in relation to the 
immunomodulatory behavior of MSCs. MSCs have also been found to inhibit proliferation and 
activation of T cells when they are subjected to mitogenic or allogenic stimulation in vitro [183].  
Examples of immunomodulatory effects of MSCs have been reported. In case of animals, the 
injection of MSCs delayed the rejection of dissimilar skin grafts. Results have also been 
encouraging in case of use of MSCs for treatment of severe graft versus host disease. 
Immunomodulatory effect of MSCs in tissue engineering can possibly be useful for avoiding the 
problem of immune rejection in case of engineered tissues developed from MSCs.  
1.5.3. Mesenchymal Stem Cell (MSC) Culture 
Despite the lack of complete understanding of the MSC behavior in vivo as mentioned 
earlier, MSCs have been isolated, expanded and have been induced to differentiate into different 
lineages to corroborate their utility for tissue engineering and other therapeutic applications. The 
present in vitro methods for isolation and expansion of MSCs from bone marrow and some of the 
issues related to their in vitro culture would be discussed in brief under this section. 
Differentiation of the MSCs through the components of the cell culture medium would also be 
discussed briefly.  
1.5.3.1. Mesenchymal Stem Cell (MSC) Isolation 
MSCs can be isolated from the bone marrow aspirates collected from superior iliac crest 
of the pelvis, tibia and femur in case of humans [184]. In case of animals, MSCs can be isolated 
from the same bone sites as in humans. Percoll density centrifugation is a common technique for 
the centrifugation of MSCs. It involves use of solutions with high density but low viscosity and 
low osmotic pressure. Mononucleated cells obtained from bone marrow by this technique are 
seeded on the tissue culture polystyrene dish with the required changes of cell culture medium 
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composed of basal medium, growth supplements (e.g. L-glutamine) and antibiotic. During the 
process of cell culture medium, non-adherent cells considered to be hematopoetic cells are 
removed and the adherent cells are the mesenchymal stem cells (MSCs) [185]. An alternative to 
this technique is the enzyme digestion technique that can be used to isolate MSCs from solid 
tissues such as bone and cartilage. In enzyme digestion technique, collagenase enzyme is used to 
cleave the collagen present in these solid tissues to release the cells and the released cells are 
then collected by washing and centrifugation. The MSCs obtained by enzyme digestion of tissues 
are similar to those obtained from bone marrow aspirates with respect to their differentiation 
potential and phenotype. Although the enzyme digestion technique has been found to give a high 
yield of MSCs, this technique has not been standardized [186].  The purity of the MSC 
population obtained by both these techniques has been under question and this has led to 
development of other techniques of to get an enriched population of MSCs. Techniques such as 
isolation of MSCs based on their cell surface markers, magnetic bead sorting and fluorescence-
activated cell sorting have been developed for the purpose of MSC enrichment [186].  
1.5.3.2. Mesenchymal Stem Cell (MSC) Expansion 
Requirement of MSCs in considerable numbers for bone tissue engineering and other 
clinical applications has made MSC expansion important. Due to their low numbers in the bone 
marrow and also some of the other tissue sources, they need to be cultured by using appropriate 
methods to get the required numbers without having an effect on their capabilities. Factors such 
as the culture media and its components need to be considered in this case. 
Cell culture medium for MSC culture consists of two important components; viz. basal 
medium and the serum. Basal medium contains glucose, amino acids and inorganic ions such as 
calcium, magnesium, potassium, sodium and phosphate. The yield of MSCs during their 
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expansion is affected by components of cell culture medium, cell plating density and also the 
surface quality of the tissue culture plastic used for their expansion [186]. It has been reported 
that culture medium containing alpha Modified Eagle’s Medium (α-MEM) as the basal medium 
is more favorable for MSC expansion. Also, culture medium containing DMEM, low glucose 
levels and L-alanyl-L-glutamine (Glutamax) has been reported to be conducive for better 
proliferation of MSCs. Greater stability of L-alanyl-L-glutamine as compared to L-glutamine has 
been cited as the reason for the better proliferation of MSCs [186, 187]. The nature of the serum 
also has an effect on the expansion of MSCs and several comparative studies have been 
performed between animal sera (fetal calf serum and fetal bovine serum) and human serum. 
Considering the different results from these studies, it is difficult to draw definite conclusions 
regarding the most suitable serum for in vitro MSC expansion. Besides this, questions exist over 
the use of MSCs cultured in medium containing animal serum since they can trigger immune 
reactions when used for clinical applications. Growth factors such as basic fibroblast growth 
factor (bFGF), platelet derived growth factor (PDGF), epidermal growth factor (EGF) and 
insulin growth factors (IGF) are added to culture medium for MSC expansion. bFGF is the most 
common growth factor that is used in culture medium for MSC expansion and maintaining their 
multipotentiality. Antibiotics are also added to the cell culture medium to avoid contamination in 
very low concentrations (up to one percent).  
1.5.3.3. Media for Inducing Osteogenic Differentiation in MSCs 
For bone tissue engineering applications, it is necessary that the MSCs differentiate into 
an osteogenic lineage. One of the ways to induce osteogenic differentiation in MSCs derived 
from bone marrow is to add supplements to the cell culture medium containing the basal 
medium, serum and antibiotics. Supplements such as dexamethasone, L-ascorbic acid 2 
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phosphate and β-glycerophosphate are commonly added to the cell culture medium for the 
purpose of osteogenic differentiation. The quantity of dexamethasone can have an effect on 
whether the MSCs undergo osteogenic differentiation or differentiate into other lineage [185]. 
Ascorbic acid alone can also be used as a supplement in place of L-ascorbic acid 2 phosphate but 
has been found to be relatively unstable under cell culture conditions (37°C and neutral pH). Use 
of ascorbic acid in high concentrations can prove toxic for the cells and using β-
glycerophosphate is important for calcium phosphate matrix deposition by the differentiated 
MSCs. Other external factors added to culture medium such as recombinant human bone 
morphogenetic proteins and parathyroid hormone related peptides are also known to induce 
osteogenic differentiation. In case of MSCs derived from the umbilical cord blood and adipose 
tissue, the osteogenic supplements used are the same as in the case of MSCs obtained from bone 
marrow. Additional external factors can be added in case of MSCs derived from umbilical cord 
blood and adipose tissue sources. For example, external factors such as vitamin D3 and fibroblast 
growth factor can be used in case of MSCs from umbilical cord blood and polyamine spermine 
can be added in case of MSCs derived from adipose tissue [188].   
Senescence is one of the issues associated with the in vitro expansion of MSCs and has 
been widely reported. To be more specific, replicative senescence in MSCs is associated with 
permanent arrest of cell division. Under the condition of senescence, the MSCs remain alive and 
enter into a permanent growth arrest phase during their cell cycle [189]. Due to senescence, 
MSCs undergo a limited number (30-40) of population doublings in vitro. Senescence is also 
known to be accompanied by loss of multipotentiality. Reduction in the length of the telomeres 
during successive cell divisions has been linked to MSC senescence. Telomerase enzyme known 
for its role in synthesis of telomeres can have an effect on the proliferation and differentiation 
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abilities of MSCs. Methods need to be developed to activate and maintain telomerase activity in 
MSCs for their in vitro expansion.  
1.5.3.4. MSCs in Bone remodeling, Fracture repair and Their Use in Bone Tissue 
Engineering Applications 
MSCs are known to play an indirect role in bone remodeling since they can give rise to 
osteoblast progenitor cells [161].The opposing action of the osteoblasts and osteoclasts are 
important for bone tissue homeostasis. The differentiation of the osteoclasts from their 
precursors depends on the molecules expressed by the osteoblasts. Osteoblast receptors such as 
receptor activator of nuclear factor-kB (RANK), RANK ligand and decoy receptor 
osteoprotegerin interact with each other and thus regulate the formation of osteoclasts 
(osteoclastogenesis) along with bone resorption. The indirect role of MSCs in bone remodeling 
has been suggested through experiments showing expression of RANKL and osteoprotegerin in 
vitro cultured MSCs. MSCs cultured in presence of supplements such as dexamethasone used to 
promote osteogenic differentiation have been found to have increased OPG expression.   
Fracture healing has been classified as indirect or direct fracture healing. In case of direct 
fracture healing, MSCs from the perivascular regions are known to contribute more as compared 
to the MSCs from the periosteum. In case of indirect fracture healing, both intramembranous and 
endrochondral bone formation are known to take place. For intramembranous fracture healing, 
MSCs from the periosteum differentiate into osteoblasts and form bone. For endrochondral 
fracture healing, chondroprogenitors form a cartilagenous callus that is followed by entry of 
blood vessels, recruitment of chondroclasts and osteoprogenitors to form a woven bone.  
Knowledge about the role of MSCs in bone remodeling and fracture repair alongwith its 
properties discussed in the previous sections encourage its use for bone tissue engineering 
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applications. MSCs have been used in studies related to tissue engineering using scaffolds made 
up of different materials such as chitosan [190], poly(L-lactic acid) [191], collagen [192], 
polycaprolactone [193] and alginate [194]. In addition to development of materials for use of 
MSCs in bone regeneration, it is becoming increasingly important to study the different types of 
stimuli affecting MSC differentiation. Identifying the role of different types of stimuli in MSC 
differentiation can also help in designing better material systems and improving the present 
tissue engineering approach.  
1.6. Polymer Clay Nanocomposites (PCNs) and Potential of Na-MMT Clay for Bone Tissue 
Engineering 
Research on PCNs was spurred by reports of significant enhancement in mechanical 
properties of PCNs by Toyota research group in 1990 [195]. Since then several studies have 
reported the effect of addition of sodium-montmorillonite (Na-MMT) nanoclay on permeability 
[196-198], flammability [199, 200] and biodegradability [201] of PCNs besides the significant 
enhancement in mechanical properties [24]. Extensive simulation [202-204] and experimental 
studies [205, 206] performed by our group led to the development of “altered phase model”  for 
PCNs according to which a significant volume of the polymer is affected by molecular level 
interactions between the constitutents of PCNs that causes change in crystallinity of the polymer 
in the altered zone around the intercalated clay particles [207]. This change in crystallinity is 
responsible for significant enhancement in nanomechanical properties of PCNs.  
The reinforcing ability of Na-MMT clay can be used to enhance the mechanical 
properties of polymeric scaffolds used in tissue engineering. Besides this our previous studies 
have shown that Na-MMT clay intercalated with organic molecules (modifiers) affects the 
nanomechanical properties and polymer crystallinity. Ability of Na-MMT clay to affect 
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nanomechanical properties can be useful to influence cell behavior since the cells are responsive 
to mechanical cues from their surrounding environment. Effect on crystallinity of PCNs due to 
addition of Na-MMT clay can be useful to influence degradation of polymeric scaffolds since 
change in polymer crystallinity affects ingress of the surrounding medium and thus the 
degradation of the polymer under physiological (aqueous) environment. Following factors were 
also considered for the use of MMT clay in this work: 
1. Reported use of Na-MMT clay for drug-delivery and drug-release applications [30, 208, 
209]. 
2. Ability of MMT clays to be excreted from the body [28]. 
3. Medicinal use of MMT clay to treat disorders such as ulcers, diarrhea and 
hyperthyroidism [210]. 
4. The nanoscale dimension of MMT sheet can be used for affecting the cell response since 
the cell protrusions (filopodia and lamellipodia) are more responsive to nanoscale 
features [6]. 
5. The human bone also consists of ions such as sodium, magnesium, silicon, zinc and 
carbonate in addition to the mineral apatite. Silicon is known to affect bone formation 
rate, pattern [10] and also involved in early stages of bone calcification [211]. MMT clay 
consists of ions such as silicon, magnesium, aluminum and therefore can be useful for 
bone tissue engineering studies 
Use of Na-montmoriilonite (Na-MMT) nanoclay for designing polymer composite 
scaffolds for bone tissue engineering is a major focus of this work. Na-MMT clay was used in 
this work to design polymer composite scaffolds based on the hypothesis that Na-MMT clays are 
capable of enhancing mechanical properties of polymer based scaffolds. The problem of 
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imparting mechanical properties to bone tissue engineering scaffolds extends across different 
scales (molecular to macroscale). Besides this, studies have indicated that designing polymer-
clay nanocomposites (PCNs) at molecular level can be useful to have better control over their 
physical properties across higher length scales. Therefore a materials design strategy beginning 
at the molecular level was used in which Na-MMT clay was modified with unnatural amino 
acids and this modified MMT clay was further used for experimental investigations involving 
Fourier Transform Infrared (FTIR) spectroscopy, X-ray diffraction and biocompatibility 
assessment. Based on these investigations, 5-aminovaleric acid modified MMT clay was used to 
prepare chitosan-polygalacturonic acid (ChiPgA) bipolymer composite scaffolds and these 
scaffolds were studied for their suitability for bone tissue engineering applications that also 
included studies related to the response of osteoblasts (bone cells) to ChiPgA scaffolds 
containing modified MMT clay compared to ChiPgA scaffolds containing hydroxyapatite (a 
material known for its favorable cell response). Chitosan was used on the basis of its known 
bicompatibility, wound healing ability, antimicrobial properties and minimal foreign body 
reaction.  Polygalacturonic acid (PgA) is a de-esterified form of pectin. Pectin has been reported 
for its use in food industry and for producing drugs. Besides this, pectin has also been reported 
for its favorable effect on proliferation of osteoblasts [212]. Considering multiple requirements 
of bone tissue engineering scaffolds, especially osteoinductivity and osteoconductivity, bone-like 
apatite was mineralized in 5-aminovaleric acid clay using a processing route based on 
biomineralization in bone to obtain a novel three-component nanoclay-hydroxyapatite hybrid (in 
situ HAPclay). This nanoclay-HAP hybrid was used to prepare ChiPgA composites (films and 
scaffolds) and response of osteoblasts, hMSCs in the absence of osteogenic supplements to these 
composites was comprehensively studied using biological assays and imaging. In situ HAPclay 
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was also used to prepare synthetic polymer composites (films and scaffolds). Polycaprolactone 
(PCL), a synthetic and an aliphatic polyester, was used for this purpose considering its 
versatility, lesser complexities compared to biopolymers and immense prospects for tissue 
engineering applications. Apart from studying the response of hMSCs to these synthetic 
composites, the effect of incorporation of in situ HAPclay on the nanomechanical properties, in 
vitro degradation and scaffold microstructure was studied. Sub-micron scale morphology of the 
mineralized ECM formed on these synthetic PCL composites was studied using atomic force 
microscopy (AFM) and the mineralized ECM components (mineral, collagen) were compared to 
their natural bone counterparts for similarities in dimensions, arrangement.  
1.7. Objectives of Research  
The specific objectives of this research are as follows: 
1. To modify and thus intercalate Na-MMT clay with unnatural amino acids.  
2. To characterize the modified Na-MMT clays using experimental techniques such as FTIR 
spectroscopy, XRD and assess the biocompatibility of the modified clays using relevant 
cells (osteoblasts).  
3. To fabricate chitosan-polygalacturonic (ChiPgA) biopolymer complex based composite 
scaffolds containing unnatural amino acid modified Na-MMT clay and perform 
comparative studies using these scaffolds related to their biocompatibility with 
osteoblasts, microstructure, porosity, swelling properties and their spectroscopic 
characterization (FTIR spectroscopy). 
4. To mineralize bone-like apatite in Na-MMT clay intercalated with unnatural amino acid 
using a processing route based on biomineralization in bone and thus make this clay more 
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effective for imparting bone formation ability and improved mechanical properties to 
bone tissue engineering composites (films and scaffolds). 
5. To characterize the nanoclay-hydroxyapatite (HAP) hybrid (also known as in situ 
HAPclay) using FTIR spectroscopy, XRD, transmission electron microscopy (TEM) and 
scanning electron microscopy (SEM). 
6. To prepare ChiPgA biopolymer complex based composites (films and scaffolds) 
containing in situ HAPclay and study the response of osteoblasts and human 
mesenchymal stem cells (hMSCs) to these composites without the use of osteogenic 
supplements. 
7. To study the microstructure of ChiPgA/in situ HAPclay scaffold, surface morphology of 
ChiPgA/in situ HAPclay films and determine the porosity, swelling ratios of ChiPgA/in 
situ HAPclay scaffolds. 
8. To perform a unique two-stage cell seeding experiment using hMSCs as a strategy to 
enhance tissue (bone) formation under in vitro conditions on polymer composites 
containing in situ HAPclay. 
9. To fabricate synthetic polymer (polycaprolactone) composite films and scaffolds 
containing in situ HAPclay and perform studies related to the response of hMSCs to these 
composites, scaffold microstructure, surface morphology (for films), nanomechanical 
properties (for films) and in vitro degradation under accelerated conditions (for 
scaffolds). 
10. To study cell-dependent bone mineral formation mechanisms on PCL/in situ HAPclay 
films (an engineered synthetic polymer composite based substrate) using scanning 
electron microscopy (SEM) and SEM-EDS (energy dispersive spectroscopy) 
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1.8. Organization of Dissertation 
This dissertation is organized into different chapters as follows: 
1) Chapter 1: This chapter give an introduction to tissue engineering. It also gives a brief 
overview of the significant factors related to the use of 3D scaffolds and also presents 
reasons for using 2D substrates (films) for tissue engineering. It further describes 
different materials and methods used for fabricating tissue engineering scaffolds. This 
chapter also discusses polymer clay nanocomposites (PCNs) and their potential for bone 
bone tissue engineering and presents factors considered while selecting materials used for 
this research work.  
2) Chapter 2: This chapter presents design of organomodified clays using unnatural amino 
acids and discusses these clays as potential biomaterials for bone tissue engineering 
3) Chapter 3: Studies related to fabrication of ChiPgA biopolymer composite scaffolds 
containing unnatural amino acid modified nanoclay and indicating their suitability for 
bone tissue engineering are presented in this chapter 
4) Chapter 4: This chapter describes the preparation, characterization of nanoclay-
hydroxyapatite (HAP) hybrid (also known as in situ HAPclay) based on 
biomineralization in bone and presents results related to response of osteoblasts (bone 
cells) to ChiPgA biopolymer composites containing in situ HAPclay 
5) Chapter 5: This chapter describes preparation of ChiPgA/in situ HAPclay composites 
using two different methods and the response of human mesenchymal stem cells 
(hMSCs) to these composites along with other studies indicating their suitability for bone 
tissue engineering 
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6) Chapter 6: This chapter discusses the fabrication of synthetic polymer (polycaprolactone) 
composites (films and scaffolds) containing in situ HAPclay and presents results from 
experimental investigations related to response of hMSCs to these composites, 
characterization of these composites using different imaging techniques and 
nanoindentation, ultrastructure of mineralized ECM formed on these composites and in 
vitro biodegradation studies (for scaffolds) 
7)  Chapter 7: This chapter discusses cell dependent bone mineral formation mechanisms in 
brief and presents observations  from experiments involving cell dependent mineral 
formation on engineered synthetic polymer (polycaprolactone) composites 
8)  Chapter 8: This chapter presents summary and important conclusions of the research 
presented in this dissertation 
9)  Chapter 9: This chapter attempts to present future directions for bone tissue engineering 
research and closely related fields       
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CHAPTER 2. DESIGN OF ORGANOMODIFIED NANOCLAYS USING 
UNNATURAL AMINO ACIDS AS BIOMATERIALS FOR BONE TISSUE 
ENGINEERING2 
This chapter presents studies related to design of organomodified clays using unnatural 
amino acids for bone tissue engineering applications. The contents of this chapter have been 
published in Katti, K.S., Ambre, A.H., Katti, D. R. Use of unnatural amino acids for design of 
novel organomodified clays as components of nanocomposite biomaterials. Philosophical 
Transactions of The Royal Society A. 2010; 368:1963-1980.  
2.1. Introduction 
Tissue engineering is “an interdisciplinary field of research that applies the principles of 
engineering and life sciences towards the development of biological substitutes that restore, 
maintain, or improve tissue function” [1]. The main focus of tissue engineering is the 
development of materials with adequate mechanical properties that favor tissue formation, 
differentiation and regeneration. In this regard, there has been a continuous thrust in recent years 
for developing composite systems using polymers and fillers in the micrometer-nanometer range 
that can satisfy the requirements such as biocompatibility, biodegradability, surface properties 
and mechanical properties needed for materials used for tissue engineering. 
In addition, extensive research on polymer-clay nanocomposites (PCNs) since 1990 when 
Toyota research group [2] reported significant findings for nylon/clay nanocomposites has paved 
the way for developing advanced composite materials based on polymer-clay composite systems. 
                                                          
2The contents of this chapter were co-authored by Avinash Ambre (second author) and Drs. 
Kalpana Katti and Dinesh Katti. Avinash Ambre conducted literature review, performed all 
experiments, drew conclusions and wrote, revised all the sections in this chapter. Drs. Kalpana 
Katti and Dinesh Katti assisted in discussion and proofreading of all the sections.  
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Polymer-clay nanocomposites (PCNs) are composites that consist of clay particles having at least 
one of their dimensions in nanometer range dispersed in a polymer matrix [3]. PCNs show 
significant improvement in properties as compared to neat polymer and polymers containing 
micron-size fillers. Several studies have reported that PCNs  show  improvement in mechanical 
properties [2, 4-11], decrease in gas permeability [12-15] and flammability [16, 17] and also 
affect the biodegradability of biodegradable polymers [18]. There has also been a considerable 
interest in modeling & simulation and development of new theories for PCNs. A recent 
simulation study has reported the development of an altered phase concept for PCNs [19]. 
According to this study, molecular-level interactions between polymer and clay in PCNs create 
an “altered polymer phase” with different elastic properties as compared to the neat polymer. 
This “altered polymeric phase” was responsible for the increase in mechanical properties of 
PCNs. In another simulation study related to PCNs, it was found that the properties of the clay 
and polymer and the interactions at the interfaces between them change the properties of both the 
polymer and clay that played an important role in the mechanical behavior of PCNs [20].  
Montmorillonite (MMT) clay has been an important constituent of PCNs that is 
responsible for their significantly improved or changed properties. Sodium montmorillonite (Na-
MMT) is a layered silicate from the family of 2:1 phyllosilicates [3, 21, 22]. There is one 
octahedral alumina sheet between two silica tetrahedral sheets in each layer of MMT (Figure 
2.1.). The thickness of each layer is in the nanometer range and its lateral dimension is in 
micrometer range. Isomorphic substitutions take place in the layers of Na-MMT that generate 
negative charge, which is balanced by the exchangeable cations such as sodium, calcium and 
magnesium present in the interlayer spacing. Pure MMT clay is hydrophilic and can be made 
organophilic by exchanging the cations present in the interlayer with cationic surfactants such as 
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alkylammonium or alkylphosphonium ions. The cationic surfactants may also increase the 
interlayer spacing and thus facilitate the intercalation of the polymeric species in the interlayer 
[3, 21-23]. 
 
Figure 2.1. Model of the atomic structure of Na-MMT clay 
 
Although MMT clay has medicinal properties and several studies involving the use of 
MMT clay for drug release and drug delivery applications have been carried out till date, a 
limited number of studies related to the utilization of MMT for structural application in 
biomaterials have been reported. Few studies related to the use of chitosan and MMT have been 
reported [24-27]. Xu et al. prepared chitosan/MMT nanocomposite films with an improved 
tensile strength [28]. Wang et al. [26] prepared exfoliated-intercalated chitosan/MMT 
nanocomposites and found that the presence of MMT clay improved the thermal properties and 
increased the hardness and elastic modulus of the composites. Lin et al. [29] developed 
chitosan/clay nanocomposites that showed an improvement in tensile strength and a decrease in 
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in vitro degradation. In our previous work, we synthesized a novel chitosan/ 
MMT/hydroxyapatite (HAP) nanocomposite that showed significant increase in nanomechanical 
property as compared to the chi/HAP and chi/MMT composites [30]. Also, 
polycaprolactone/MMT nanocomposites were prepared by electrospinning that exhibited 
improved stiffness as compared to neat polycaprolactone without any significant decrease in the 
ductility of the polymer [31]. Zheng et al. [32] developed a gelatin/MMT-chitosan scaffold that 
showed an improvement in mechanical properties due to the addition of MMT and also found 
that the degradation rate was affected by the MMT clay content. 
Modification of clays plays an important role in the preparation of nanocomposites since 
it can affect the final properties of the nanocomposites. The extent of intercalation of the polymer 
in the interlayer spacing of clay is affected by the interactions between the polymer and the 
functional groups of the modifier used for clay modification. Our prior simulation study in using 
amino acids to intercalate clays has indicated that clays may be intercalated with amino acids 
[33]. In addition, our work involving PCNs indicated the role of chain length and functionality of 
a modifier on the ability to intercalate the clay [34]. Hence, we chose amino acids with longer 
chains as modifiers in this work. Molecular dynamics simulation studies related to PCNs have 
shown the importance of the effect of interactions between polymer, organic modifiers and clay 
on the crystallinity and nanomechanical properties of PCNs [35]. Also, we found that organic 
modifiers affect the crystallinity and nanomechanical properties of the prepared PCNs [36]. 
Therefore, it is essential to use an appropriate modifier to obtain the required properties in the 
composites. In order to use MMT clay for structural application in biomaterials, it is necessary to 
increase its interlayer spacing and simultaneously maintain or improve its biocompatibility. 
Unnatural amino acids possess the potential to be used as modifiers that can increase the 
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interlayer spacing of clay and also maintain or improve its biocompatibility. These are the “non-
genetically coded amino acids” [37] that are either natural or synthetic and are gaining 
significance in drug research. They find use as chiral building blocks, molecular scaffolds in 
constructing combinatorial libraries and molecular probes for better understanding of biological 
systems [37, 38]. In this work, we hypothesize that MMT clays modified using unnatural amino 
acids based on molecular level materials design approach are biocompatible and have potential 
to be used as biocompatible constituents for increasing mechanical properties of bone tissue 
engineering scaffolds. Modifying/intercalating sodium montmorillonite (Na-MMT) clay with 
unnatural amino acids, characterization of Na-MMT clay modified with unnatural amino acids 
using X-ray diffraction (XRD) and Fourier transform infrared spectroscopy (FTIR) and studying 
the bicompatibility of unnatural amino acid Na-MMT clays with osteoblasts (bone cells) were 
the objectives of this study. Three different unnatural amino acids (Figure 2.2.) were used for 
modifying MMT clay. X-ray diffraction (XRD) was used to study the intercalation of amino 
acids in the MMT clay. The modified clays were also characterized by Fourier transform infrared 
(FTIR) spectroscopy and the biocompatibility of the modified MMT clay was assessed through 
cell culture experiments. 
2.2. Materials 
Na-Montmorillonite (Swy-2, Crook County, WY) with a cationic exchange capacity of 
76.4 mequiv/100g was obtained from the Clay Minerals Repository at the University of 
Missouri, Columbia, Missouri. The three amino acids, viz.: (±2) Aminopimelic acid, 5-
Aminovaleric acid, DL-2- Aminocaprylic acid were obtained from Sigma-Aldrich. Silver nitrate 
(0.1 N) was purchased from Anachemia chemicals and 1 N hydrochloric acid (HCL) was 
purchased purchased from VWR International. Chitosan (> 85% deacetylated) and 
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polygalacturonic acid (~95 % enzymatic) were obtained from Sigma-Aldrich. In order to perform 
cell culture experiments, HyQ Dulbecco’s Modified Eagle’s Medium (DMEM)—12 (1:1) from 
Hyclone, G418 solution (antibiotic) from JR Scientific were used. Osteoblast cells (cell line 
number CRL-11372) and fetal bovine serum (FBS) were purchased from American Type Culture 
Collection (ATCC). 
 
Figure 2.2. Molecular structure of unnatural amino acids 
2.3. Experiments 
2.3.1. Preparation of Modified Montmorillonite (MMT) Clays 
Sodium montmorillonite (Na-MMT) was ground into fine powder and then screened 
through # 325 sieve (45 µm). Five grams of this fine and sieved sodium MMT was placed in an 
oven for heating for 12 hours at 60ºC. Sodium MMT was then dispersed into 400 ml deionized 
(DI) water preheated to 60ºC. In another beaker, 1.9 grams of amino acid was added to 100 ml 
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DI water preheated to 60ºC. The pH of the amino acid solution used was maintained at 1.8 by 
adding 0.1 N HCL. The amino acid solution was then added to the MMT clay suspension and the 
resulting solution was stirred vigorously for 1 hour under pH of 1.8 at 60ºC. The modified 
montmorillonite (MMT) was separated by centrifuging and further washed several times with DI 
water until the Cl- ions were completely removed from the clay. The filtrate obtained after 
centrifuging was titrated with 0.1 N silver nitrate. The titration procedure was repeated until no 
white precipitate was formed that indicated the complete removal of chloride ions. Finally, the 
modified clay was placed in an oven for 24 hours at 70ºC for 24 hours. The modified clay was 
then ground and passed through # 325 sieve (45 µm). The aforementioned method of preparation 
of modified clays was used for preparation of modified clays with the three amino acids used in 
this study. 
2.3.2 Preparation of Chitosan-PgA-HAP-MMT Composite Films 
Chitosan (Chi) and polygalacturonic acid (PgA) solutions were prepared separately by 
dissolving 1 gram each of chitosan and polygalacturonic acid to 100 ml deionized water. Acetic 
acid was used for dissolving chitosan in deionized water and diluted sodium hydroxide solution 
was used for dissolving polygalacturonic acid in deionized water. Chitosan solution was added 
dropwise to polygalacturonic acid solution and the resulting mixture was sonicated to obtain 
ChiPgA polyelectrolyte complex solution. Hydroxyapatite (HAP) was prepared by using wet 
precipitation method [39]. HAP (20 wt %) and MMT clay modified with 5-aminovaleric acid (10 
wt %) were dispersed in deionized water by sonication separately and added to the ChiPgA 
polyelectrolyte complex solution. The resulting mixture was sonicated for proper mixing of HAP 
and modified clay. Films were prepared by adding the ChiPgAHAPMMT solution (1: 10 
dilution) to tissue culture polystyrene Petri dishes (60 mm OD x 15 mm H) and subsequent 
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evaporation under atmospheric conditions. These films were used for determining 
biocompatibility through cell culture.   
2.3.3. XRD Characterization 
The XRD experiments on powdered clay samples were done by using X-ray 
diffractometer (model Philips X’pert, Almelo, Netherlands) equipped with secondary 
monochromator and Cu-tube using CuKα radiation of wavelength 1.54056 Å. The d-spacing of 
clay structure was calculated from the XRD data using Bragg’s diffraction law. The scan range 
used was 2θ = 2-30º and the scan rate used was 2°/min. Powdered MMT clay and modified clay 
samples were placed in an aluminum mount prior to performing the XRD scan.  
2.3.4. FTIR Characterization 
FTIR experiments were conducted using a Thermonicolet, Nexus, 870 spectrometer with 
a KBr beam splitter in the range of 4000-400 cm-1 at a spectral resolution of 4 cm-1 and mirror 
velocity of 0.158 cm s-1. FTIR experiments were performed by using transmission technique. 
Samples for FTIR experiments in the form of pellets were prepared from mixture of KBr and 
powdered clay. The samples were placed in the universal sample holder for conducting the FTIR 
experiments.  
2.3.5. Cell Culture 
Powdered MMT and modified clays (1.5 mg each) were placed in tissue culture 
polystyrene Petri dishes and then sterilized by placing these Petri dishes for 2.5 hours under 
ultraviolet (UV) light. Tissue culture polystyrene Petri dishes without clay samples were also 
sterilized under UV light. 40,000 osteoblast cells (passage # 7) were then seeded in to these Petri 
dishes (60 mm OD x 15 mm H) having actual growth area of 19.5 cm2. Cells in the Petri dishes 
were then allowed to grow in the presence of 1.5 ml cell culture medium that consisted of 90 % 
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HyQ DMEM-12 (1:1), 10 % FBS and 0.6 % G418 solution (antibiotic) for each sample. The 
Petri dishes containing the samples were then placed in an incubator at 37º C and at 5 % CO2. 
The growth of the cells in Petri dishes containing the clays was investigated by taking 
photographs after 48 hours of seeding the cells on the powdered clay samples by using an 
inverted microscope. Two Petri dishes (duplicates) were used for each type of modified clay and 
also the unmodified clay. Twenty photographs were taken for each type of clay from these 
duplicates and number of cells in each of these twenty photographs were used for calculating the 
cell density.   
For determining the biocompatibility of the ChiPgAHAPMMT films, osteoblast cells 
were seeded on these films in the Petri dishes. Osteoblast cells [CRL 11372, American Type 
Culture Collection (ATCC)] at 95 % confluence were obtained from T-flasks. 0.5 ml cell 
solution was added to the Petri dishes containing the films along with 1.5 ml cell culture 
medium. The attachment of osteoblast cells on the films was observed under an inverted 
microscope.  
2.3.6. Statistical Analysis 
One-way ANOVA was used for performing statistical analysis with Minitab software and 
probability values less than 0.05 (p < 0.05) were considered statistically significant. 
2.4. Results and Discussion 
2.4.1. XRD Results 
The XRD patterns of MMT clay and MMT clay modified with the three amino acids used 
in this study are shown in Figures 2.3. (a, b & c).The peak corresponding to d001 plane of pure 
MMT clay is observed at 2θ= 8.842º. The d001 spacing at this value of 2θ is 9.992 Å. In case of 
MMT clay modified with (±2) aminopimelic acid, the peak appears at 2θ= 7.943º, which 
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corresponds to a b d001 spacing of 11.121 Å. For MMT clay modified with 5-aminovaleric acid, 
the peak appears at 2θ= 6.912º that corresponds to a d001 spacing of 12.771 Å. The peak for 
MMT clay modified with DL-2-aminocaprylic acid is seen at 2θ= 6.757º that corresponds to d001 
spacing of 13.070 Å. Thus, the d001 spacing of MMT clay shows an increase after modification 
with amino acids that indicates the formation of an intercalated structure. Figure 4 shows the 
comparative increase in interlayer spacing of MMT clay after modification with the amino acids. 
It is observed that the increase in interlayer spacing is the highest in case of MMT clay modified 
with DL-2-aminocaprylic acid. The difference in the extent of increase in interlayer spacing may 
be due to difference in the positions or number of the –COOH and –NH2 groups in the three 
amino acids. DL-2-aminocaprylic acid has one extra –CH2- group besides the methyl –CH3 
group as compared to (±2) aminopimelic acid and 5-aminovaleric acid. This suggests that the 
increase in d-spacing of the MMT clay can be affected by the length of the hydrocarbon chain 
and the position of the functional groups in the intercalating molecule. 
2.4.2. FTIR Results of (±2) Aminopimelic Acid, 5-Aminovaleric Acid, DL-2-Aminocaprylic 
Acid, MMT Clay and MMT Clay Modified with (±2) Aminopimelic Acid, 5-Aminovaleric 
Acid, DL-2- Aminocaprylic Acid 
Figures 2.4. (a,b) show the FTIR spectra for the three amino acids within the 4000-400 
cm-1 region and 2000-1260 cm-1 region respectively. Table 2.1. shows the band assignments of 
the bands seen in this region. The bands in the 1680-1682 cm-1 region are due to the 
intramolecular hydrogen bonding due to the carboxylic groups in the three amino acids. Figure 
2.5. (a-c) shows the FTIR spectra for MMT clay and MMT clay modified with the three amino 
acids. The corresponding band assignments are given in Table 2.2. Further discussion about the 
FTIR spectra shown in figure 2.5. (a-c) is given in following paragraphs under this section. 
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Figure 2.3. XRD pattern of a) MMT and MMT modified with 5-aminovaleric acid, b) XRD 
pattern of MMT and MMT modified with (±)-2-aminopimelic acid, c) XRD pattern of MMT and 
MMT modified with DL-2-aminocaprylic acid 
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Figure 2.5. (a) shows the FTIR spectra of the modified clays within the 4000-400 cm-1 
range. Figure 2.5. (b) shows the spectra for the clays modified with the three amino acids within 
the 3800-2100 cm-1 range. The clays modified with amino acids show a shift in the band position 
corresponding to the structural OH group as compared to pure MMT clay. In Figure 2.5. (c), it is 
observed that there are differences in the FTIR spectra of the modified clays and the pure MMT 
clay. In case of the clays modified with the amino acids, bands are seen at 1733 cm-1, 1716 cm-1 
and 1731 cm-1 that indicate the presence of the amino acids in the modified clays. These bands 
are attributed to the C=O stretching bands of the carboxylic group in the amino acid. There is a 
shift in the position of the C=O stretching band to a lower frequency by 16 cm-1 in case of MMT 
clay modified with5-aminovaleric acid that suggests hydrogen bonding interactions between 5-
aminovaleric acid and MMT clay. Figure 2.5. (c) also shows that there is a shift in the band 
positions associated with H-O-H deformation in case of clays modified with the three amino 
acids. Also, the bands in the 1681-1680 cm-1 region observed in case of the three amino acids are 
absent in case of all the three modified clays that indicates that the intramolecular hydrogen 
bonding of the three amino acids is broken due to the possible interaction of the amino acids with 
the clay. Figure 2.6. (a) shows the second derivative spectrum of the modified clays in the 1645-
1600 cm-1 region. It is seen that in case of clays modified with 5-aminovaleric acid and DL-2-
aminocaprylic acid, there is an overlap of two bands in this region. The bands near the 1616 cm-1 
in case of clays modified with 5-aminovaleric acid and DL-2-aminocaprylic acid may be due to 
the N-H deformation vibrations that arise due to the presence of these acids in MMT clay. The 
absence of N-H deformation in near 1616 cm-1 in case of clay modified with (±2) aminopimelic 
acid may be attributed to the presence of two carboxylic groups that may mask the effect of 
presence of the amine group of (±2) aminopimelic acid. Figure 2.6. (b) shows the FTIR spectra 
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of modified and unmodified clays within the 1394-835 cm-1 region. The corresponding second 
derivative spectrum for this region is given in figure 2.6. (c). The band assignments for this 
region are given in Table 2.2. There are shifts in the Si-O stretching vibrations in case of clays 
modified with the amino acids. These shifts may be attributed to the interaction between the 
protonated amine group and the surface oxygen of silica tetrahedral. Also, the band at 1210 cm-1 
position observed in case of pure MMT clay seems to be absent in case of clays modified with 5-
aminovaleric acid and DL-2-aminocaprylic acid. This may be an implication that the crystal 
structure of MMT clay has changed due to intercalation of amino acids in MMT clay. Therefore, 
the unpolarized infrared beam is unable to cause Si-O out-of-plane stretching vibration in case of 
the modified clays. 
2.4.3. Cell Culture Results 
The number of osteoblast cells grown in the presence of MMT clay and MMT clay 
modified with amino acids was counted manually from the images taken with an inverted 
microscope after 48 hours of seeding the osteoblast cells. The cell density (cells/mm2) for the 
modified clay samples was calculated and plotted as shown in Figure 2.7. (a & b). The images in 
Figure 2.8. shows that the osteoblast cells are attached and grow in the presence of MMT clay 
and MMT clay modified with the amino acids. The growth of osteoblast cells is comparatively 
high in case of MMT clay modified with 5-aminovaleric acid and comparatively low in case of 
MMT clay modified with DL-2-aminocaprylic acid. Among the modified MMT clays, MMT 
clay modified with 5-aminovaleric acid showed relatively higher biocompatibility.  
Figure 2.9. shows that osteoblast cells were able to attach on the ChiPgAHAPMMT 
films. This indicates that the MMT clay modified with 5-aminovaleric acid has potential for 
biomaterial applications. 
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Figure 2.4. FTIR spectra of the three unnatural amino acids within the a) 4000-400 cm-1 range 
and b) 2000-1260 cm-1 range 
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Table 2.1. Band assignment for amino acids 
 
Band position (cm-1) Band assignment 
3777, 3754, 3752 O-H and N-H stretching 
3723, 3713, 3706 O-H and N-H stretching 
2369, 2338, 2319 N-H+ stretching 
1681, 1680 C=O stretching vibration (intramolecular hydrogen bonding 
in carboxylic acids) 
1732, 1731, 1728 C=O stretching  
1584, 1588 R-COO – symmetric stretching 
1534, 1504, 1489, 
1468 
N-H vibrations 
 
 
Figure 2.5. FTIR spectra of MMT clay modified with amino acids within the a) 4000-400 cm-1 
range, b) 3800-2100 cm-1 range, c) 2040-1535 cm-1 range 
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Figure 2.5. FTIR spectra of MMT clay modified with amino acids within the a) 4000-400 cm-1 
range, b) 3800-2100 cm-1 range, c) 2040-1535 cm-1 range (continued) 
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Figure 2.6. Second derivative FTIR spectra of MMT clay modified with amino acids within the 
a) 1655-1595 cm-1 range, c) 1394-835 cm-1 range and FTIR spectra of clay modified with amino 
acids within the b) 1394-835 cm-1 range 
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Table 2.2. Band assignment for MMT clay and MMT clay modified with amino acids 
Band 
position 
(cm-1) 
Sample Band assignment  
3646 MMT clay O-H stretching of structural OH group  
1638 H-O-H deformation 
1211 Si-O out-of- plane stretching 
1179,1054, 
989 
Si-O stretching 
910 Al-OH deformation 
874 Al-FeOH deformation 
3628 MMT clay modified 
with (±2) aminopimelic 
acid 
O-H stretching of structural OH group  
2932 Asymmetric C-H stretching 
1635 H-O-H deformation 
1207 Si-O out-of- plane stretching 
1047 Si-O stretching 
915 Al-OH deformation 
882 Al-FeOH deformation 
3626 MMT clay modified 
with 5-aminovaleric 
acid 
O-H stretching of structural OH group  
3259 N-H symmetric stretching 
1716 C=O stretching 
1635 H-O-H deformation 
1616 N-H deformation 
987 Si-O stretching 
916 Al-OH deformation 
883 Al-FeOH deformation 
3627 MMT clay modified 
with DL-2-
aminocaprylic acid 
O-H stretching of structural OH group  
2934 Asymmetric C-H stretching  
2860 Symmetric C-H stretching  
1731 C=O stretching 
1634 H-O-H deformation 
1615 N-H deformation 
1050, 984 Si-O stretching 
914 Al-OH deformation 
879 Al-FeOH deformation 
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Figure 2.7. Comparative cell density data after 48 hours for a) MMT clay and MMT clay 
modified with the three amino acids, b) MMT clay, MMT clay modified with the three amino 
acids and tissue culture polystyrene Petri dishes (p < 0.05). Statistically significant differences in 
cell density were observed in case of modified MMT clays and polystyrene Petri dishes 
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Figure 2.8. Inverted microscope images of osteoblasts cultured in a) tissue culture polystyrene 
(TCPS) Petri dishes, b) TCPS Petri dishes containing MMT clay, c) TCPS Petri dishes 
containing MMT clay modified with aminovaleric acid, d) TCPS Petri dishes containing MMT 
clay modified with aminocaprylic acid, e) TCPS Petri dishes containing MMT clay modified 
with aminopimelic acid. Scale bars (a-e) – 500 µm 
 
 
Figure 2.9. Inverted microscope image of osteoblast cells seeded on ChiPgAHAPMMT films 
after 4 days. Scale bar-500 µm 
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2.5. Conclusions 
MMT clay was intercalated with three unnatural amino acids: (±2) Aminopimelic acid, 5-
Aminovaleric acid and DL-2-Aminocaprylic acid. The intercalation of the clays by all the three 
amino acids was confirmed by XRD. Transmission FTIR experiments of clays modified with the 
three amino acids showed shifts in band positions of C=O vibration that were indicative of 
interactions between the amino acids and MMT clay. Our prior work on molecular dynamics 
simulations of interactions between constituents of PCNs indicates that significant non-bonded 
interactions, such as here observed between clay and modifier, have a large impact on the final 
mechanical response of the nanocomposite. Cell culture experiments showed that all the three 
modified clays were biocompatible. Thus, the MMT clays modified with the three amino acids 
used in this study show potential for structural application in biomaterials as indicated by the cell 
behavior on the ChiPgAHAPMMT films prepared by using the modified clay. 
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CHAPTER 3. BIOPOLYMER COMPOSITE SCAFFOLDS CONTAINING 
NANOCLAY FOR BONE TISSUE ENGINEERING 
Fabrication of chitosan-polygalacturonic acid (ChiPgA) composite scaffolds containing 
5-aminovaleric acid (an unnatural amino acid) modified clay and studies showing their suitability 
for bone tissue engineering applications are presented in this chapter. The contents of this 
chapter have been published in Ambre, A.H., Katti, K.S., Katti, D.R. Nanoclay Based Composite 
Scaffolds for Bone Tissue Engineering Applications, ASME Journal of Nanotechnology for 
Engineering and Medicine. 2010, 1, 031013 
3.1. Introduction 
Extensive studies have been done in the field of tissue engineering since early 1990s 
when Langer and Vacanti introduced tissue engineering as an interdisciplinary field that 
combines the principles of engineering and life sciences to develop constructs useful for 
improving, maintaining or restoring the function of a tissue [1]. In the hindsight it can be realized 
that most of these studies are concerned with maintaining or restoring the function of a tissue and 
have corroborated that cells, scaffold and growth factors are the three important and basic 
components of tissue engineering. Bone tissue engineering constitutes an important area in the 
field of tissue engineering. The importance of bone tissue engineering has been augmented by 
the functional traits of bone such as providing structural support to the body, protecting the vital 
internal organs, facilitating body movement and acting as a reservoir of calcium and phosphate 
based minerals [2, 3]. Also, the increase in the number of knee and hip replacement surgeries 
over the past few years together with the limitations of current treatment methods such as 
autografts, allografts, metallic and ceramic implants have contributed to the increase in the 
importance of bone tissue engineering [4]. 
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As mentioned earlier, cells, scaffold and growth factors are the three basic and important 
components of tissue engineering. As far as bone tissue engineering studies are concerned, the 
cells that can be used are differentiated cells such as osteoblasts or undifferentiated cells such as 
mesenchymal stem cells. Bone morphogenetic proteins (BMPs), transforming growth factor beta 
(TGF-β), fibroblast growth factors (FGFs), insulin growth factor I and II (IGF I/II) and platelet 
derived growth factors (PDGF) are some examples of growth factors that have been used for 
bone tissue engineering studies [4]. Scaffolds are the three dimensional porous structures that 
form a critical part of tissue engineering studies. Although there have been studies involving the 
use of ceramics such as hydroxyapatite for the preparation of scaffolds, most of the bone tissue 
engineering studies involve the use of polymers (natural and synthetic) and fillers such as 
hydroxyapatite, bioactive glass for the preparation of composite scaffolds. Biocompatibility, 
biodegradability, high porosity, adequate pore size (100-500 µm), interconnected pores and 
adequate mechanical properties are the basic requirements of a scaffold for tissue engineering 
applications. On the basis of studies done in the past, it can be understood that biocompatibility 
and biodegradability can be controlled by the choice of polymers (natural or synthetic) whereas 
the scaffold architecture (porosity, pore size and interconnectivity of pores) can be controlled by 
the use of an appropriate processing technique. One of the most important challenges in bone 
tissue engineering is the development of scaffolds with appropriate mechanical properties. The 
mechanical properties of a scaffold are supposed to be an outcome of the combination of factors 
such as materials used in the fabrication of scaffolds and the scaffold architecture. The overall 
success of a scaffold for tissue engineering applications depends on attaining a balance of the 
basic requirements for a scaffold mentioned earlier that further adds to the challenges associated 
with tissue engineering.  
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The purpose of scaffold in tissue engineering is to create an environment that is similar to 
the in vivo environment that favors the growth of cells and subsequent formation of a tissue. 
These scaffolds are intended to mimic the structure of the extracellular matrix since the cells 
respond to the mechanical properties, chemical properties and the structural features of the 
extracellular matrix [5, 6]. As far as bone tissue is concerned, the osteoblasts are sensitive to the 
mechanical and chemical signals that are conveyed through the intercellular interactions and the 
interactions between the cells and the surrounding extracellular matrix. Further, the connections 
in between the osteocytes and between the osteoblasts and osteocytes are supposed to form a 
three dimensional network responsible for transduction of mechanical stimuli and thus affect 
bone homeostasis [7]. Since the cells are supposed to attach, grow and form a tissue on the 
scaffold, it is necessary that the proper mechanical signals are relayed between the cells and the 
substrate constituting the structural features of the scaffold for proper tissue regeneration. 
Besides this, the scaffold should have adequate overall mechanical properties for bearing the 
weight of the regenerating tissue. Thus, it appears that the mechanical properties of the scaffold 
should be adequate from a lower scale to a higher scale for its optimum performance.  
It has already been mentioned that the mechanical properties of the scaffold can be 
modulated by the proper choice of the materials or the fabrication technique that affects the 
scaffold architecture. Polymeric materials of natural or synthetic origin can be used for the 
preparation of composite scaffolds. Natural polymers possess molecule sequences that are 
similar to the sequences found in the extracellular matrix macromolecules that favor cell 
attachment but are limited by possibilities of batch-to-batch variation and lack of control over 
their properties. On the other hand, the properties of synthetic polymers can be controlled by 
introducing proper functional groups using different synthesis routes but they lack the molecule 
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sequences that are found in the macromolecules present in the extracellular matrix [8, 9]. Some 
examples of natural polymers that have been used for bone tissue engineering studies are 
chitosan [10, 11], collagen [12, 13], cellulose [14, 15], starch [16, 17] and silk fibroin [18, 19]. 
Aliphatic polyesters such as poly (lactic-co-glycolic acid) (PLGA) [20] and poly (lactic acid) 
(PLA) [21], polycaprolactone [22], polyphosphazene [23], poly (propylenefumarate) [24] are 
some examples of synthetic polymers that have been used previously for studies related to bone 
tissue engineering. Hydroxyapatite and bioactive glass are the fillers that have been extensively 
used for the preparation of composite scaffolds used for bone tissue engineering studies due to 
their osteoconductive properties. Electrospinning, freeze-drying preceded by phase separation 
and particulate leaching are some of the methods that are used for the fabrication of scaffolds. 
The electrospinning process is useful for preparing fibers having dimensions that fall in the range 
of extracellular matrix proteins but is limited by the use of organic solvents and difficulties in 
producing a uniform porous structure. The freeze-drying method preceded by phase separation is 
useful for producing scaffolds of varying size and shape having morphologies that can be 
controlled by varying the freezing temperature and concentration of polymer solutions. 
Particulate leaching is useful for preparing scaffolds with specific pore size and porosity but 
involves use of organic solvents and difficulties in obtaining interconnected pores.  
The challenge of developing scaffolds with adequate mechanical properties presents a 
unique problem in the field of tissue engineering due to the dependence of the mechanical 
properties of a scaffold on several factors mentioned earlier. There seem to be two possible ways 
to overcome this problem; viz., by creating hierarchical structures from the molecular scale to  
the macroscale same as those that are supposed to be present in the extracellular matrix or by 
using nanosized fillers to create polymer composite scaffolds [5, 25]. Due to the very low 
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probability of completely mimicking the hierarchical structures present in the extracellular 
matrix, strategies that involve the fabrication of nanofibrous composites containing nanosized 
fillers may prove useful. Electrospinning, polyelectrolyte complexation and self-assembly 
methods involving the use of nanosized fillers mixed with polymers may be used for this 
purpose. Various studies have suggested that polymer nanocomposites containing nanosized 
fillers can prove to be useful not only to get a favorable cell response but also for achieving 
adequate mechanical properties [5, 25, 26]. Polymer-clay nanocomposites (PCNs) seem to 
possess tremendous potential with regard to the aspect of achieving adequate mechanical 
properties. The work on the use of montmorillonite (MMT) clay for the preparation of PCNs was 
pioneered by the Toyota research group in 1990 when they reported significant improvement in 
mechanical properties of the PCNs composed of low MMT clay loadings [27]. Subsequently, 
MMT clay was used for the preparation of PCNs in various studies that reported increase in 
mechanical properties [28-33], decrease in gas permeability [34, 35] and flammability [36, 37] 
and effect on biodegradability [38] after the addition of MMT clay. MMT clay is a layered 
silicate with one octahedral sheet between two tetrahedral sheets in each layer and thickness of 
each layer in the nanometer range that contributes to its high aspect ratio [38]. According to the 
traditional view, the observed increase in the mechanical properties of nanocomposites has been 
attributed to the high aspect ratio of the MMT clay sheets that leads to the increase in polymer-
filler interactions. Various experimental and simulation studies carried out in our group led to the 
development of an “altered phase model” that attributed the enhancement in the mechanical 
properties of the PCNs to the formation of “altered phase” having different crystallinity and 
elastic properties due to the molecular level interactions between the modifier, clay and the 
polymer [39]. In one of the previous simulation studies carried by our group, it was also found 
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that the attractive interactions between the functional groups of a modifier and the polymer 
accompanied by the repulsive interactions between the polymer backbone and the modifier were 
responsible for the change in crystallinity and an increase in the nanomechanical properties of 
PCNs [40].  
Modifiers are organic molecules that are used to modify the clay to increase the 
miscibility of clay in the polymer. The backbone chain length and the functional groups present 
in the modifier affect the d-spacing of the clay [41]. Also, it was found in this study that the 
backbone chain length of the modifier has more influence on the d-spacing of the clay than the 
functional groups present in the modifier. In addition to this, the potential of intercalating MMT 
clay with amino acids was brought forth by previous simulation studies carried out in our group 
[41]. The medicinal property of MMT clay such as its ability to adsorb various types of toxins 
and its ability to cross the gastrointestinal barrier [42-46] along with its drug-carrying and drug-
delivery abilities [47-51] encourage its use for tissue engineering applications. It has been 
reported that these clays are excreted from the body since they are unable to be absorbed by the 
intestinal tract and they can also be dissolved by the acids present in the stomach or the bowel 
[52] . In addition to this, clays have also been used as an oral laxative and as an antidiarrhoeal 
[52]. These findings imply that clay can be suitable for tissue engineering applications where it is 
necessary that the degradation products obtained from the scaffold materials are excreted without 
having any adverse effect on the normal body functions.  
The modifiers used in our previous studies were used for modification of MMT clay that 
was further used for the preparation of PCNs intended for structural applications and hence they 
were not investigated for their biocompatibility. So, on the basis of the results obtained from our 
previous studies and reported antibacterial activity we chose three unnatural amino acids having 
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a longer backbone chain length as compared to the natural amino acids for modifying the MMT 
clay [53]. It was found that the three unnatural amino acids were able to intercalate the MMT 
clay and these unnatural amino acid modified clays were biocompatible. Further, it was observed 
that the MMT clay modified with 5-aminovaleric acid had better biocompatibility amongst the 
modified clays along with an increase in interlayer spacing of 2.779 Aº and therefore it was 
further used for preparing polymer composite films. It was found that the human osteoblast cells 
were able to adhere on these polymer composite films [53]. 
The use of montmorillonite clay for bone tissue engineering applications needs to be 
investigated further. Among the few studies that have been previously carried out earlier, MMT 
clay was used for preparing nanocomposites to study the effect of clay addition on the 
mechanical properties of polymers such as chitosan [54], polycaprolactone [55] and gelatin [56] 
to explore their potential for biomaterial applications. There have also been few studies focused 
on the use of MMT clay for preparing nanocomposites for tissue engineering applications [51, 
57]. But the use of MMT clays modified with unnatural amino acids in the preparation of 
polymer composite scaffolds for bone tissue engineering does not seem to have been reported 
elsewhere.  
In the present work, we used MMT clay modified with 5-aminovaleric acid for the 
preparation of polymer composite scaffolds for bone tissue engineering studies. The choice of 
the MMT clay modified with 5-aminovaleric acid was based on the results obtained from our 
previous studies that showed that MMT clay modified with 5-aminovaleric had increased d-
spacing and slightly better biocompatibility than the other two modified MMT clays [53]. 
Polyelectrolyte system consisting of chitosan and polygalacturonic acid was used for the 
preparation of composite scaffolds based on the properties of these polymers that are favorable 
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for tissue engineering applications. Chitosan (Chi) is a natural polymer known for its 
biocompatibility, antimicrobial activity, wound healing ability and minimal foreign body 
reaction [58]. Polygalacturonic acid is a de-esterified form of pectin found in the cell walls of 
plants and is known to be favorable for cell adhesion and proliferation [59]. The choice of these 
polymers in the present study was also based on our previous studies related to chitosan-
polygalacturonic-hydroxyapatite composite scaffolds [60, 61]. This study is based on the 
hypothesis that scaffolds containing unnatural amino acid modified clay are capable of providing 
a favorable environment for adhesion and proliferation of osteoblasts (bone cells) and can also 
have enhanced mechanical properties due to addition of modified MMT clay. Fabrication of 
ChiPgA scaffolds containing 5-aminovaleric acid modified clay, characterization of fabricated 
clay based scaffolds and studying the biocompatibility of these clay based scaffolds with 
osteoblasts were the objectives of this study. The polymer composite scaffolds fabricated in this 
study were studied for their biocompatibility using the MTT assay and were further characterized 
by scanning electron microscopy (SEM). FTIR studies, studies to determine the swelling ratio 
and porosity were also carried out to further characterize the composite scaffolds containing 
modified MMT clay.  
3.2. Materials and Methods 
3.2.1. Materials 
Polymers such as chitosan (≥ 85 % deacetylated, molecular weight 190000-310000) and 
polygalacturonic acid (approx. 95 % enzymatic, molecular weight 25000-50000) were bought 
from Sigma Aldrich. 5-aminovaleric acid used for modifying the montmorillonite clay was also 
obtained from Sigma Aldrich. Na-montmorillonite (Na-MMT) (Swy-2, Crook County, WY) clay 
having a cationic exchange capacity of 76.4 mequiv/100g was procured from the Clay Minerals 
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Repository at the University of Missouri, Columbia, Missouri. The raw materials used for the 
preparation of synthetic hydroxyapatite (HAP) such as sodium phosphate (Na2HPO4) and 
clacium chloride (CaCl2) were obtained from J.T. Baker and EM Sciences respectively. HyQ 
Dulbecco’s modified Eagle’s medium (DMEM)-12 (1:1) from Hyclone, G418 antibiotic from JR 
scientific and fetal bovine serum (FBS) from American Type Culture Collection (ATCC) were 
used for the preparation of cell culture medium. Human osteoblast cells (cell line number-CRL 
11372) were also obtained from ATCC for cell culture experiments.  
3.2.2. Modification of Na-MMT Clay 
The detailed procedure for modifying Na-MMT clay with 5-aminovaleric acid has been 
documented elsewhere [53]. The procedure can be summarized as follows:  
A suspension of Na-MMT clay was prepared by dispersing Na-MMT clay in deionized water at 
60°C and a solution of 5-aminovaleric acid in deionized water having pH 1.8 was added to the 
Na-MMT clay suspension at 60°C. The resulting mixture of clay and amino acid solution was 
stirred vigorously for 1 hour followed by centrifuging, washing, drying, grinding and sieving to 
get a fine powder of MMT clay modified with 5-aminovaleric acid.  
3.2.3. Preparation of Hydroxyapatite 
Synthetic hydroxyapatite (HAP)  was prepared by using a wet precipitation method 
described elsewhere [62]. According to this method, a liter of CaCl2 solution (19.9 mM) was 
added to a liter of Na2HPO4 solution (11.9 mM) at a pH of 7.44 followed by stirring for 12 hours 
and subsequent drying of the precipitate obtained after centrifuging. The dried precipitate was 
further ground and then sieved to obtain a powder of synthetic hydroxyapatite.  
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3.2.4. Preparation of Chitosan/Polygalacturonic Acid (ChiPgA) Composite Scaffolds 
The preparation of ChiPgA composite scaffolds was based on a method reported 
previously [60, 61]. Separate solutions of chitosan and polygalacturonic acid solutions were 
prepared in deionized water. Acetic acid and diluted sodium hydroxide solution were used for 
dissolving chitosan and polygalacturonic acid respectively. ChiPgA polyelectrolyte solution was 
prepared by adding chitosan solution dropwise to the polygalacturonic acid solution followed by 
sonication. This was followed by addition of MMT clay modified with 5-aminovaleric acid and 
synthetic HAP (both dispersed in deionized water separately by sonication) to the resultant 
ChiPgA polyelectrolyte solution to obtain the ChiPgA composite solution. The ChiPgA 
composite solution was then frozen at -20°C and then freeze dried at -85°C, 200 mtorr pressure. 
Porous scaffold was obtained after freeze drying of the ChiPgA composite scaffold. ChiPgA 
composite scaffolds having four different compositions were prepared;, viz., ChiPgA (0 wt % 
HAP + 0 wt % clay modified with 5-aminovaleric acid), ChiPgAHAP ( 20 wt % HAP + 0 wt % 
clay modified with 5-aminovaleric acid), ChiPgAMMT (0 wt% HAP + 10 wt % clay modified 
with 5-aminovaleric acid) and ChiPgAHAPMMT (20 wt % HAP + 10 wt % clay modified with 
5-aminovaleric acid).  
3.2.5. Characterization 
3.2.5.1. MTT Assay 
In MTT assay, a yellow colored dye known as (3-(4, 5 dimethylthiazol-2)-2, 5-
diphenyltetrazolium bromide) is reduced by the action of a dehydrogenase enzyme to a purple 
colored product known as formazan. This purple colored formazan is solubilized and the 
intensity of this purple colored solubilized formazan is read by using a spectrophotometer. The 
intensity values obtained from the spectrophotometer indicate the number of live cells. For 
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performing MTT assay, scaffolds of four different compositions as mentioned earlier were used. 
Triplicate scaffold samples of each composition were separately placed in wells (e.g. 3 samples 
of scaffolds containing 10 wt % modified clay in 3 different wells) of 24-well polystyrene plates 
and sterilized under ultraviolet light for 2 hours. After sterilization, 0.4 ml cell culture medium 
was added to each well of the plate containing the scaffolds followed by incubation for 2 hours at 
37°C, 5 % CO2. 2 x 10
5 human osteoblast cells (passage # 6) were then seeded on these scaffolds 
and 0.4 ml of cell culture medium was subsequently added. The cell seeded scaffolds were then 
incubated at 37°C, 5 % CO2 for a period of 3 days and 12 days. Then the scaffolds were washed 
with phosphate buffer saline (PBS) solution after the removal of cell culture medium. 
Subsequently, 600 µL fresh cell culture medium and 60 µL MTT solution (5 mg/mL PBS) were 
added followed by incubation at 37°C, 5 % CO2 for 4 hours. The resulting medium was then 
replaced by 0.7 ml dimethyl sulfoxide (DMSO) followed by incubation at 37°C, 5 % CO2 for 4 
hours. Absorbance readings were then taken at 570 nm using a spectrophotometer. Three 
readings were obtained for each scaffold sample. The complete cell culture medium used for this 
assay was made by adding 0.6 ml G418 antibiotic to a mixture of HyQ DMEM (90 %) and FBS 
(10 %).  
3.2.5.2. Fourier Transform Infrared (FTIR) Spectroscopy Studies 
Photoacoustic FTIR experiments were carried out on ChiPgA composite scaffolds of four 
different compositions; viz. ChiPgA, ChiPgAHAP, ChiPgAMMT and ChiPgAHAPMMT 
mentioned earlier. ThermoNicolet, Nexus 870 spectroscopy instrument equipped with MTEC 
model 300 photoacoustic accessory was used for performing these experiments. Linear 
photoacoustic spectra was collected after 1000 scans in the range of 4000-400 cm-1 range at a 
mirror velocity of 0.15 cm/s.  
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3.2.5.3. Scanning Electron Microscopy (SEM) studies 
Scanning electron microscopy (SEM) studies were carried out on dry ChiPgA, 
ChiPgAHAP, ChiPgAMMT and ChiPgAHAPMMT scaffolds to study the microstructure of the 
scaffolds using a JEOL JSM-6490LV scanning electron microscope. SEM imaging was also 
performed on the scaffolds seeded with human osteoblast cells. For this purpose, the cell-seeded 
scaffold samples after being incubated for the required time were washed with PBS and then the 
cells on these scaffolds were fixed using glutaraldehyde. The scaffold samples were then 
dehydrated in ethanol series (10, 30, 50, 70 and 100 % (v/v)) and then finally the 100% ethanol 
was substituted with hexamethyldisilazane (HMDS) before drying them. The dried scaffolds 
were then mounted, gold sputtered and imaged.  
3.2.5.4. Swelling Studies 
ChiPgA, ChiPgAHAP, ChiPgAMMT and ChiPgAHAPMMT scaffold samples 
(triplicates) were weighed and then immersed in phosphate buffer saline (PBS, pH 7.2). The 
scaffolds immersed in PBS were further incubated at 37°C for 6 hours, 12 hours and 24 hours. 
The scaffold samples were then removed and weighed. Three samples each were used for the 
scaffolds of four different compositions used in these studies. The swelling ratio was calculated 
according to the following formula: 
swelling ratio = (W-W0) / W0 x 100,  
where, W= weight of dry scaffold, W0= weight of wet scaffold 
3.2.5.5. Determination of Porosity 
The porosity of the scaffolds was determined by calculating the apparent density of the 
scaffold samples (quadruplicates) and the solid density of the composite. The apparent density of 
the scaffolds was calculated by measuring the mass and the density of the scaffolds and further 
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using the equation ρ = mV-1, where m represents the mass of the scaffolds and V represents the 
volume of the scaffolds. The porosity of the scaffolds was further calculated by using the 
following formula: 
Porosity = (1- ρ /ρs), where ρ = apparent density, ρs= solid density 
The values for density of the solid composite are shown in Table 3.2. 
3.2.5.6. Mechanical Properties 
For determining the compressive mechanical properties, the ChiPgA composite scaffold 
samples [sextuplicates (n = 6)] of different compositions were compressed at 1 mm/min using 
MTS 858 materials testing servo- mechanical test frame (Materials Testing Solutions, Eden 
Prairie, MN, USA). The scaffold samples used for compression testing had diameter of 10 mm 
and length 10 mm. The compressive elastic modulus for the scaffolds was calculated from the 
slope of the initial linear region of the stress-strain curve. 
3.2.5.7. Statistical Analysis 
 One-way ANOVA was used for performing statistical analysis and probability values less 
than 0.05 (p < 0.05) were considered statistically significant. Analysis was performed using 
Minitab software.  
3.3. Results and Discussion 
3.3.1. MTT Assay 
Figure 3.1. shows the results obtained from MTT assay done on ChiPgA, ChiPgAHAP, 
ChiPgAMMT and ChiPgAHAPMMT scaffolds. These results indicate that the human osteoblast 
cells are able to live and grow on the ChiPgA composite scaffolds. Interestingly, it can be seen 
from these results that the number of live cells (indicated by absorbance values) in case of 
ChiPgA scaffolds containing MMT clay modified with 5-aminovaleric acid is comparable to 
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ChiPgA scaffolds containing only hydroxyapatite (HAP) known for its osteoconductive 
properties. After 12 days culture, ChiPgA composite scaffolds containing modified MMT clay 
and hydroxyapatite (HAP) show statistically higher absorbance values (proportional to cell 
numbers) compared to ChiPgA scaffolds without modified clay or HAP. Absorbance values for 
scaffolds containing only modified MMT clay and only HAP were comparable with each other. 
ChiPgA scaffolds containing both modified MMT clay and HAP showed statistically higher 
absorbance values compared to ChiPgA scaffolds, ChiPgA scaffolds containing only modified 
MMT clay and only HAP. Differences between absorbance values observed after 3 days and 12  
days culture were statistically significant except for ChiPgA scaffolds. The ChiPgA scaffolds 
containing MMT clay modified with 5-aminovaleric acid (ChiPgAMMT and ChiPgAHAPMMT) 
appear to be biocompatible and seem to provide an environment favorable for the growth of 
human osteoblast cells. 
 
Figure 3.1. Comparative plot of results obtained from MTT assay on ChiPgA based composite 
scaffolds. (description of this plot given under section 3.3.1) 
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3.3.2. Photoacoustic Fourier Transform Infrared Spectroscopy (PA-FTIR) 
Figure 3.2. (a,b) shows the spectra obtained from PA-FTIR experiments done on the 
ChiPgA composite scaffolds of four different compositions. Figure 3.2. (a) shows the spectra 
obtained in the 4000-400 cm-1 range from the scaffolds of different compositions. The bands 
from the functional groups present in chitosan (Chi) and polygalacturonic acid (PgA) and the 
bands from hydroxyapatite and MMT clay are supposed to be present in the lower region of the 
spectra and therefore spectral region from 1925-430 cm-1 wavenumber is presented in Figure 3.2. 
(b). Bands are observed close to the positions 1597 cm-1 and 1412 cm-1 in the PA-FTIR spectra 
of all ChiPgA composite scaffold samples that correspond to the asymmetric and symmetric 
stretching of dissociated carboxylic groups present in PgA. Also, bands are seen near the 1522 
cm-1 position in the spectra of all the ChiPgA composite scaffolds that corresponds to the NH3
+ 
vibration and appear to come from chitosan due to conversion of –NH2 to –NH3+. The presence 
of bands corresponding to dissociated carboxylic groups and NH3
+ vibration in the spectra of the 
ChiPgA composite scaffolds is indicative of formation of a polyelectrolyte complex between 
chitosan and polygalacturonic acid. The phosphate bands are known to be present in the region 
around 1000 cm-1 region, but these seem to be overlapped by the bands arising from vibrations of 
C-O-C glycosidic linkages in chitosan and polygalacturonic. This makes it is difficult to identify 
the phosphate bands from hydroxyapatite (HAP) in the ChiPgA composite scaffolds containing 
HAP. The bands seen near 566 cm-1 in case of ChiPgA composite scaffolds containing HAP are 
absent in case of ChiPgA composite scaffolds not containing HAP and are attributed to the OPO 
bending of phosphate present in HAP. Also, the bands around 527 cm-1 and 468 cm-1 present in 
case of ChiPgAMMT and ChiPgAHAPMMT scaffolds are not present in ChiPgA and 
ChiPgAHAP scaffolds and these band positions appear to correspond to the Si-O-Al and Si-O-Si 
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vibrations from MMT clay modified with 5-aminovaleric acid. From the PA-FTIR spectra of the 
scaffolds, it can be said that MMT clay modified with 5-aminovaleric acid was successfully 
incorporated in the ChiPgA polyelectrolyte based scaffold system. The band assignments for 
band positions shown in Figure 3.2. are shown in Table 3.1. 
 
 
Figure 3.2. PA-FTIR spectra of ChiPgA based scaffolds: a) in the 4000-400 cm-1 region and b) 
in the 1925-430 cm-1 region 
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Table 3.1. PA-FTIR band assignments for ChiPgA composite scaffolds 
 
Wavenumber (cm-1) Band assignment 
ChiPgA ChiPgAHAP ChiPgAMMT ChiPgAHAPMMT 
1666 1665 1665 1665 Amide I bands from acetamide 
group of chitosan 
1597 1599 1599 1597 Antisymmetric stretching of 
COO-1 group 
1522 1524 1520 1524 Assymetric NH3
+ deformation 
vibration 
1412 1418 1416 1414 Symmetric stretching of 
carbonyl from COO-1 group 
1322 1325 1325 1323 CH bending vibrations of the 
ring 
1152 1153 1155 1155 C-O-C in glycosidic linkage 
1102 1101 1103 1103 C-O-C in glycosidic linkage 
1015 1012 1014 1014 Skeletal vibrations involving 
C-O stretching 
953 954 952 954 Symmetrical ring vibration of 
pyranose  
892 893 891 893 CH deformation vibration of 
β-pyranose 
831 829 834 831 CH deformation vibration of 
pyranose 
638 640 642 640 OH out of plane bending 
- 566 - 564 γ4  O-P-O bending 
- - 527 528 Si-O-Al vibration from clay 
- - 467 468 Si-O-Si bending from clay 
 
3.3.3. Scanning Electron Microscopy (SEM) Studies 
Figure 3.3. (a-d) show the scanning electron microscopy (SEM) images of ChiPgA, 
ChiPgAHAP, ChiPgAMMT and ChiPgAHAPMMT scaffolds. The microstructure of these 
scaffolds appears to be different from each other despite the same processing method being the 
same for the fabrication of these scaffolds. The SEM images of ChiPgAMMT and 
ChiPgAHAPMMT scaffolds show a different microstructure as compared to the microstructure 
of ChiPgA and ChiPgAHAP scaffolds. Compartment like features are seen in the microstructure 
of ChiPgAMMT and ChiPgAHAPMMT scaffolds. This implies that addition of MMT clay 
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modified with 5-aminovaleric acid has an effect on the microstructure of ChiPgA scaffolds. 
Figures 3.4. (a-d) show the SEM images of ChiPgA, ChiPgAHAP, ChiPgAMMT and 
ChiPgAHAPMMT scaffolds with human osteoblast cells. It can be seen from these images that 
the human osteoblast cells are able to grow in these scaffolds. In case of ChiPgA scaffolds, the 
cells appear to have a round morphology whereas the cells have a relatively flat morphology in 
case of ChiPgAHAP, ChiPgAMMT and ChiPgAHAPMMT scaffolds. In some cases, the cells 
are flat and also appear to take the shape of the substrate constituting the scaffold pore walls.   
 
 
Figure 3.3. SEM image of a) dry ChiPgA scaffold, b) dry ChiPgAHAP scaffold, c) dry 
ChiPgAMMT scaffold, d) dry ChiPgAHAPMMT scaffold 
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Figure 3.4. SEM image of a) ChiPgA scaffold seeded with human osteoblasts, b) ChiPgAHAP 
scaffold seeded with human osteoblasts, c) ChiPgAMMT scaffold seeded with human 
osteoblasts, d) ChiPgAHAPMMT scaffold seeded with human osteoblasts. Arrows (black color) 
indicate osteoblasts having spherical morphology and flat morphology (conforming to the 
scaffold pore walls and bridging the pores)  
 
3.3.4. Swelling Studies 
Figure 3.5. shows the plot of results obtained from swelling studies done on ChiPgA 
composite scaffolds. Statistically significant differences in swelling ratios were observed after 6 
hours between ChiPgA scaffolds without any fillers (modified MMT clay, HAP) and ChiPgA 
composite scaffolds containing HAP, modified MMT clay or both. Swelling ratios for ChiPgA 
and ChiPgAHAP scaffolds after 12 hours showed statistically significant differences compared 
to swelling ratios obtained after 6 hours. Overall, it appears that the extent of change in the 
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swelling ratio is higher in case of ChiPgA and ChiPgAHAP scaffolds from 6 hours of immersion 
time to 12 hours of immersion time than the extent of change in swelling ratio from 12 hours of 
immersion time to 24 hours of immersion time. Also, it can be seen that the swelling ratio of 
ChiPgAHAPMMT scaffolds does not appear to change much over an immersion time of 24 
hours as compared to the ChiPgA, ChiPgAHAP and ChiPgAMMT scaffolds. Besides this, the 
swelling ratio of ChiPgAMMT and ChiPgAHAPMMT scaffolds appears to be comparable to 
ChiPgA and ChiPgAHAP scaffolds after 12 hours and 24 hours of soaking time. This indicates 
that the addition of MMT clay known for its high swelling capacity does not affect much the 
swelling ratio of ChiPgAMMT and ChiPgAHAPMMT scaffolds after soaking time of 6 hours. 
The swelling capacity of the ChiPgA composite scaffolds indicates that the cells and the 
nutrients can reach the interior parts of these scaffolds. 
 
 
Figure 3.5. Comparative plot of results obtained from swelling studies on ChiPgA based 
scaffolds. (description for plot given under section 3.3.4.) 
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3.3.5. Porosity of Scaffolds 
Figure 3.6. shows a comparative plot of the ChiPgA composite scaffolds. It can be seen 
from these plots that all the four different scaffolds have porosities greater than 90 percent. This 
satisfies the need of high porosity for scaffolds in tissue engineering applications. It is known 
that a scaffold needs to have high porosity for effective transport of nutrients throughout the 
scaffold and also for developing adequate vasculature around a regenerating tissue.  
Table 3.2. Apparent and solid density values of ChiPgA composites 
Property ChiPgA ChiPgAHAP ChiPgAMMT ChiPgAHAPMMT 
Apparent 
density 
0.02366 ± 
0.00173 
 
0.02385 ± 
0.00112 
 
0.02413 ± 
0.00180 
 
0.02434 ± 0.00257 
 
Solid 
density 
0.4651 ± 0.2031 
 
0.4849 ± 
0.1086 
 
0.6166 ±0.0387 
 
0.5335 ± 0.0114 
 
 
3.3.6. Mechanical Properties of Scaffolds 
 
Figure 3.7. represents a typical stress-strain curve obtained for ChiPgA, ChiPgAHAP,  
ChiPgAMMT and ChiPgAHAPMMT scaffolds. The stress-strain curve seems to have three 
regions; viz. initial linear region, a plateau region and densification region. According to Gibson 
and Ashby, such stress-strain curves are seen in the case of porous (cellular) materials [63]. They 
explained that the initial linear region is dependent on the bending of the cell (pore) walls. The 
plateau region results due to the collapse of the cells (pores). After the cells (pores) are 
completely collapsed, the opposing cell (pore) walls make contact with each other and further 
compress the solid that gives rise to the densification region where rapid stress increase is 
observed. Figure 3.8. shows a comparative plot of the compressive elastic moduli of ChiPgA 
based composite scaffolds. It can be seen that values of the compressive elastic modulus of 
ChiPgAHAP, ChiPgAMMT and ChiPgAHAPMMT scaffolds is in the 4-6 MPa range and higher 
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than that of ChiPgA scaffolds. Differences in elastic moduli values of ChiPgA and ChiPgA 
composite scaffolds were statistically significant. The high porosity of the ChiPgA composite 
scaffolds seems to have an effect on the mechanical properties of these scaffolds and hence the 
values of elastic moduli of the scaffolds are much less as compared to the compressive elastic 
modulus of cancellous bone (0.05-5 GPa). 
 
Figure 3.6. Comparative plot showing the percentage porosity of ChiPgA based scaffolds 
 
 
Figure 3.7. Typical stress-strain curve obtained from compression test on ChiPgA based 
scaffolds 
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Figure 3.8. Comparative plot of the compressive elastic moduli of the ChiPgA based scaffolds. 
Differences in elastic moduli values of ChiPgA and ChiPgA composite scaffolds were 
statistically significant.  
 
3.4. Conclusions 
Scaffolds based on chitosan/polygalacturonic acid (ChiPgA) complex containing 
montmorillonite (MMT) clay modified with 5-aminovaleric acid were successfully prepared by 
freeze-drying technique. The microstructure of the scaffolds containing the modified MMT clay 
was affected due to the addition of this modified clay as seen in the scanning electron 
microscopy (SEM) images. This was despite the same processing technique being used for the 
fabrication of all the ChiPgA scaffolds of different composition. Experiments related to the 
biocompatibility of the ChiPgA composite scaffolds showed that human osteoblast cells were 
able to live and grow in them. The MTT assay also indicated that the number of osteoblast cells 
in ChiPgA scaffolds containing the modified clay was comparable to ChiPgA scaffolds 
containing hydroxyapatite (HAP) known for its osteoconductive properties. Overall, the ChiPgA 
composite scaffolds were found to be biocompatible. This was also indicated by the SEM images 
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of the ChiPgA composite scaffolds seeded with human osteoblast cells. Photoacoustic-FTIR 
(PA-FTIR) experiments on the ChiPgA composite scaffolds indicated formation of a 
polyelectrolyte complex between chitosan and polygalacturonic acid. PA-FTIR studies also 
showed that the MMT clay modified with 5-aminovaleric acid was successfully incorporated in 
the ChiPgA based scaffolds.  
Swelling studies on ChiPgA composite scaffolds showed the swelling ability of the 
scaffolds that indicated that the cells and the nutrients would be able to reach the interior parts of 
the scaffolds. In addition to this, the ChiPgA scaffolds had a porosity greater than 90 percent that 
satisfies the requirement of high porosity for scaffolds used in tissue engineering studies. High 
porosity facilitates the nutrient transport throughout the scaffold and also plays a role in the 
development of adequate vasculature throughout the scaffold. Compressive mechanical tests on 
the scaffolds showed that the ChiPgA composite scaffolds had compressive elastic moduli in the 
range of 4-6 MPa and appear to be affected by the high porosity of the scaffolds.  
It can be thus said that the ChiPgA composite scaffolds containing MMT clay modified with 5-
aminovaleric acid are biocompatible. Also, the ChiPgA scaffolds containing the modified MMT 
clay appears to satisfy some of the basic requirements of scaffolds for tissue engineering 
applications. Although the compressive mechanical properties of the scaffold are lower as 
compared to cancellous bone, biocompatibility of the ChiPgA composite scaffolds containing 
MMT clay modified with 5-aminovaleric acid provides good scope for further optimizing the 
processing parameters to control the architecture of these scaffolds.  
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CHAPTER 4. NANOCLAYS WITH BIOMINERALIZED 
HYDROXYAPATITE FOR BONE REGENERATION 
This chapter presents the preparation of a novel three component nanoclay-
hydroxyapatite (HAP) hybrid using a processing route based on biomineralization in bone. This 
hybrid (also known as in situ HAPclay) prepared by mineralizing HAP in modified clay was 
characterized and further used for preparing biopolymer composites for bone regeneration. 
Details about in situ HAPclay characterization, use of in situ HAPclay for preparing biopolymer 
composites and studies related to the use of these prepared composites for bone regeneration are 
also presented in this chapter. The contents of this chapter have been published in Ambre, A.H., 
Katti, K.S., Katti, D.R. In situ Mineralized Hydroxyapatite on Amino Acid Modified Nanoclays 
as Novel Bone Biomaterials. Materials Science and Engineering C. 2011; 31: 1017-1029 
4.1. Introduction 
The introduction of tissue engineering by Langer and Vacanti [1] in the early 1990s 
explained how an interdisciplinary approach can be used for generating tissues to replace or 
repair damaged tissues. Besides this, Langer and Vacanti also put forth the idea of placing cells 
on porous structures known as “scaffolds” that serve as a guiding “template” for the generation 
of vascularized tissues. Most of the studies till date report the use of scaffolds based on 
polymeric or polymeric composite materials. This can be attributed to the ability to control the 
properties in case of synthetic polymers and the presence of biomolecule sequences favoring cell 
attachment in case of natural polymers. Moreover, the possibilities of controlling mechanical 
properties, cell behavior and subsequent tissue formation by incorporating fillers in polymers 
have made polymer composites an interesting subject for studies in tissue engineering.  In 
several studies related to bone tissue engineering, hydroxyapatite (HAP) has been used for the 
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preparation of polymer composite scaffolds due to its attributes such as osteoconductivity, non-
toxicity and non-immunogenecity. Similarly, bioactive glass and other calcium phosphate based 
compounds with variable compositions of calcium and phosphate, variable crystallinity and 
phases have also been for studies related to tissue engineering. The human bone consists of ions 
such as carbonate, sodium, fluorine, magnesium, zinc, silicon and aluminum along with 
hydroxyapatite [2]. Ions such as magnesium are supposed to affect the mineralization of bone 
whereas silicon ions are supposed to affect the bone formation rate and pattern [2]. Studies 
involving bioactive glasses indicate that silicon affects their surface reactions [3] and can also 
instigate bone formation [4]. The effect of various types of ions on cell behavior and bone tissue 
formation can be investigated by using minerals or ceramics containing ions such as carbonate, 
sodium, silicon, fluorine, magnesium, zinc and aluminum. There have been studies on the 
preparation and use of silicon substituted hydroxyapatite discs, granules and compacted powders 
for studying their effect on osteoblasts [5], their in vivo behavior [3] and bioactivity [6]. These 
studies indicate that the presence of silicon affects the cell behavior and tissue formation. 
Keeping in mind the tissue engineering approach, incorporation of fillers containing silicon, 
carbonate, sodium, magnesium, zinc to prepare polymer composite scaffolds can prove useful for 
regeneration of bone tissue. Also, developing scaffolds with adequate nanoscale (for scaffold 
walls) and macroscale (for the scaffold architecture) mechanical properties favorable for bone 
regeneration constitutes an important part of tissue engineering. The use of montmorillonite 
(MMT) clays for preparing polymer composite scaffolds may prove useful in this respect.  
Research related to polymer-clay nanocomposites (PCNs) since 1990 has shown that 
addition of MMT clay in small quantities can lead to an improvement in mechanical properties 
[7-10] and have an effect on properties such as gas permeability [11-13], flammability [14, 15] 
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and biodegradability. The effectiveness of MMT clay in affecting the various properties has been 
conventionally attributed to the high aspect ratio of MMT clay that increases the polymer-clay 
interactions. In order to get more insight into this effectiveness of MMT clay, several 
experimental and simulation studies done in our group led to the development of “altered phase” 
model. This model explains the formation of “altered phase” with different crystallinity and 
elastic properties as a result of molecular interactions between the three components; viz., 
polymer, clay and modifier [16]. A prior simulation study carried out in our group indicated that 
there are attractive interactions between the functional groups of a modifier and polymer. These 
interactions along with the repulsive interactions between the polymer backbone and the 
modifier affect the crystallinity and increase the nanomechanical properties of PCNs [17]. 
Besides this, the backbone chain length and the functional groups in modifiers (organic 
molecules) used to modify the clay have an effect on the d-spacing of clay and also the 
nanomechanical properties of PCNs [18].  
The medicinal properties of MMT clay [19] and studies related to its pharmaceutical 
applications [20-22] suggest that MMT clay may prove useful for tissue engineering 
applications. In addition to this, its ability to be excreted from the body and to be dissolved by 
acids present in the stomach emphasize its possible utility for tissue engineering applications. 
Polymer-clay nanocomposites based on chitosan, polycaprolactone and gelatin studied for 
biomaterial applications highlight the effect of addition of clay on mechanical properties of the 
resulting PCNs [23-25]. Studies related to the effect of addition of MMT clay on the behavior of 
cells have been very few [26, 27]. Therefore, it is necessary to enhance our understanding on the 
effect of addition of MMT clay to PCNs on the behavior of cells to extend the use of PCNs for 
tissue engineering applications. In our previous work, we used three unnatural amino acids as 
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modifiers for MMT clay on the basis of their backbone chain length and previous reports of 
antibacterial activity. Results obtained from this work showed that amongst the clays intercalated 
with the three amino acids, MMT clay modified with 5-aminovaleric acid had improved 
biocompatibility [28]. The MMT clay modified with 5-aminovaleric acid was used for preparing 
chitosan/polygalacturonic acid (ChiPgA) composite scaffolds in another study [29]. It was found 
that human osteoblast cells were able to proliferate on the ChiPgA composite scaffolds and the 
overall properties of these scaffolds indicated that these scaffolds satisfied some of the important 
requirements for tissue engineering applications.  
In case of bone tissue engineering, it is necessary to develop material systems that in 
addition to supporting the growth and proliferation of osteoblast cells also favor the formation of 
a bone tissue. Studies have indicated that materials with nanoscale features can be useful for 
eliciting a cellular response that would lead to bone formation [30]. Therefore, it is expected that 
the addition of nanosize fillers may prove advantageous for preparing polymer composites to be 
used for bone tissue engineering applications. The modification of nanosize MMT clay with 
organic molecules and its subsequent incorporation in PCNs has been found to be an effective 
method for improving the mechanical properties of PCNs. The use of HAP known for its 
osteoconductive properties for bone tissue regeneration has been demonstrated through several 
studies. Nanosize filler having properties of both MMT clay and HAP may prove useful for 
improving the mechanical properties and affecting the tissue regeneration capabilities of a 
polymer composite scaffold. As mentioned earlier, results from our previous study showed that 
polymer scaffolds containing modified MMT clay favored the growth of human osteoblast cells. 
In order to further improve the effectiveness of the modified clay for bone tissue engineering 
applications, synthesizing apatite or calcium phosphate based compound in the modified clay by 
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using the modified MMT clay as a kind of template may prove a useful approach. This approach 
can also be one of the ways of preparing nanosize fillers having properties of MMT clay and 
HAP. Non-collagenous proteins in bone such as osteocalcin, osteonectin, osteopontin, etc. are 
the possible sites of “biomineralization” in bone [31]. Likewise, the functional groups present in 
a modifier used for modifying MMT clay can possibly serve as sites for the growth of apatite or 
calcium phosphate based compound in clay. The schematic shown in Figure 4.1. explains the 
possible approach of growing apatite or calcium phosphate based compound in clay by using the 
functional groups of the modifier.  
 
Figure 4.1. Schematic of the possible approach used for growing apatite or calcium phosphate 
based compound in modified clay by using the functional groups of the modifier 
 
This work reports a novel method of synthesizing apatite using MMT clay modified with 
5-aminovaleric acid. The modified MMT clay with mineralized apatite named as in situ HAPclay 
was characterized by Fourier Transform Infrared Spectroscopy (FTIR) and X-ray diffraction 
(XRD). The in situ HAPclay was then used in the preparation of chitosan/polygalacturonic acid 
(ChiPgA) composite films. The ChiPgA system has been previously investigated in our group for 
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bone tissue engineering [32-35]. The response of the human osteoblasts on these films was 
studied by using inverted optical microscopy. The ChiPgA films containing in situ HAPclay 
were also characterized by FTIR. We hypothesize that in situ HAPclay synthesized by a novel 
method based on biomineralization in bone is capable of enhancing the osteoconductive 
properties and mechanical properties of polymer composites containing in situ HAPclay. Thus, 
the overall objectives of this work were synthesis of in situ HAPclay, characterization of in situ 
HAPclay using XRD and infrared spectroscopy and assessing osteoconductive properties of 
polymer composites containing in situ HAPclay through cell culture experiments involving bone 
cells (osteoblasts). 
4.2. Materials and Methods 
4.2.1. Materials 
SWy-2, Crook County, Wyoming sodium montmorillonite (Na-MMT) clay with a cation 
exchange capacity of 76.4 mequiv/100g from the Clay Minerals Repository at the University of 
Missouri, Columbia, Missouri was used in this study for experiments. The modifier 5-
aminovaleric acid was purchased from Sigma Aldrich. Sodium phosphate (Na2HPO4) from J.T. 
Baker and calcium chloride (CaCl2) from EM Sciences were used for preparing in situ HAPclay. 
Chitosan (≥ 85 % deacetylated, molecular weight 190000-310000) and polygalacturonic acid 
(approx. 95 % enzymatic, molecular weight 25000-50000) from Sigma Aldrich were used for the 
preparation of composite films. The complete cell culture medium was made from HyQ 
Dulbecco’s modified eagle’s medium (DMEM)-12 (1:1) from Hyclone, fetal bovine serum 
(FBS) from American Type Cell Culture Collection (ATCC) and G418 antibiotic from JR 
scientific. Human osteoblast cells (cell line number: CRL 11372) from ATCC were used for cell 
culture experiments. 
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4.2.2. Preparation of Modified MMT Clay 
5-aminovaleric acid was used for modifying MMT clay according to the procedure 
described in our previous work [28]. To summarize, 5-aminovaleric acid solution in deionized 
water having pH 1.8 was added to the Na-MMT clay suspension in deionized water at 60°C and 
the mixture obtained was vigorously stirred for 1 hour. This was followed by centrifuging, 
washing of the modified clay separated from deionized water by centrifuging to remove chloride 
ions, drying at 70°C, grinding and sieving for obtaining a fine powder of modified MMT clay.  
4.2.3. Synthesis of In Situ HAPclay and Hydroxyapatite (HAP) 
MMT clay modified with 5-aminovaleric acid according to procedure described in 4.2.2. 
was dispersed in 23.8 mM solution of Na2HPO4 in deionized water by stirring for 2 hours. A 
39.8 mM solution of CaCl2 in deionized water was added to the modified clay - Na2HPO4 
suspension. The pH of the resulting solution was maintained at 7.4 and this solution was further 
stirred for 8 hours. The subsequent precipitate obtained was allowed to settle for 24 hours and 
water over the settled precipitates was poured off. The water remaining in the precipitates was 
removed by centrifuging and the separated precipitate was further dried at 70°C. The dried 
precipitate was sieved through a 45 µm sieve after grinding to obtain a fine powder. This powder 
known as in situ HAPclay was used for further experiments.  
HAP was prepared on the basis of wet precipitation method reported in our previous 
studies [36]. For preparing HAP, 39.8 mM solution of CaCl2 was added to 23.8 mM solution of 
Na2HPO4. This was followed by stirring, settling of precipitates, centrifuging, drying and sieving 
to obtain HAP powder. 
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4.2.4. Preparation of Chitosan/Polygalacturonic Acid (ChiPgA) Composite Films 
Containing In Situ HAPclay 
The method for ChiPgA composite films containing in situ HAPclay used in this work is 
based on the method of preparing ChiPgA composite polyelectrolyte complexes that were used 
in our previous studies for preparing scaffolds [29, 32, 33]. For preparing the ChiPgA composite 
films containing in situ HAPclay in the present study, changes were made in the sequence of 
addition of in situ HAPclay as compared to our previous studies. A schematic of the procedure 
for preparing films is shown in Figure 4.2. Chitosan and polygalacturonic acid solutions were 
prepared in deionized water by using acetic acid to dissolve chitosan and diluted sodium 
hydroxide solution to dissolve polygalacturonic acid. In situ HAPclay was dispersed in deionized 
water by sonication and added to chitosan solution. The solution obtained was added dropwise to 
the polygalacturonic acid solution. This final solution of chitosan, in situ HAP clay and 
polygalacturonic acid was sonicated to obtain a ChiPgA composite solution containing in situ 
HAPclay. Films of different compositions consisting in situ HAPclay in the range of 10 wt % to 
20 wt % were prepared. For cell culture experiments, the ChiPgA composite solution was diluted 
with deionized water and the diluted solution was used for preparing composite films in tissue 
culture Petri dishes (60 mm OD x 15 mm H, growth area 19.5 cm2) by air drying at room 
temperature.  
4.2.5. Characterization 
4.2.5.1. Transmission FTIR Spectroscopy Studies 
Transmission FTIR spectroscopy studies were performed using powdered samples of 
MMT clay modified with 5-aminovaleric acid, in situ HAPclay and HAP. The powdered samples 
sandwiched between two silicon windows were placed in a universal sample holder for 
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performing the experiments. ThermoNicolet, Nexus, 870 spectrometer equipped with a KBr 
beam splitter was used for performing these experiments in the range of 4000-400 cm-1. Spectral 
resolution of 4 cm-1 and a mirror velocity of 0.158 cm/s for collecting 100 scans was used for 
each sample in these experiments.  
 
Figure 4.2. Schematic for preparing ChiPgA films containing in situ HAPclay (In situ HAPclay 
was prepared using MMT clay modified with 5-aminovaleric acid)  
 
Transmission FTIR spectroscopy studies were also performed on 
chitosan/polygalacturonic acid (ChiPgA) and ChiPgA composite films containing 12.5 wt % in 
situ HAPclay using the same instrument and sample holder as for the FTIR experiments on 
powdered samples. The spectral resolution and mirror velocity was also the same as for the FTIR 
experiments on powdered samples. 
4.2.5.2. X-ray Diffraction (XRD) Experiments 
XRD experiments were performed on powdered samples of MMT clay modified with 5-
aminovaleric acid, in situ HAPclay and HAP. X-ray diffractometer from Philips X’pert, Almelo, 
The Netherlands was used for these experiments. The diffractometer used for these experiments 
was equipped with a secondary monochromator and Cu-tube using CuKα radiation of 
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wavelength 1.54056 A°. The powdered samples were scanned in the range of 2θ= 2° to 60° at a 
scan rate of 0.3 min-1.  
4.2.5.3. Cell Culture Experiments 
The ChiPgA composite films obtained by air-drying the composite solution in Petri 
dishes (growth area 19.5 cm2) were sterilized by placing the Petri dishes with films (~ 4.986 cm 
diameter) under ultraviolet light for 1.5 hours. 3 x 105 human osteoblast cells (ATCC, CRL 
11372, passage # 9) were seeded on these films and 3 ml of complete cell culture medium was 
then added. The Petri dishes containing films seeded with human osteoblasts were then incubated 
at 37°C, 5 % CO2 for a cell culture period of 36 days (for films containing 10 wt % and 20 wt % 
in situ HAPclay). In case of osteoblast seeded films containing 12.5 wt % in situ HAPclay, cell 
culture period was 16 days and for osteoblast seeded films containing 15 wt % in situ HAPclay, 
cell culture period was 12 days. ChiPgA films containing different weight percent compositions 
of in situ HAPclay were used for cell culture studies considering the potential changes in 
mechanical properties (for films and scaffolds) and microstructure of scaffolds according to the 
content of in situ HAPclay. Mechanical properties and microstructure of scaffolds may have to 
be tailored according to the requirements at bone defect site by varying the in situ HAPclay 
content. Therefore ChiPgA films with different weight compositions of in situ HAPclay were 
used to show the suitability of films for cellular events favoring bone formation. The behavior 
(attachment, pattern/cluster formation) of the seeded cells was observed using an inverted 
microscope (Axiovert 40, Zeiss) after every 4 days during the cell culture period. Media was 
changed after every two days.  
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4.3. Results and Discussion 
4.3.1. Transmission FTIR Spectroscopy 
Figure 4.3. shows the transmission FTIR spectra of modified MMT clay, in situ 
HAPclay, mixture of modified MMT clay with HAP and hydroxyapatite (HAP) in the 4000-400 
cm-1 range. For further analysis of these spectra, regions with data limits from 4000-2000 cm-1 
and 2000-400 cm-1 were used. These regions of the spectra are shown in Figures 4.4. and 4.5.  
In Figure 4.4., it can be seen that the band positions 3568 cm-1 and 3571 cm-1 are seen in 
case of in situ HAPclay and HAP. These band positions correspond to the hydroxyl stretching 
bands observed in HAP [37]. The presence of the hydroxyl stretching band in in situ HAPclay 
indicates the formation of HAP in the modified MMT clay. The band positions at 3631 cm-1 and 
3628 cm-1 seen in the modified MMT clay and the (HAP + modified MMT clay) mixture 
correspond to the stretching of the structural –OH groups present in modified MMT clay. It can 
be seen that the band corresponding to the stretching of the structural –OH groups of modified 
MMT clay is not distinctly visible in in situ HAPclay. This seems to be because the band 
corresponding to the structural –OH group in modified MMT clay are masked by the stretching 
of the hydroxyl ions and the stretching of –OH in the water adsorbed in the interstices of HAP 
formed in the in situ HAPclay. Figure 4.5. shows the spectra in the 2000-400 cm-1 region for the 
powdered samples mentioned previously. The purpose of obtaining a spectrum of a mixture of 
modified MMT clay and HAP was to make more obvious the changes in band positions and 
appearance or disappearance of bands in case of in situ HAPclay. The presence of band at 1702 
cm-1 in modified MMT clay and at 1706 cm-1 in the (HAP + modified MMT clay) mixture can be 
attributed to the C=O stretching of the carboxylic group present in the amino acid. In the 
spectrum of in situ HAPclay, a broad band is seen around the 1623 cm-1 wavenumber position. 
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Figure 4.3. Transmission FTIR spectra of modified MMT clay, in situ HAPclay (in situ HAP 
prepared using modified clay), mixture of HAP and modified MMT clay and hydroxyapatite 
(HAP) in the 4000-400 cm-1 range 
 
Figure 4.4. Transmission FTIR spectra of modified MMT clay, in situ HAPclay (in situ HAP 
prepared using modified MMT clay), mixture of HAP and modified MMT clay and 
hydroxyapatite (HAP) in the 4000-2000 cm-1 range 
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Figure 4.5. Transmission FTIR spectra of modified MMT clay, in situ HAPclay (in situ HAP 
prepared using modified MMT clay), mixture of HAP and modified MMT clay and 
hydroxyapatite (HAP) in the 2000-400 cm-1 range 
 
The broad band around 1623 cm-1 indicates change in the chemical environment of the 
functional group that gives rise to the band at 1623 cm-1 and appears to overlap bands due to the 
vibrations of other functional groups in in situ HAPclay. The band at 1702 cm-1 that appears due 
to the C=O stretching of the carboxylic group seems to be shifted to a lower wavenumber 
position at 1541 cm-1 in case of in situ HAPclay. This shift is indicative of the dissociation of 
carboxylic group. Also, a band position at 1347 cm-1 is seen in case of in situ HAPclay. Band 
positions 1541 cm-1 and 1347 cm-1 can be attributed to the C=O asymmetric and symmetric 
vibrations in the dissociated carboxylic groups. During the preparation of in situ HAPclay the 
modified MMT clay is added to a solution of sodium phosphate that has a pH in the basic range. 
This possibly seems to favor the dissociation of the carboxylic group in the sodium phosphate 
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solution and these dissociated carboxylic groups seem to further interact with the calcium. The 
difference in the symmetric and asymmetric stretching vibration of the dissociated carboxylic 
group of 194 cm-1 in case of in situ HAPclay is an indication of chelation with calcium ions in 
the in situ HAPclay [38-40]. The presence of a free electron pair in the oxygen of dissociated 
carboxyl group and empty 3d orbitals in calcium ions favor chelation between the dissociated 
carboxyl group and calcium ions in the in situ HAPclay [41]. Also, the higher charge density of 
the calcium ions and greater tendency of the calcium ions to accept electrons favors chelation of 
these ions with the dissociated carboxyl group [42]. The formation of chelate between the 
carboxylate group and the calcium ions possibly plays an important role in the nucleation of 
hydroxyapatite [43]. A band position corresponding to the symmetric NH3
+ deformation 
vibration in modified MMT clay and in situ HAPclay is seen at 1499 cm-1. Thus, the  NH3
+ 
seems unlikely to be involved in interactions with calcium or phosphate in in situ HAPclay. The 
band positions seen in the spectra of modified MMT clay and mixture of modified MMT clay 
with HAP at 1287 cm-1 and 1281 cm-1 respectively are due to the OH deformation in the 
carboxylic group of amino acid. The absence of this band in the spectrum of in situ HAP clay is 
suggestive of further evidence of the dissociation of carboxylic group of amino acid. The 
vibrations associated with -CH2- deformation arising from the backbone of 5-aminovaleric acid 
are seen in the case of modified MMT clay in the 1465-1407 cm-1 region. These vibrations are 
also seen in case of mixture of modified MMT clay with HAP. In case of in situ HAPclay, these 
bands are also seen but are shifted to different wavenumber positions. These shifts indicate the 
involvement of 5-aminovaleric acid (modifier) in the formation of HAP in the modified MMT 
clay. 
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Band position 1634 cm-1 in HAP corresponds to the H-O-H deformation of adsorbed 
water in HAP. In case of in situ HAPclay, appearance of a band corresponding to the H-O-H 
deformation at 1634 cm-1 can thus be expected. But, it is seen that the band corresponding to H-
O-H deformation appears at 1623 cm-1 in in situ HAPclay (second derivative of the in situ 
HAPclay spectrum in Figure 4.6.). This may be due to the overlap of different bands around the 
1623 cm-1 region.  
 
Figure 4.6. Second derivative spectra of modified MMT clay, in situ HAPclay (in situ HAP 
prepared using modified MMT clay), mixture of HAP and modified MMT clay and 
hydroxyapatite (HAP) in the 2000-400 cm-1 range 
 
The region of the spectra from 1200 cm-1 to 400 cm-1 in Figure 4.5. shows spectral 
features that is useful for studying the changes that may take place in the Si-O vibrations of 
modified clay and also other vibrations such as Al-O, Al-Mg and Al-Fe vibrations. Also, this 
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region of the spectra provides information regarding the phosphate vibrations known to be 
present in hydroxyapatite. The bands at 1154 cm-1, 1143 cm-1 and 1144 cm-1 in the spectra of in 
situ HAPclay, mixture of modified MMT clay with HAP and HAP respectively correspond to the 
γ6 vibration of phosphate ion of HPO42- in hydroxyapatite. HPO42- has been found to enter into 
the crystal lattice of biological and synthetic apatites at specific sites in the lattice [36]. In case of 
in situ HAPclay, the position of the γ6 vibration of phosphate ion is at a higher wavenumber that 
may be due to the greater interaction of HPO4
2- with its neighboring chemical environment. This 
band corresponding to the γ6 vibration of phosphate ion of HPO42- is not seen in case of modified 
MMT clay. The band at 1130 cm-1 seen in modified MMT clay corresponds to the Si-O 
stretching vibration. This band appears to have shifted to a lower wavenumber position of 1119 
cm-1 that may be due to the non-bonded interactions with the calcium or phosphate ions in in situ 
HAPclay. The bands at 920 cm-1, 877 cm-1, 730 cm-1 and 783 cm-1 in in situ HAPclay indicate 
the presence of modified MMT clay. The band at 1016 cm-1 in in situ HAPclay can be attributed 
to the γ3 vibration of phosphate ion in HAP formed in in situ HAPclay. The band corresponding 
to the γ3 vibration of phosphate ion in HAP is seen at 1027 cm-1. The lower γ3 vibration 
frequency of phosphate ion in in situ HAPclay also indicates difference in the nature of 
molecular interactions and chemical environment of the phosphate ion in in situ HAPclay. Also, 
this may also due to the different symmetry of the hydroxyapatite formed in in situ HAPclay. 
Band corresponding to the γ4 phosphate vibration at 600 cm-1 in in situ HAPclay provides further 
evidence of presence of hydroxyapatite in in situ HAPclay. Presence of band corresponding to 
the γ4 phosphate vibration at 551 cm-1 at a lower wavenumber position compared to the position 
of the same type of vibration in hydroxyapatite at 570 cm-1 further indicates the difference in 
symmetry of hydroxyapatite formed in in situ HAPclay and nature of interactions of phosphate 
141 
 
ions with its surroundings. In case of in situ HAPclay, the difference in the symmetry of HAP 
formed in it may be due to the differences in its formation process as compared to the formation 
of hydroxyapatite (HAP). In the modified MMT clay, the functional groups of the modifier used 
are supposed to provide the sites of nucleation and growth in it. The symmetry of HAP grown at 
these sites would thus depend on the orientation of the functional groups of the modifier in the 
modified MMT clay. Also, the different type of ions in this grown hydroxyapatite may 
experience different chemical environments that may have an effect on their vibration 
frequencies. It is difficult to assign the band position 457 cm-1 observed in in situ HAPclay to the 
γ2 phosphate vibration since this band may be result of a shift of either the SiOSi deformation 
vibration (470 cm-1) seen in modified MMT clay or may be result of shift of phosphate vibration 
seen in hydroxyapatite (470 cm-1).  
On comparing the different spectra shown in Figure 4.5., it can be thus said that there are 
molecular level interactions between the functional groups of the modifier and the inorganic ions 
of the hydroxyapatite formed in it. As explained earlier, the shift of the C=O stretching vibration 
due to dissociation of carboxylic group, disappearance of band associated with OH deformation 
of carboxylic group and difference in the vibration frequencies of the phosphate ions as 
compared to the modified clay-HAP mixture and HAP are some of the obvious indicators of the 
molecular level interactions in in situ HAPclay. Figure 4.7. shows the transmission FTIR spectra 
of ChiPgA and ChiPgA films containing in situ HAPclay. For the purpose of further analysis, 
spectra in the regions 4000-2000 cm-1 and 2000-400 cm-1 have been presented in Figures 4.8. 
and 4.9. In Figure 4.9., a shoulder band at 1743 cm-1 in case of ChiPgA film indicates the 
presence of some undissociated carboxylic groups from PgA whereas in case of ChiPgA film 
containing in situ HAPclay no band is seen around 1743 cm-1 region. This indicates that almost 
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all the carboxylic groups are dissociated in case of ChiPgA film containing in situ HAPclay. The 
bands 1618 cm-1 and 1622 cm-1 in case of ChiPgA and ChiPgA film containing in situ HAPclay 
arise from the asymmetric stretching of the dissociated carboxylate groups. The bands at 1413 
cm-1 and 1429 cm-1 arise from the symmetric stretching of the dissociated carboxylate groups in 
ChiPgA and ChiPgA containing in situ HAPclay. The higher vibration frequency of symmetric 
stretching of the dissociated carboxylate groups in ChiPgA containing in situ HAPclay may be 
due to the interaction of these groups with in situ HAPclay. The occurrence of CH bending 
pyranose ring vibrations at 1331 cm-1 in case of ChiPgA film containing in situ HAPclay as 
compared to 1324 cm-1 in ChiPgA film also indicates interaction of the ChiPgA polyelectrolyte. 
Similarly, it is also observed that the pyranose ring vibration in ChiPgA film containing in situ 
HAPclay occurs at 772 cm-1 as compared to 760 cm-1 in ChiPgA which further implies presence 
of interactions between the polyelectrolyte and the in situ HAPclay. The overlap of the 
phosphate vibrations of in situ HAPclay expected to occur around the 1000 cm-1 region with the 
vibrations arising from the ring of ChiPgA polyelectrolyte makes band assignment of phosphate 
vibrations difficult in this region. The increase in the width of the band around 1000 cm-1 region 
in case of ChiPgA film containing in situ HAPclay as compared to the spectra of ChiPgA film 
seems to imply the overlap of bands arising from phosphate vibrations and the ring vibrations of 
the ChiPgA polyelectrolyte. Although, a weak band at 857 cm-1 in case of ChiPgA film 
containing in situ HAPclay is seen, it is difficult to say whether this band is due to the shift of the 
Mg-OH (877 cm-1) or FeOH (833 cm-1) vibration seen in case of in situ HAPclay. This band thus 
indicates the presence of in situ HAPclay. Similarly, the band at 466 cm-1 is also an indication of 
in situ HAPclay in the ChiPgA film. Tables 4.1.-4.4. give the FTIR band assignments. 
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Figure 4.7. Transmission FTIR spectra of ChiPgA film and ChiPgA film containing in situ 
HAPclay in the 4000-400 cm-1 range 
 
 
Figure 4.8. Transmission FTIR spectra of ChiPgA film and ChiPgA film containing in situ 
HAPclay in the 4000-2000 cm-1 range 
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Figure 4.9. Transmission FTIR spectra of ChiPgA film and ChiPgA film containing in situ 
HAPclay in the 1950-400 cm-1 range 
 
Table 4.1. FTIR band assignments for modified MMT clay 
 
Band position 
(cm-1) 
Band assignment Reference 
3738,3697,3631 OH stretching vibrations [44-46] 
1702 C=O stretching of undissociated carboxyl 
group 
[47] 
1618 H-O-H bending vibration of interlayer in 
modified MMT 
[46, 48] 
1499 NH3
+ vibration [47] 
1465, 1437, 
1409 
-CH2- deformation vibration [47] 
1287 -OH deformation of the carboxylic group [47] 
1222 Si-O out-of-plane stretching [46] 
1130 Si-O stretching [45, 46] 
1066 Si-O stretching [45, 46] 
1001 OH deformation linked to the cation [49] 
918 Al-OH deformation [45, 46, 50] 
879 Fe-OH deformation [45, 46] 
842 Mg-OH deformation [45, 46] 
799,777 Si-O stretching of quartz and silica [17, 45, 46] 
689 Si-O deformation [45, 46] 
630 Coupled Al-O and Si-O vibration [45, 46] 
526 Al-OSi deformation  [45] 
470 Si-OSi deformation [45] 
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Table 4.2. FTIR band assignments for in situ HAPclay 
Band 
position 
(cm-1) 
Band assignment Reference 
3739 H-O-H asymmetric  stretching of  water in HAP [51] 
3697 H-O-H symmetric   stretching of  water in HAP [52] 
3568 OH stretching of hydroxyl group in HAP [37, 51, 52] 
1623 H-O-H bending vibration of adsorbed water in HAP [53] 
1541 Asymmetric C=O stretching in dissociated carboxylic 
group 
[38] 
1499 symmetric NH3
+ deformation vibration [47] 
1458, 
1417 
-CH2- deformation vibration [47] 
1347 symmetric C=O stretching  in dissociated carboxylic 
group 
[47] 
1154 γ6 vibration of phosphate ion of HPO42- [53, 54] 
1016 γ3 phosphate vibration  [37] 
965 γ1 P-O stretching vibration of phosphate  [36, 37] 
920 Al-OH deformation [45, 46] 
877 Fe-OH deformation [45, 46] 
783 Si-O stretching of quartz and silica [45, 46] 
730 Si-O deformation perpendicular to optical axis [45] 
600 γ4 phosphate vibration [37] 
551 γ4 phosphate vibration [36, 37] 
 
Table 4.3. FTIR band assignments for hydroxyapatite (HAP) 
Band position 
(cm-1) 
Band assignment Reference 
3739 H-O-H asymmetric  stretching of  water in HAP [51] 
3696 H-O-H symmetric   stretching of  water in HAP [52] 
3571 OH stretching of hydroxyl group in HAP [37, 51, 52] 
1634 H-O-H bending vibration of adsorbed water in HAP [53] 
1144 γ6 vibration of phosphate ion of HPO42- [53, 54] 
1027 γ3 phosphate vibration  [37] 
951 γ1 P-O stretching vibration [36, 37] 
860 P-O(H) stretching vibration [36, 37] 
603 γ4 phosphate vibration [37] 
570 γ4 phosphate vibration [36, 37] 
470 γ2 phosphate vibration [36] 
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Table 4.4. FTIR band assignments for ChiPgA and ChiPgA in situ HAPclay composite film 
Band position 
(cm-1) 
Band assignment Reference 
2937,2933 Asymmetric C-H  stretching [47] 
2880,2877 Symmetric C-H stretching [47] 
1743 C=O stretching of undissociated carboxylic groups 
in PgA 
[34, 47] 
1657,1661 Amide I bands from chitosan  
1618,1622 Asymmetric stretching vibration of dissociated 
carboxyl group 
[34, 47] 
1530,1526 Asymmetric NH3
+ deformation vibration [47] 
1413,1429 Symmetric stretching of dissociated carboxylic 
group 
[34, 47] 
1324,1331 CH bending vibrations of the rings from ChiPgA [47] 
760,772 Pyranose ring vibration [47] 
643,645 OH out of plane bending [47] 
429 Mg-O vibration from modified MMT clay [45] 
 
4.3.2. X-ray Diffraction Studies 
Figure 4.10. (a, b) shows the XRD plots of modified MMT clay, in situ HAPclay and 
hydroxyapatite (HAP). A distinct peak corresponding to (001) plane is seen in case of modified 
MMT clay at 2θ position of 6.896° (d001=12.81 A°). In case of in situ HAPclay (Figure 4.10.b), 
this peak appears to have shifted to a higher 2θ position of 7.182° (d001=12.3 A°) that indicates a 
decrease of 0.51 A° in the d001 spacing of the modified MMT clay. This may be attributed to 
change in the interaction of the modifier molecules with the MMT clay sheets due to possible 
nucleation of apatite at the functional groups of the modifier. In the transmission FTIR spectra of 
in situ HAPclay, it was observed that the undissociated carboxylic group seen in case of 
modified MMT clay is absent in case of in situ HAPclay. FTIR spectra also indicated that these 
carboxylic groups had dissociated. The possible reason for the dissociation of carboxylic group 
was the dispersion of modified MMT clay in the basic sodium phosphate solution during 
preparation of in situ HAPclay. Therefore, the change in the interactions of modifier molecules 
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with the MMT clay sheets due to this dissociation can be supposed to be initiated when the 
modified clay is dispersed in sodium phosphate solution and continue during the nucleation of 
apatite after the addition of calcium chloride solution to the sodium phosphate solution. The 
involvement of carboxylic groups in chelation with the carboxylic groups as observed by FTIR 
studies also implies a change in the conformation of the carboxylic group. This can also 
contribute to the change in the interactions between the modifier and the MMT clay sheets. 
Moreover, our previous experimental and simulation studies have shown that the functional 
groups of the modifier have an effect on the d-spacing of MMT clay [18]. During the process of 
preparation of in situ HAPclay, changes in the undissociated carboxylic group of modified MMT 
clay due to dissociation and chelation is likely to contribute to the observed change in the d-
spacing of MMT clay.  
In Figure 4.10. (a), it is observed that there are similarities in the XRD plots of in situ 
HAPclay and HAP. Peaks seen in case of XRD plot of hydroxyapatite (HAP) are also seen in of 
in situ HAPclay. This gives an indication of presence of apatite in in situ HAPclay. Peak 
positions 25.95°, 28.33°, 31.74°, 32.29°, 45.44°, 49.47° corresponding to planes (002), (102), 
(211), (112), (203) and (213) seem to have shifted to different 2θ positions in case of in situ 
HAPclay that indicates that the apatite in in situ HAPclay has different lattice parameters as  
compared to hydroxyapatite (HAP). Peak shift observed in XRD studies can be attributed to 
several factors such as dislocations, stacking faults, twinning, microstresses, internal stresses, 
grain boundaries, point defects, chemical heterogeneity, precipitates and inclusions [55]. 
Residual stresses that include internal stresses and microstresses have also been known to be 
responsible for peak shifts observed in XRD studies [56]. Mechanical, thermal and chemical 
factors can contribute to the residual stresses. In case of preparation of in situ HAPclay, chemical 
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factors such as the precipitation of apatite may contribute to the residual stress generation that 
results in the observed peak shifts of HAP. Also, the presence of a different chemical 
environment for nucleation of apatite in modified MMT clay can have an effect on the kinetics 
and growth of apatite that can also contribute to the difference in peak positions of apatite seen in 
case of in situ HAPclay. The peak positions seen at 27.52° and 19.86° in case of modified MMT 
clay appear to be shifted to a lower 2θ position to 26.58° and 19.77° respectively in case of in 
situ HAPclay. These shifts indicate a change in the lattice parameters of modified MMT clay. 
The difference in the positions of the peaks from modified MMT clay and HAP in case of in situ 
HAPclay thus indicates changes in the crystal structure of modified MMT clay due to 
precipitation of apatite and also the differences in the lattice parameters of the apatite 
precipitated (formed) in in situ HAPclay. 
4.3.3. Cell Culture Studies 
The purpose of cell culture experiments involving the use of in situ HAPclay was to 
study the attachment and cluster/pattern formation by anchorage dependent cells such as 
osteoblasts on engineered ChiPgA films containing in situ HAPclay. As discussed earlier under 
section 4.2.5.3., ChiPgA films with different weight percentage composition (between 10 wt % 
to 20 wt %) of in situ HAPclay were prepared and human osteoblast cells were cultured on these 
films. Initially, the behavior (attachment and cluster/pattern formation) of human osteoblast cells 
on ChiPgA films containing 10 wt % and 20 wt % in situ HAPclay was observed under an 
inverted microscope for a cell culture period of 36 days. From the images shown in Figures 4.11. 
& 4.12., it can be seen that the human osteoblasts were able to adhere and form clusters on the 
ChiPgA films containing 10 wt % and 20 wt % in situ HAPclay. Observations related to culture 
period required for cluster formation and size of clusters are described in further paragraphs. 
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Figure 4.10. X-ray diffraction plots of modified MMT clay, in situ HAPclay (in situ HAP 
prepared using modified MMT clay), mixture of HAP and modified MMT clay and 
hydroxyapatite (HAP). a) in the range 2θ = 2° to 60°, b) in the range 2θ = 2° to 30°  
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Cluster formation was observed after 8 days and 4 days on ChiPgA films containing 10 
wt % in situ HAPclay and ChiPgA films containing 20 wt % in situ HAPclay respectively. 
Clusters of size approximately 80 µm-800 µm were observed in case of ChiPgA films containing 
10 wt % in situ HAPclay. In case of ChiPgA films with 20 wt % in situ HAPclay, clusters were 
in approximately 80 µm-1470 µm size range. The size of clusters on ChiPgA/in situ HAPclay 
composite films appeared to increase during cell culture. Clusters of size ~ 500 µm and greater 
were also observed after 24 days in case of ChiPgA films with 10 wt % in situ HAPclay and after 
20 days for ChiPgA films with 20 wt % in situ HAPclay. Considering the prospects of tailoring 
the properties of ChiPgA composites by varying the in situ HAPclay content, osteoblasts were 
cultured on ChiPgA films containing 12.5 wt % and 15 wt % in situ HAPclay. Since it was 
intended to observe if similar cellular events (attachment, cluster formation) occurred in case of 
ChiPgA films containing 12.5 wt % and 15 wt % in situ HAPclay, cell culture experiments of 
duration less than 36 days were performed. Besides this osteoblast cluster formation was 
observed after 4-8 days culture as discussed previously in case of films with 10 wt % and 20 wt 
% in situ HAPclay. Osteoblast adhesion and cluster formation was also observed (figures 4.13. 
and 4.14.) in case of ChiPgA films with 12.5 wt % and 15 wt % in situ HAPclay. Size of 
osteoblast clusters observed during 16 days culture in case of films with 12.5 wt % in situ 
HAPclay was approximately in 80 µm-500 µm range and cluster formation was observed after 4 
days. In case of films with 15 wt % in situ HAPclay, cluster formation was observed after 8 days 
and size of clusters observed was approximately in 80 µm-1370 µm range during 12 days of 
culture. Also, it was observed that relatively larger clusters (close to 1340 µm) were formed after 
4 days. Events such as cell adhesion and clustering are known to play an important role in 
formation and mineralization of a bone nodule [57]. Therefore, it appears that ChiPgA films 
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containing in situ HAPclay provide a favorable environment for the events involved in the 
formation of a bone nodule. It can be thus said that the ChiPgA films containing in situ HAPclay 
are biocompatible and also appear to show potential for bone tissue regeneration. Moreover, it 
was observed that the human osteoblast cells were able to adhere and form clusters on ChiPgA 
films with composition of in situ HAPclay from 10 wt % to 20 wt %. This indicates that the 
percentage composition of in situ HAPclay can be varied while fabricating ChiPgA composite 
films and scaffolds to control mechanical properties and the architecture in case of three 
dimensional scaffolds.   
 
Figure 4.11. Inverted microscope images of human osteoblast cells cultured on ChiPgA films 
containing 10 wt % in situ HAPclay after a) 4 days, b) 8 days, c) 12 days, d) 16 days, e) 20 days, 
f) 24 days, g) 28 days, h) 32 days, i) 36 days (scale bar on lower right hand side – 500 µm) 
 
152 
 
 
Figure 4.12. Inverted microscope images of human osteoblast cells cultured on ChiPgA films 
containing 20 wt % in situ HAPclay after a) 4 days, b) 8 days, c) 12 days, d) 16 days, e) 20 days, 
f) 24 days, g) 28 days, h) 32 days, i) 36 days (scale bar on lower right hand side – 500 µm) 
 
 
 
Figure 4.13. Inverted microscope images of human osteoblast cells cultured on ChiPgA films 
containing 12.5 wt % in situ HAPclay after a) 4 days, b) 8 days, c) 12 days, d) 16 days (scale bar 
on lower right hand side – 500 µm) 
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Figure 4.14. Inverted microscope images of human osteoblast cells cultured on ChiPgA films 
containing 15 wt % in situ HAPclay after a) 4 days, b) 8 days, c) 12 days (scale bar on lower 
right hand side – 500 µm) 
 
4.4. Conclusions 
A novel method of mineralizing hydroxyapatite using the functional groups of the 
modifier that serve as possible sites of mineralization in MMT clay modified with 5-
aminovaleric acid was developed. Transmission FTIR experiments on in situ HAPclay indicated  
chelation of the dissociated carboxylate groups with the calcium ions suggesting the mechanism 
for nucleation of HAP. FTIR spectroscopy studies also indicated the presence of phosphate 
vibrations similar to those observed in HAP. The phosphate vibrations observed in case of in situ 
HAPclay were at different wavenumber positions as compared to those present in HAP and 
mixture of HAP with the modified MMT clay. This indicated that there were interactions 
between the modified MMT clay and the ions present in the apatite that was possibly mineralized 
in the modified MMT clay. Difference in the wavenumber positions of phosphate vibrations in 
case of in situ HAPclay also indicated possible differences in the symmetry of the apatite  
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possibly mineralized in modified MMT clay. XRD studies indicated the presence of apatite in in 
situ HAPclay and also the differences in the lattice structure of this apatite precipitated (formed)  
in in situ HAPclay. Also, XRD data for in situ HAPclay showed that there were changes in the 
crystal structure of the modified MMT clay due to precipitation of apatite. ChiPgA films 
containing in situ HAPclay were prepared and characterized by transmission FTIR experiments. 
These experiments showed that molecular level interactions existed between the ChiPgA 
polyelectrolyte and the in situ HAPclay. Cell culture experiments were carried out by culturing 
human osteoblast cells on the ChiPgA films containing in situ HAPclay and it was observed 
through inverted microscope images that the osteoblasts were able to adhere and form clusters on  
these films. Thus, the ChiPgA films containing in situ HAPclay was biocompatible and also 
favored events that are supposed to play an important role in the process of bone nodule 
formation. It was also found that the osteoblast cells were able to adhere on ChiPgA films 
containing different weight percent compositions of in situ HAPclay that can prove useful for 
tailoring properties of ChiPgA films and scaffolds for bone tissue engineering studies.  
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CHAPTER 5. USE OF NANOCLAYS FOR MEDIATING MESENCHYMAL 
STEM CELL DIFFERENTIATION 
This chapter presents the use of nanoclay-hydroxyapatite (HAP) hybrid also known as in 
situ HAPclay for the fabrication of biopolymer composites (scaffolds and films) and the response 
of human mesenchymal stem cells (hMSCs) to these composites. The contents of this chapter 
have been published in Ambre, A.H., Katti, D.R., Katti, K.S. Nanoclays Mediate Stem Cell 
Differentiation and Mineralized ECM formation on Biopolymer Scaffolds. Journal of 
Biomedical Materials Research Part A. 2013; 101 A: 2644-2660. 
5.1. Introduction 
Tissue engineering introduced by Langer and Vacanti [1] is one of the most promising 
approaches in regenerative medicine to rectify tissue defects arising from pathological conditions 
and injuries sustained. In addition, tissue engineering strategies present relatively less invasive 
routes and capability to cure tissue defects by natural processes, compared with conventional 
treatment methods. Scaffolds, cells, and growth factors used for supplementing cell culture 
media are vital components that can be modulated for successful tissue regeneration in tissue 
engineering. Scaffolds can be designed to provide the required biophysical and biochemical 
signals to the cells for tissue formation in a three dimensional environment similar to the in vivo 
environment. The limited availability of autologous tissue biopsies restricts the number of cells 
available for regeneration in case of large tissue defects. Also, cells obtained from such tissue 
biopsies exhibit limited proliferation and tissue formation abilities [2] in addition to improper 
phenotype expression for certain cell types [3]. Cells for tissue engineering need to be obtainable 
through existing cell isolation techniques with low donor site morbidity, show “immunological 
compatibility” and maintain a stable phenotype while being receptive to signals from the 
161 
 
surrounding environment [3-5]. Mesenchymal stem cells (MSCs) can proliferate in an 
undifferentiated state and also maintain their capability to differentiate into different cell 
lineages. The differentiation of MSCs is non-spontaneous unlike the embryonic stem cells and 
can be controlled by using appropriate stimuli (chemical, mechanical and electrical). MSCs also 
have also been reported for their “immunosuppressive” effects [6-8] although research related to 
this property of MSCs continues to evolve. These cells exert suppressive effects on cells (e.g. T, 
B and natural killer cells) involved in the immune system [6, 9]. This makes possible the use of 
allogeneic MSCs for regenerating a defective tissue in a host using tissue engineering principles. 
Although bone marrow has been the major source of MSCs, these cells are also found in 
different tissues. Thus, the important attributes of MSCs and their potential to be a major cell 
source for tissue engineering has stimulated research focused on the behavior of MSCs seeded on 
engineered scaffolds. 
Materials synthesis and materials processing for developing scaffolds that satisfy tissue 
engineering requirements (biocompatibility, biodegradability, porosity, pore size and adequate 
mechanical properties) have been the focus of several studies. Biodegradable polymers (natural 
and synthetic) and ceramics have been used as major components for preparing scaffolds in such 
studies. The brittleness of ceramics, relatively inadequate mechanical properties of natural 
polymers, and inadequacy of biodegradable polymers for tissue formation in absence of 
appropriate stimuli despite favoring cell attachment restricts their independent use for preparing 
scaffolds. Difficulties in designing scaffolds with hierarchical organization similar to the 
extracellular matrix necessitate consideration of feasible strategies for preparing scaffolds. One 
of them is combining polymeric materials with fillers that impart tissue formation abilities and 
provide adequate mechanical properties to the resulting polymer scaffolds. Hydroxyapatite 
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(HAP) has been used in studies related to bone tissue engineering due to its biocompatibility, 
non-immunogenicity and osteoconductivity [10-12]. Ions such as carbonate, sodium, magnesium 
and silicon present in bone along with apatite have been reported for their effect on processes 
related to bone mineralization and formation [10, 13, 14]. Silicon-substituted HAP was used in 
some studies to study in vivo bioactivity [14, 15] and its effect on osteoblasts [16]. Studies 
related to silicon based materials such as bioactive glass suggested effect of silicon on osteoblast 
proliferation, bone metabolism and bioactivity shown by bioactive glass [14]. Introducing 
elements such as silicon, magnesium etc. in HAP and subsequent use of this substituted HAP for 
preparing engineered biomaterials is one of the methods used for influencing cell behavior and 
tissue formation. Another approach can be the use of silicate minerals such as montmorillonite 
(MMT) clay for preparing polymer composite scaffolds that can influence cellular events 
involved in bone formation and possibly have suitable mechanical properties for bone 
regeneration at the defective site. 
MMT clay belongs to the family of 2:1 phyllosilicates, and is a layered silicate with one 
octahedral alumina sheet between two tetrahedral silica sheets [17].  Nanometer thickness of 
each layer in MMT clay gives it a high aspect ratio and can also be useful for obtaining cellular 
response favoring tissue formation since nanoscale features favor cell adhesion and protein 
adsorption [18-20].  High aspect ratio and its capacity to be intercalated with small organic 
molecules known as modifiers by exchanging the interlayer alkali metal ions such as sodium 
have contributed to the extensive use of MMT for preparing polymer-clay nanocomposites 
(PCNs) since their introduction by Toyota research group in 1990 [21]. PCNs have shown 
improvement in mechanical properties [17, 22-24], improvement in biodegradability [17], 
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reduced gas permeability [25-27] and flammability [28, 29] due to presence of MMT clay. 
Investigation of PCNs by our group through several experimental and simulation studies 
led to development of ‘‘Altered Phase Theory of PCNs’’ that postulates that molecular 
interactions between polymer, clay, and modifier lead to formation of an ‘‘altered phase’’ 
around clay particles in PCNs of the scale of 10 s of nanometers, which has significantly 
different physical properties the polymer [30]. In another study, interaction energies 
evaluated between different components of polymer and modifier in PCNs using molecular 
dynamics simulation showed that molecular interactions affect crystallinity and nanomechanical 
properties of PCNs [31]. Also, one of our previous studies showed that a modifier’s backbone 
chain length and its functional groups affect MMT clay d-spacing and nanomechanical properties 
of PCNs [32]. Our modeling studies have indicated the potential of amino acids to be intercalated 
into clay galleries [33]. Further, medicinal properties [34], reported use for pharmaceutical 
applications [35-40] and ability to be excreted from the body [41] seem to make MMT suitable 
for use in tissue engineering studies.  
PCNs based on chitosan [42], polycaprolactone [43] and gelatin [44] have been studied 
for their mechanical properties as potential biomaterials. Few studies showing the effect of PCNs 
on cell behavior [45-47] have been reported with one of them focused on drug release 
applications [45]. Bone tissue engineering applications require use of cells such as osteoblasts or 
MSCs. Understanding the effect of an engineered biomaterial on cellular behavior is crucial for 
its progress towards its application as a scaffold that can overcome difficulty of achieving 
mechanical properties adequate to withstand the load at the defective site in vivo. Studying the 
behavior of osteoblasts and MSCs on biomaterials containing MMT clay can improve our 
understanding related to the optimal use of MMT clay for modulating cell behavior. 
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Our prior studies related to use of MMT clay for bone tissue engineering applications 
involved use of three unnatural amino acids for modifying MMT clay [48]. Longer backbone 
chain length of these acids as compared to the natural amino acids [33] based on our previous 
study showing the  effect of backbone chain length of modifiers on mechanical behavior [32] and 
their reported antimicrobial activity were considered as the selection criteria. MMT clays 
modified with these unnatural amino acids showed an increase in interlayer spacing and were 
found to be biocompatible with human osteoblasts. Improved biocompatibility and interlayer 
spacing increase were observed in case of MMT clay modified with 5-aminovaleric acid 
compared to MMT clays modified with the other two unnatural amino acids. In further studies, 
MMT clay modified with 5-aminovaleric acid was used for preparing chitosan/polygalacturonic 
acid (ChiPgA) composite scaffolds [49]. These scaffolds supported proliferation of osteoblasts 
and were able to satisfy basic tissue engineering requirements. In subsequent studies, a novel 
biomimetic nanoclay-HAP hybrid (in situ HAPclay) based on biomineralization concept reported 
for bone was prepared by mineralizing HAP on MMT clay intercalated with 5-aminovaleric acid 
to further improve the osteoconductive properties of MMT clay and extend its usefulness for 
bone tissue engineering [50]. Fourier Transform infrared (FTIR) spectroscopy studies indicated 
that the carboxyl group in 5-aminovaleric acid was involved in mineralization of HAP in 
modified clay. Cell culture experiments were performed by culturing human osteoblasts on 
ChiPgA films containing different loadings of in situ HAPclay. Adhesion and cluster formation 
by human osteoblasts was observed on these films that are important events involved in 
formation of bone nodules. Thus the biomimetic nanoclay-HAP hybrid (in situ HAPclay) was 
found to provide a favorable environment for growth and proliferation of osteoblasts and impart 
osteogenic characteristics to the resulting composites.  
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Here, we report investigation related to the use of biomimetic in situ HAPclay for 
preparation of chitosan/polygalacturonic (ChiPgA) composite scaffolds and films. It is 
hypothesized that the biomimetic HAP-nanoclay hybrid (in situ HAPclay) is capable of 
enhancing osteoinductive and osteoconductive abilities along with mechanical properties 
of resulting polymer composite based scaffolds. Preparation of ChiPgA/in situ HAPclay 
composite films and scaffolds, characterization of ChiPgA/in situ HAPclay composite scaffolds 
and films and studying the behavior (attachment, viability, differentiation) of MSCs on 
ChiPgA/in situ HAPclay composite films and scaffolds were the objectives of this study. For this 
purpose, behavior of undifferentiated MSCs derived from human bone marrow was studied on 
these ChiPgA composite scaffolds and films in the absence of any osteogenic supplements or 
soluble differentiation factors commonly used in cultures for differentiation of MSCs. Cell 
culture assays and staining methods were used for studying MSC behavior. Microscopy 
techniques (phase contrast microscopy, scanning electron microscopy (SEM), atomic force 
microscopy) were used to study MSC adhesion on ChiPgA composite scaffolds and films, 
microstructure of the fabricated composite scaffolds and nanoscale morphology of composite 
films. The primary goal was to investigate the osteoinductive and osteoconductive response and 
potential of the biomimetic nanoclay-HAP system to influence differentiation of MSCs.  
Strategies to enhance the amount of tissue formed under in vitro conditions through 
experiments involving tissue engineering principles can be useful for approaching the difficulties 
related to repair of large tissue defects. Optimization of cell numbers and also the concentration 
of soluble factors (for growth and differentiation) in cell culture medium are some of the 
strategies that are being investigated in several studies related to tissue engineering for enhancing 
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tissue formation. MSCs can undergo events such as proliferation and differentiation when 
cultured on engineered biomaterials. MSCs are known to deposit ECM as they differentiate 
toward an osteogenic lineage. Proteins such as collagen, fibronectin, elastin, and laminin present 
in the ECM can have an effect on the proliferation and differentiation of MSCs. Also, 
proliferation and differentiation of MSCs involve complex sequence of events. Murine MSCs 
have been reported to undergo a ‘‘predifferentiation growth arrest’’ stage in the process of 
differentiation where the MSCs acquire the ability to differentiate and at the same time can 
regain their ability to proliferate if provided with appropriate amount of growth factors [51]. 
Human MSCs have also been reported to undergo ‘‘growth arrest’’ during differentiation [52]. 
Considering factors such as the potential of the ECM proteins to assist cell proliferation and 
differentiation along with the “growth arrest” stage of MSCs during differentiation, a two-stage 
cell seeding experiment was performed in the present work. MSCs were seeded at two different 
stages (time points) on ChiPgA/in situ HAPclay films during cell culture experiments. 
Observations indicating ECM formation made during SEM studies on MSC-seeded ChiPgA 
composite scaffolds and Alizarin Red S staining experiments on MSC-seeded ChiPgA composite 
films (method A) were also considered for performing the two-stage cell seeding experiments.  
5.2. Materials and Methods 
5.2.1. Materials 
Sodium-montmorillonite (Na-MMT) clay used for experiments, SWy-2 (Crook County, 
Wyoming), was obtained from the Clay Minerals Repository at the University of Missouri, 
Columbia. This clay has a cation exchange capacity (CEC) of 76.4 mequiv/100 g according to 
the specifications provided by the supplier. 5-aminovaleric from Sigma Aldrich, sodium 
phosphate (Na2HPO4) from J.T. Baker and calcium chloride (CaCl2) from EM Sciences were 
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used for preparing in situ HAPclay. Chitosan (≥ 85 % deacetylated and molecular weight 
190,000-310,000) and polygalacturonic acid (approx. 95 % enzymatic and molecular weight 
25,000-50,000) both from Sigma Aldrich were used for preparing composite films and scaffolds 
used in these studies. MSCGMTM (mesenchymal stem cell growth medium) BullekitTM (PT-
3001) consisting of mesenchymal stem cell basal medium (MSCBMTM, PT-3238) and 
MSCGMTM SingleQuotsTM purchased from Lonza, Walkersville, MD was used as cell culture 
medium for human mesenchymal stem cells (MSCs). Human mesenchymal stem cells (PT-2501) 
obtained from bone marrow were purchased from Lonza for cell culture experiments. 
5.2.2. Method for Preparing Modified MMT Clay 
Procedure described in our previous studies was used for modifying Na-MMT clay [48-
50]. Briefly, solution of 5-aminovaleric acid (pH 1.8, temperature 60°C) was added to Na-MMT 
clay suspension in DI water (pre-heated to 60°C). The resultant mixture at pH 1.8 and 60°C was 
stirred vigorously for an hour followed by centrifuging to remove deionized water, further 
washing to remove chloride ions, drying at 70°C, grinding and finally sieving that yielded a fine 
powder.  
5.2.3. Preparation of In Situ HAPclay 
In situ HAPclay was prepared according to procedure described in our previous work 
[50]. Modified MMT clay prepared as per the procedure described in the previous section was 
dispersed in Na2HPO4 solution (23.8 mM) and stirred for 2 hours. CaCl2 solution (39.8 mM) was 
then added to the suspension obtained by mixing modified MMT clay with Na2HPO4 solution. 
The resultant mixture maintained at pH 7.4 was stirred for 8 hours. The precipitates obtained 
were then allowed to settle, which was followed by centrifuging to remove water from the settled 
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precipitates. After this the precipitates were dried at 70°C, subjected to grinding and sieved to get 
a fine powder.  
5.2.4. Fabrication of Chitosan/Polygalacturonic Acid (ChiPgA) Composite Films and 
Scaffolds  
Based on our previous studies [49, 50, 53, 54], polyelectrolyte complexation between 
polymers such as chitosan (Chi) and polygalacturonic acid (PgA) was used for preparing 
ChiPgA/in situ HAPclay composite films and scaffolds. Two different sequences were used 
while adding in situ HAPclay in this work for preparing the ChiPgA composite scaffolds and 
films. Accordingly, the methods of preparing ChiPgA/in situ HAPclay composite scaffolds and 
films were known as method A and method B. A schematic of these two methods is shown in 
Figure 5.1.  
 
Figure 5.1. Schematic representing methods of preparation of ChiPgA/in situ HAPclay 
composite films and scaffolds 
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Preparation of chitosan and polygalacturonic acid solutions in deionized water by using 
acetic acid to dissolve chitosan and diluted sodium hydroxide solution to dissolve 
polygalacturonic acid were the initial steps in these methods. In method A, chitosan solution was 
added drop-wise to polygalacturonic acid solution and the resultant mixture was sonicated. In 
situ HAPclay dispersed in deionized water by sonication was then added to the sonicated mixture 
of Chi and PgA. Resultant mixture of Chi, PgA and in situ HAPclay was sonicated and further 
stirred to get a ChiPgA composite solution. For fabricating scaffolds, the ChiPgA composite 
solution was centrifuged, frozen at -20°C and then freeze-dried (at -85°C, 200 mTorr pressure). 
ChiPgA composite films were prepared by diluting (1:10) the ChiPgA composite solution 
obtained in deionized water and drying this diluted solution at room temperature in tissue culture 
Petri dishes and wells of 24-well polystyrene plates. Method B involved stages that were used for 
preparing ChiPgA/in situ HAPclay composite solution in our prior work [50]. This involved 
mixing of sonicated in situ HAPclay suspension in deionized water with chitosan solution. The 
chitosan-in situ HAPclay solution was then added dropwise to the PgA solution followed by 
sonication and further stirring to get a ChiPgA/in situ HAPclay solution. Scaffolds and films 
from this ChiPgA composite solution were prepared by following the methods described above. 
ChiPgA/in situ HAPclay composite films and scaffolds containing 20 wt % in situ HAPclay were 
thus prepared and used for further experiments.  
5.2.5. Scanning Electron Microscopy (SEM) Studies 
Microstructure of the fabricated ChiPgA/in situ HAPclay composite scaffolds was 
studied using JEOL JSM-7600F analytical high resolution field-emission scanning electron 
microscope. For studying the adhesion of MSCs to the ChiPgA composite scaffolds, SEM 
imaging was performed on the composite scaffolds seeded with MSCs using JEOL JSM-6490LV 
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scanning electron microscope. Scaffold samples (approx. 10mm diameter and 3mm thickness) 
seeded with MSCs were washed with PBS after incubation and then fixed using glutaraldehyde 
(2.5 %). Ethanol series (10 % v/v, 30 % v/v, 50 % v/v, 70 % v/v and 100 %) was used for 
dehydrating the fixed scaffold samples, which were dried subsequently after replacing 100 % 
ethanol with hexamethyldisilazane. The fixed and dried MSC-seeded scaffold samples were then 
coated with gold, mounted and imaged. Similar procedure was used for imaging the fabricated 
ChiPgA composite scaffold samples except the fixing and dehydration steps. 
5.3. Cell Culture Studies 
5.3.1. Phase Contrast Microscopy and Atomic Force Microscopy 
ChiPgA/in situ HAPclay composite films prepared in 24-well polystyrene plates and Petri 
dishes were sterilized under ultraviolet (UV) light for 1.5 hours. The sterilized films were 
incubated at 37°C, 5 % CO2 in cell culture medium overnight. Subsequently, 4.4 x 10
4 human 
MSCs were seeded in each well on the composite films and these MSC seeded films were 
incubated at 37°C, 5 % CO2 under humidified conditions up to 31 days. During this cell culture 
period, phase contrast images were taken using Axiovert 40, Zeiss phase contrast/inverted 
microscope to study the behavior (cell attachment, cell clustering) of MSCs on the ChiPgA 
composite films. The films seeded with MSCs in 24-well polystyrene plates were also used for 
MTT assay (described later). Human MSCs (5.78 x 104) were also seeded on ChiPgA composite 
films in Petri dishes and the Petri dishes were then incubated at 37°C, 5 % CO2 for 26 days. 
Media was changed after every 3 days. Phase contrast imaging was performed to study behavior 
(cell attachment, clusters or any patterns formed by cells) of MSCs on the films in Petri dishes 
(60 mm outer diameter x 15 mm height, actual growth area 19.5 cm2) and these MSC seeded 
film samples were subsequently used for Alizarin Red S staining (described later). Human MSCs 
171 
 
up to passage 5 were used for all cell culture experiments. ChiPgA composite films containing in 
situ HAPclay prepared for cell culture experiments were also imaged using an atomic force 
microscope (AFM). Phase imaging under laboratory conditions was performed using 
MultimodeTM atomic force microscope having a Nanoscope III a controller and J-type piezo 
scanner from Veeco Metrology Group, Santa Barbara, CA. for this purpose. Tapping ModeTM 
mode of AFM and tips made from antimony (n) doped Si were used for imaging the samples.  
5.3.2. MTT Assay 
MTT assay was performed for studying the viability of MSCs seeded on ChiPgA 
composite films and scaffolds. MTT (3-(4, 5 dimethylthiazol-2)-2, 5-diphenyltetrazolium 
bromide) reagent used for performing MTT assay is reduced by mitochondrial dehydrogenase 
enzyme in live cells to formazan. This reduction causes formation of MTT purple colored 
formazan that is further solubilized and the intensity of solubilized formazan indicates the 
number of live cells. Human MSCs were seeded on ChiPgA/in situ HAPclay films in 24-well 
polystyrene plates as described earlier. MTT assay was performed on these cell seeded films 
after a period of 14, 21 and 31 days. Briefly, 75 µL MTT solution (5mg/ml PBS) and 500 µL 
serum-free DMEM were added to each well after washing the MSC seeded films with phosphate 
buffer saline (PBS). Remaining solution from the wells was aspirated after incubation for 12 
hours and 500 µL DMSO was added to solubilize the formazan crystals. Absorbance values of 
the supernatant (400 µL) at 570 nm were then read using a microplate spectrophotometer (Bio-
Rad, Benchmark Plus). Readings were thus obtained for quadruplicate sample sets.  
Separate MTT assay experiments were carried out on ChiPgA/in situ HAPclay scaffolds 
prepared by method A and method B. The scaffold samples sterilized under UV light were 
incubated at 37°C, 5 % CO2 in cell culture medium overnight prior to cell seeding. In case of 
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ChiPgA composite scaffolds prepared by method A, 4.8 x 104 human MSCs were seeded in each 
of the scaffold containing wells and the scaffold samples were then incubated at 37°C, 5 % CO2 
under humidified conditions up to 25 days. Scaffolds samples were then washed with PBS and 
90 µL MTT solution (5mg/ml PBS) along with 600 µL serum-free DMEM was added to each 
well. After incubation for 12 hours, scaffold samples were carefully transferred to unused wells 
of the 24-well plates and 600 µL DMSO was added to solubilize the formazan crystals. 
Absorbance values of the supernatant (500 µL) were then read using a microplate 
spectrophotometer (Bio-Rad, Benchmark Plus) for quadruplicate sample sets. In a separate 
experiment, 3.4 x 104 human MSCs were seeded in each of the wells containing composite 
scaffolds prepared by method B followed by incubation of the scaffolds at 37°C, 5 % CO2 up to 
28 days. MTT assay was performed using the same method as the one used for scaffolds 
prepared by Method A.  
5.3.3. Alizarin Red S Staining 
ChiPgA composite film samples (prepared by Method A) seeded with human MSCs were 
washed with PBS after incubation for 26 days and fixed by immersing them overnight in 2.5 % 
glutaraldehyde. Samples fixed with 2.5 % glutaraldehyde were then washed with PBS and then 
stained with Alizarin Red S dye (2 grams/100 ml deionized water, pH=4.10-4.15). Further, the 
samples were washed with cell culture grade water to remove excess dye and images were 
captured using a phase contrast/inverted microscope (Axiovert 40, Zeiss).  
5.3.4. Alkaline Phosphatase (ALP) Assay  
Separate ALP assay experiments to study differentiation of MSCs were performed on 
MSC seeded ChiPgA composite scaffolds prepared by Method A and Method B. In case of 
experiments involving scaffolds prepared by Method A, 7.7 x 104 MSCs were seeded in each of 
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the scaffold containing wells. In a separate experiment, 4.67 x 104 MSCs were seeded in each of 
the wells containing composite scaffolds prepared by Method B.  MSC seeded scaffold samples 
were washed with PBS after incubation for 15 and 22 days. Subsequently 850 µL Triton X-100 
(1 v/v % solution) was added to each of the scaffold containing wells. This was followed by two 
cycles of freezing-thawing (-70°C-37°C) of the scaffold samples immersed in Triton X-100 (1 
v/v % solution). Cell lysates (250 µL) were transferred to new 24-well plate and 250 µL p-
Nitrophenyl Phosphate (pNPP) was added to the cell lysates. The plates were incubated for 45 
minutes at room temperature and 3N NaOH (70 µL) was added to the wells. Absorbance 
readings at 405 nm were then read using a microplate spectrophotometer (Bio-Rad, Benchmark 
Plus).  
5.3.5. Two-stage Cell Seeding Experiment 
ChiPgA/in situ HAPclay films were prepared by method A as mentioned previously in 
petri dishes and seeded with 9.3 x 104 MSCs. After incubation for 22 days, fresh MSCs (9 x 10 4) 
from a different passage were again seeded on the films. The MSC seeded films were further 
incubated up to 39th day and were then stained with Alizarin Red S dye as described earlier. 
Images of the stained samples were taken with a phase contrast microscope. 
5.4. Swelling Studies 
          ChiPgA/in situ HAPclay scaffolds were weighed, immersed in PBS (pH=7.2) and then 
incubated at 37°C for 7hrs, 13 hrs and 27 hrs. Scaffold samples were then removed from PBS, 
weighed and swelling ratio was calculated according to the following formula: 
Swelling ratio = (W1-W0)/W0 x 100  
W0 = dry weight of the scaffold 
W1= wet weight of the scaffold 
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5.5. Scaffold Porosity 
The porosity of scaffolds was calculated by determining the apparent density and solid 
density of the material constituting the scaffolds. Apparent density was determined by 
considering the mass and volume of the scaffolds. The solid density was determined by using a 
pycnometer. Following formula was used for calculating the percentage porosity of scaffolds: 
% porosity = (1-ρa/ρs) x 100 
ρa = apparent density of scaffold 
ρs = solid density of scaffold material 
5.6. Statistical Analysis 
Student’s t-test performed using Minitab software was used for data analysis. 
Experiments were performed in quadruplicate except for swelling studies and porosity studies 
(where experiments were performed in triplicate). One-way ANOVA was used performing 
statistical analysis for comparing more than two different samples. Probability values less than 
0.05 (p < 0.05) were considered statistically significant. 
5.7. Results and Discussion 
5.7.1. Scanning Electron Microscopy (SEM)  
SEM micrographs of ChiPgA and ChiPgA/in situ HAPclay scaffolds fabricated by using 
the freeze-drying technique are shown in Figures 5.2. (a-f). All the scaffolds appear to be porous 
and have pore size near to 100 µm and above. The microstructure of ChiPgA/ in situ HAPclay 
scaffolds prepared by method A appears to be more similar to the ChiPgA scaffolds not 
containing any in situ HAPclay. In case of ChiPgA/ in situ HAPclay scaffolds prepared by 
method B, the microstructure appears to have compartmentalized features not seen in ChiPgA 
and ChiPgA composite scaffolds prepared by method A.  
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Figure 5.2. SEM micrographs of ChiPgA scaffolds with in situ HAPclay (20 wt %): a) & b) – 
scaffolds prepared by Method A, c) & d) scaffolds prepared by Method B and ChiPgA scaffolds 
without in situ HAPclay [e) & f)]. Images b), d), f) are magnifications of regions shown in 
images a), c), e) 
 
The sequence of preparing the ChiPgA composite solutions in method A and method B 
seems to have an effect on the differences in the microstructure between the fabricated scaffolds. 
One of the possible reasons for these differences between the microstructure of scaffolds is that 
the in situ HAPclay has more opportunity to interact with chitosan (Chi) and polygalacturonic 
acid (PgA) in case of ChiPgA composite solution prepared by following the sequence in method 
A. Polyelectrolyte formation between Chi and PgA is a consequence of interactions between –
NH3
+ and –COO- groups of Chi and PgA. Addition of in situ HAPclay to Chi prior to mixing of 
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Chi with PgA (using sonication) increases the possibility of interactions between in situ HAPclay 
with Chi and PgA. This can be possible through the available phosphate and calcium ions of in 
situ HAPclay interacting with unmixed Chi and PgA respectively. In our previous studies, it was 
observed that factors such as polymer concentration and freezing temperature used for scaffold 
fabrication have an effect on their microstructure [54]. SEM studies in present work suggest that 
the microstructure of the ChiPgA composite scaffolds is influenced by the order of mixing of in 
situ HAPclay with the polymers used and can be one of the methods to modify the 
microstructure of the ChiPgA composite scaffolds maintaining the same processing (freezing and 
freeze drying) conditions. 
Figures 5.3. (a-f) and 5.4. (a-d) show SEM micrographs of ChiPgA/in situ HAPclay 
composite scaffolds seeded with human MSCs. Viability of cells and their attachment to 
engineered scaffolds is an indicator of their suitability for tissue engineering applications. The 
SEM micrographs indicate that human MSCs are able to survive and attach to the ChiPgA/in situ 
HAPclay composite scaffolds. In case of ChiPgA/in situ HAPclay composite scaffolds prepared 
by method A, SEM micrographs taken after 7 days of culture indicate presence of human MSCs 
having both flat and spherical morphology. The SEM micrographs also seem to indicate that 
most of the MSCs have flat morphology after 19 days of culture. SEM micrographs taken after 
27 days of culture indicate formation of mineralized extracellular matrix by MSCs in the 
ChiPgA/in situ HAPclay scaffolds. For ChiPgA/in situ HAPclay composite scaffolds prepared by 
method B, SEM micrographs [Figure 5.4. (a-d)] show human MSCs with a flat morphology 
attached to the scaffolds. These micrographs taken after 18 days of culture indicate good 
attachment and spreading of the MSCs on the scaffolds (prepared by method B). Also, signs of 
formation of mineralized ECM by MSCs are visible on these scaffolds [Figure 5.4. (d)]. 
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ChiPgA/in situ HAPclay scaffolds prepared by both methods (method A and method B) appear 
to favor attachment and viability of human MSCs. In case of ChiPgA/in situ HAPclay films 
prepared by both methods, differences in MSC behavior (attachment) were observed. These 
observations are described under section 5.7.2.  
 
Figure 5.3. (a-f) SEM micrographs of human MSCs on ChiPgA/in situ HAPclay scaffolds 
(prepared by Method A) after a) & b) – 7 days, c) & d) – 19 days, e) & f) 27 days of culture. 
Solid black arrows indicate cells and dotted black arrows indicate regions of scaffold pore 
walls/scaffold material. Solid white arrows represent extracellular matrix (ECM) 
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Figure 5.4. (a-d) SEM micrographs of human MSCs on ChiPgA/in situ HAPclay scaffolds 
(prepared by Method B) after 18 days of culture. Solid black arrows indicate cells and dotted 
black arrows indicate regions of scaffold pore walls/scaffold material. Solid white arrows 
represent extracellular matrix (ECM) 
 
5.7.2. Phase Contrast Microscopy 
Phase contrast images taken to study the behavior of human MSCs on ChiPgA/in situ 
HAPclay composite films are shown in Figures 5.5.(a-f), 5.6.(a-f) and 5.7.(a-h). Numerous 
studies in tissue engineering have suggested the cellular behavior is affected by scaffold 
microstructure, chemical composition of the scaffold, mechanical properties and biodegradability 
of the scaffold. Scaffolds are designed to present the cells with necessary but complex 
microenvironment similar to the one existing in vivo. The interdependency of the factors related 
to scaffolds affecting cellular behavior can make it difficult to develop our understanding of 
individual roles of these factors on cell behavior. Studying cell behavior on 2D substrates (films) 
can be helpful to understand the effect of materials used for preparing scaffolds on cell behavior.  
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Figure 5.5. (a-f) Phase contrast images of human MSCs on ChiPgA/in situ HAPclay films 
prepared by Method A over a culture time of 21 days: a), b) – 4 days, c), d) – 8 days and e), f) – 
21 days indicating formation of MSC clusters of similar shape and similar size range ( ~100-250 
µm) 
 
Figure 5.5. (a-f) shows MSCs on ChiPgA/in situ HAPclay films prepared by method A in 
wells of 24-well plates. Formation of cell clusters (appearing to be nodules) by MSCs adhered to 
these films was seen from day 4 of cell culture and such clusters were seen consistently over a 
cell culture time of 21 days. Figure 5.6. (a-f) shows phase contrast images of MSCs on 
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ChiPgA/in situ HAPclay films prepared by method B. Also, in this case formation of cell clusters 
by MSCs was seen from day 4 and consistently over a culture time of 21 days. Cluster formation 
by MSCs from day 4 was thus observed in case of ChiPgA composite films prepared by both 
methods. 
 
Figure 5.6. (a-f) Phase contrast images of human MSCs on ChiPgA/in situ HAPclay films 
prepared by Method B over a culture time of 21 days: a), b) – 4 days, c), d) – 8 days and e), f) – 
21 days. Enclosed white squares indicate clusters/nodules that appeared to be attached to 
ChiPgA/in situ HAPclay films 
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Interestingly, in case of ChiPgA/in situ HAPclay films prepared by method B the cell 
clusters (appearing to be nodules) formed were floating/detached clusters unlike those seen in 
case of MSCs seeded on ChiPgA/in situ HAPclay films prepared by method A where they were 
adhered on the films. These floating/detached clusters were in the size range of 100µm to 
500µm. Formation of detached nodules during osteogenic differentiation has been reported in 
case of rat bone marrow stem cells exposed to differentiation medium containing dexamethasone 
[55]. Chitosan particles did not affect attachment of human marrow stem cells in this study. 
Detached/floating nodules were alsoseen in our previous studies where human osteoblasts were 
seeded on ChiPgA/hydroxyapatite composite films [53]. During late stages of cell culture some 
of the nodules (indicated by enclosing square brackets in Figure 5.6.(e,f) appeared to be attached 
to the ChiPgA/in situ HAPclay films (prepared by Method B). The reasons for the formation of 
these floating MSC clusters (appearing to be nodules) have not been yet completely understood. 
One of the possible reasons can be attributed to the difference in the method of preparing 
ChiPgA/in situ HAPclay films. In case of films prepared by method B, the number of sites on in 
situ HAPclay available to the cells for interaction may be less due to mixing of in situ HAPclay 
with chitosan prior to mixing of chitosan with polygalacturonic acid achieved during sonication. 
Also, some of the nodules seen after 14 days of culture appeared to be attached, which may be 
attributed to increased exposure of the in situ HAPclay particles at some regions of the surface 
due to effect of cell culture media on the ChiPgA/in situ HAPclay films. Increased exposure of 
hydroxyapatite (HAP) particles at the surface has been reported through our previous studies in 
case of ChiPgA/HAP films with increase of soaking time in cell culture medium [56]. Increased 
exposure of in situ HAPclay particles at some regions of the film surface with increase in cell 
culture time may provide opportunities to the MSC clusters for attachment to the ChiPgA/in situ  
182 
 
HAPclay films (prepared by method B). At present this possible reasoning for the observation of 
floating MSC clusters is restricted to 2D substrates (films) made from ChiPgA/in situ HAPclay. 
 
Figure 5.7. (a-h) Phase contrast images of human MSCs on ChiPgA/in situ HAPclay films 
prepared by Method A over a culture time of 26 days in tissue culture Petri dishes: a), b) - 3days, 
c), d) - 10 days, e),f) – 22 days, g), h) – 26 days 
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5.7.3. Alizarin Red S Staining 
Human MSCs were also seeded on ChiPgA/in situ HAPclay films (prepared by method 
A) in a petri dish. Films prepared by method A were used for Alizarin Red S staining experiment 
due to formation of adhered cell clusters (appearing to be nodules) by MSCs on these films as 
seen in the phase contrast images discussed earlier. Before performing the staining experiment, 
the behavior of MSCs seeded on the films was studied by phase contrast microscopy over a cell 
culture period of 26 days. Figure 5.7. (a-h) shows that MSCs were able to attach and form 
clusters (appearing to be clusters) on the films. It can be seen that the MSCs show flat 
morphology indicating good attachment and appear to organize themselves. MSC clusters 
(appearing to be nodules) seen in Figure 5.7.(c-h) were observed from 10th day of cell culture. 
Such clusters were observed till 26th day of cell culture. Similar events of cell clustering were 
also observed in case of human osteoblasts cultured on ChiPgA/in situ HAPclay ﬁlms from 8th 
day of cell culture in our previous studies [50]. Figure 5.8. (a-d) shows Alizarin Red S stained 
nodules formed by MSCs on the ChiPgA/in situ HAPclay films. Alizarin Red S is known to form 
complex with calcium and red color development indicates presence of calcium. Red color seen 
in stained nodules [Figure 5.8. (a-d)] thus indicates presence of calcium in the nodules formed by 
MSCs and thereby formation of mineralized nodules. Alizarin Red S positive staining of nodules 
formed by MSCs also suggests differentiation of the MSCs towards osteogenic lineage. Also, 
formation of mineralized nodules in the absence of osteogenic supplements indicated the 
osteoconductive and osteoinductive capabilities of ChiPgA/in situ HAPclay composites. 
Formation of nodules during in vitro culture has been reported in case of osteoblasts [57, 58]. 
These nodules formed by osteoblasts are considered to have multiple cell layers and mineralized 
extracellular matrix. Mineralization of the extracellular matrix is accompanied by changes in 
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morphology (change to round, small morphology) of osteoblasts to facilitate cellular 
communication and nutrition to the mineralized extracellular matrix. The changes in morphology 
of osteoblasts are also suggestive of changes in gene expression taking place during the 
development and mineralization of the extracellular matrix. Rounded cells along the periphery of 
the nodules are visible in some of the phase contrast images. Formation of mineralized 
extracellular matrix is also considered as an indicator of last stage of differentiation of 
osteoblasts [58, 59].  
 
Figure 5.8. (a-d) Alizarin Red S stained nodules formed by MSCs after 26 days on ChiPgA/in 
situ HAPclay films prepared by Method A 
 
In case of ChiPgA/in situ HAPclay films (prepared by Method A), the presence of 
Alizarin Red S stained nodules also suggests possibilities of similar events involving MSCs 
differentiated towards an osteogenic lineage. Positive Alizarin Red S staining of the nodules 
formed by MSCs during the two-stage cell seeding experiment after 39 days of culture can be 
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seen in Figure 5.9. (a-d).  The calcified nodules (indicated by bright red color) having irregular 
shape in this case appear to consist of relatively dense extracellular matrix (ECM) as compared 
to those seen in Figure 5.8. (a-d). Besides this the nodules formed appear to have a relatively 
larger size (~500 microns) and more organized structure. Areas of the substrate covered by less 
dense ECM as compared to the denser matrix of the nodules (interpreted from intense red color) 
can also be seen surrounding these nodules. 
 
Figure 5.9. (a-d) Alizarin Red S stained nodules (indicated by relatively intense red color) of 
irregular shape (~ 500 µm) formed by MSCs after 39 days on ChiPgA/in situ HAPclay films 
prepared by Method A during two-stage cell seeding experiment. Mineralized extracellular 
matrix indicated by relatively less intense red color compared to the nodules appears to surround 
the irregularly shaped nodules and spread over ChiPgA/in situ HAPclay films 
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5.7.4. MTT Assay to Study MSC Viability 
MTT assay results for MSCs seeded on ChiPgA/in situ HAPclay films (shown in Figure 
5.10.) indicate that the MSCs remain viable on these films. Statistically significant differences in 
absorbance values (proportional to the number of live cells) are seen between ChiPgA/in situ 
HAPclay films prepared by method A and ChiPgA films without in situ HAPclay. In case of 
ChiPgA/in situ HAPclay films prepared by method B, significant differences in absorbance 
values were not observed compared to the ChiPgA films without in situ HAPclay. Floating 
clusters (appearing to be nodules) were formed by MSCs seeded on ChiPgA/in situ HAPclay 
films prepared by method B. Therefore, medium aspiration and washing prior to performing the 
MTT assay had to be performed carefully so that the floating nodules remained in the wells. In 
case of ChiPgA/in situ HAPclay films an increase in number of cells is observed with cell culture 
time with decrease after 21 days.  
 
Figure 5.10. MTT assay results for MSCs seeded on ChiPgA/in situ HAPclay films 
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Similarly, in case of ChiPgA/in situ HAPclay scaffolds MTT assay results [shown in 
Figure 5.11. (a,b)] indicate viability of MSCs in these scaffolds. Significant differences in 
absorbance values is seen between ChiPgA/in situ HAPclay scaffolds prepared by method A and 
ChiPgA scaffolds without clay on day 20. MSCs showed an increase in cell number till day 20 in 
case of ChiPgA/in situ HAPclay scaffolds prepared by method A and till day 22 in case of 
ChiPgA/in situ HAPclay scaffolds prepared by method B. MSCs are specialized cells capable of 
differentiation into different lineages. Reciprocal relationship between proliferation and 
differentiation has been reported in case of osteoblasts [57, 60]. In case of mesenchymal stem 
cells, the relationship between proliferation and differentiation is not yet properly understood. 
This makes it difficult to make inferences from the observations made during MTT assay. 
Besides this possible events such as formation of extracellular matrix and its mineralization 
affecting cellular behavior present additional complexities. Also, films and scaffolds containing 
in situ HAPclay were studied as separate systems having potential to support MSC viability. 
Differences between 2D substrates (films) and scaffolds with respect to cell attachment, cell 
spreading, cell morphology, physical constraints to cell migration and deformation were some of 
the reasons considered for assaying the composite films and scaffolds in separate independent 
experiments. In case of scaffolds prepared by two different methods (A and B), the extent of 
difference in surface area available for cell attachment can be more due to differences in pore 
size, pore shape and pore interconnectivity. Therefore, scaffolds prepared by different methods 
were assayed in separate experiments. Since the MTT assay experiments performed were 
independent of each other where the ChiPgA composites containing in situ HAPclay were 
compared to ChiPgA without in situ HAPclay, different parameters such as cell numbers and 
culture time were used during these experiments. Figure 5.12. (a-f) represents phase contrast 
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images of MSC seeded scaffolds after formation of formazan crystals while performing MTT 
assay. Signs of cluster formation by MSCs in ChiPgA/in situ HAPclay scaffolds prepared by 
method A are seen in Figure 5.12. (c & d). Also, it appears from these images that the MSCs are 
distributed in the ChiPgA/in situ HAPclay scaffolds.   
 
Figure 5.11. MTT assay results for MSCs seeded on ChiPgA/in situ HAPclay scaffolds: a) – 
Method A, b) – Method B 
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Figure 5.12. Formazan crystals formed in MSC seeded ChiPgA/in situ HAPclay scaffolds 
prepared by Method A during MTT assay after a), b)- 20 days and c), d)-25 days and by Method 
B during MTT assay after e), f) – 28 days. Formation of formazan crystals suggests viability of 
cells seeded on ChiPgA/in situ HAPclay scaffolds and indicates the distribution of cells, cluster 
formation by cells seeded on scaffolds 
 
5.7.5. Alkaline Phosphatase (ALP) Assay 
ALP experiments were performed to know whether ChiPgA/in situ HAPclay scaffolds 
were capable of supporting the differentiation of human MSCs. Alkaline phosphatase is 
considered as a marker for osteoblast phenotype and indicates the differentiation of MSCs in to 
osteogenic lineage. Results obtained from ALP assay (Figure 5.13.) show that MSCs seeded on 
ChiPgA/in situ HAPclay scaffolds were able to differentiate and their ALP activity (indicated by 
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absorbance values) increased as the cell culture time increased. ALP activity on day 22 was less 
in case of ChiPgA/in situ HAPclay scaffolds (prepared by Method A) compared to the ChiPgA 
scaffolds without in situ HAPclay.  
 
 
Figure 5.13. Alkaline Phosphatase (ALP) assay results for MSCs seeded on ChiPgA/in situ 
HAPclay scaffolds: a) - Method A, b) - Method B 
 
Although ALP activity indicates differentiation of MSCs, it is difficult to relate increase 
in ALP activity to the extent of differentiation. Decrease in ALP activity has been associated 
with mineralization [61, 62] and differentiation stage of MSCs to osteoblasts [62-64]. ALP has 
been reported to have a higher expression in preosteoblasts that represent a transitional stage of 
MSC differentiation to osteoblasts. These factors make it difficult to relate ALP activity to the 
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extent of MSC differentiation. Decrease in ALP levels with the mineralization of the 
extracellular matrix has been reported for the osteoblast phenotype [57]. This can be one of the 
possible reasons for the lesser ALP activity seen in case of ChiPgA/in situ HAPclay scaffolds 
due to formation of mineralized ECM. SEM micrographs [Figure 5.3.(e,f)] of MSC seeded 
ChiPgA/in situ HAPclay scaffolds suggest formation of mineralized extracellular matrix with 
increase in cell culture time.  No significant difference in ALP activity was observed between the 
ChiPgA/in situ HAPclay scaffolds prepared by Method B and ChiPgA scaffolds without in situ 
HAPclay.  
5.7.6. Swelling Studies 
Figure 5.14. shows swelling ratios of ChiPgA/in situ HAPclay scaffolds obtained after 
immersion in PBS over a time of 27 hours. It is seen that the ChiPgA scaffolds including those 
without in situ HAPclay are able to swell. Swelling of scaffolds is considered useful for tissue 
engineering applications since it allows the cells and nutrients to enter the interior of the 
scaffolds. It can be useful for in vivo applications where the body fluids (blood, plasma) need to 
be taken up by the scaffolds while implanting the scaffolds at the defective sites [65]. Swelling 
can be useful to properly fix the scaffolds at the defective site, maintain appropriate pressure and 
achieve adequate contact with the surrounding tissue (reference). However continuous swelling 
can lead to decrease in mechanical properties and exert excess pressure on the surrounding tissue 
[66]. Controlling swelling of scaffolds can be considered as one of the factors while designing 
scaffolds for tissue engineering. The swelling ratios of ChiPgA/in situ HAPclay scaffolds 
prepared by method A do not differ considerably as compared to those without in situ HAPclay. 
Differences in swelling ratios are significant in ChiPgA/in situ HAPclay scaffolds prepared by 
method B compared to those without in situ HAPclay. Swelling of scaffolds can depend on 
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factors such as its chemical composition, microstructure, wetting capability and pH value of the 
soaking medium. The differences observed in microstructure of the scaffolds through SEM 
micrographs can be considered as one of the possible factors responsible for the observed 
differences in swelling ratios of the scaffolds. Also, change in swelling ratios of the scaffolds  
appears to be more from 7 to 13 hours of immersion time as compared to immersion time from 
13 hours to 27 hours. Besides the statistically significant differences between ChiPgA and 
ChiPgA scaffolds shown in figure 5.14. , statistically significant differences in swelling ratios 
with time were observed in case of ChiPgA scaffolds from 7 to 13 hours and in case of 
ChiPgA/in situ HAPclay composite scaffolds prepared by Method B from 13 to 27 hours. 
Immersion times extending up to several days can be used but there are possibilities that the 
swelling ratios may be affected by deposition of salts/minerals from the soaking medium and 
degradation of scaffolds in the soaking medium. 
 
Figure 5.14. Swelling ratios of ChiPgA/in situ HAPclay scaffolds.  
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5.7.7. Porosity of Scaffolds 
Figure 5.15. shows the percentage porosity of ChiPgA based scaffolds. It shows that the 
porosity of all the scaffolds is above 90 percent. Percentage porosity calculations showed that the 
porosity of all scaffolds was near to 97 percent. Porosity represents void space in scaffolds and is 
known to have effect on cell migration, vascularization, tissue formation etc. It is also known 
that porosity has an effect on the mechanical properties of the scaffolds and designing scaffolds 
with porosity suitable for tissue formation as well as for obtaining adequate mechanical 
properties is one of the significant challenges of bone tissue engineering.  
 
Figure 5.15. Porosity of ChiPgA/in situ HAPclay scaffolds 
 
5.7.8. Atomic Force Microscopy 
Figure 5.15 (a-d) shows AFM phase images of ChiPgA/in situ HAPclay films. Nanoscale 
features are clearly observed in these images. In case of films prepared by Method A, the size of 
these features appears to be less uniform than in case of films prepared by Method B. In case of 
films prepared by method A, the interspersed larger features appear to be made up of smaller 
features. These differences can possibly be attributed to the differences in processing resulting 
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from sequence of mixing the components while preparing these composites. Nanoscale 
morphology is one of the factors known to affect protein adsorption and cell adhesion.  
 
 
Figure 5.16. AFM phase images of ChiPgA/in situ HAPclay films prepared by Method A [a), b)] 
and Method B [c), d)]. Differences in phase images indicate possible differences in surface phase 
distribution, surface stiffness and sample topography. Features seen in images b), d) are in the 
submicron and nanoscale range. Relatively large (~ 500-790 nm) interspersed features can be 
seen in case of films prepared by Method A [images a), b)] 
 
5.8. Conclusions 
Biomimetically prepared HAP (in situ HAPclay) on intercalated nanoclays containing 
organomodified MMT clay with hydroxyapatite (HAP) was successfully used for the fabrication 
of biopolymer (ChiPgA) scaffolds and films. Formation of mineralized nodules by MSCs on 
ChiPgA/in situ HAPclay films in the absence of osteogenic supplements demonstrated the 
osteoconductive and osteoinductive potential of ChiPgA/in situ HAPclay composites. Thus the 
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biomimetic nanoclay-HAP material system represents a new viable system for design of 
scaffolds. Cell culture assays showed that the ChiPgA/in situ HAPclay scaffolds and films were 
able to support MSC viability and differentiation (in case of scaffolds). Formation of mineralized 
nodules on ChiPgA/in situ HAPclay films by MSCs was also an indicator of differentiation of 
MSCs on ChiPgA/in situ HAPclay composites. Two-stage cell seeding experiment was 
successfully performed as a strategy to enhance tissue formation by MSCs on ChiPgA/in situ 
HAPclay composite films. It was also observed that changes in the sequence of addition of in 
situ HAPclay with ChiPgA biopolymer system had considerable influence on the microstructure 
of the scaffolds. Swelling capabilities of the fabricated ChiPgA/in situ HAPclay composites and 
their porosity indicated their suitability for tissue engineering applications.  
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CHAPTER 6. NANOCLAYS WITH BIOMINERALIZED 
HYDROXYAPATITE FOR DESIGN OF POLYCAPROLACTONE 
SCAFFOLDS FOR STEM CELL BASED BONE TISSUE ENGINEERING 
Use of nanoclays with biomineralized hydroxyapatite (in situ HAPclay) for fabrication of 
synthetic polycaprolactone (PCL) composite scaffolds and studies showing their suitability for 
mesenchymal stem cell based bone tissue engineering are presented in this chapter. The contents 
of this chapter are included in a manuscript cited as Ambre, A.H., Katti, D.R., Katti, K.S. (2014) 
Biomineralized Hydroxyapatite Nanoclay Composite Scaffolds with Polycaprolactone for Stem 
Cell Base Bone Tissue Engineering, Journal of Biomedical Materials Research Part A. 00A:000-
000, DOI: 10.1002/jbm.a.35342 (online version before inclusion in an issue) 
6.1. Introduction 
The tremendous potential of tissue engineering as an alternative to conventional 
treatment methods for repairing tissue defects has spurred research efforts in recent years 
towards developing improved/new strategies capable of overcoming the multiple challenges in 
tissue engineering. Tissue engineering introduced in the early 1990s [1] involves cell-scaffold 
(material) interactions eliciting natural tissue regeneration processes and has posed challenges 
concerning scaffolds that need to provide appropriate three-dimensional environment to the cells 
for new tissue formation. Studies till date have indicated that besides the basic requirements 
which a scaffold needs to satisfy it is also important to consider the emerging challenge of 
integrating and optimizing different properties of a scaffold from nanoscale to macroscale. Such 
integration and optimization can assist in satisfying an ensemble of properties responsible for 
making a scaffold capable of providing necessary biophysical and biochemical cues to the cells 
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for tissue regeneration. In addition to this the type of cells used can also contribute to the success 
of tissue regeneration strategies based on tissue engineering principles.  
Bone can be considered as a nanocomposite consisting of a complex hierarchical 
structure extending from nanoscale to macroscale [2]. The mechanical properties of bone 
attributed to this hierarchical structure enables it provide the required structural support and 
facilitate movement. Designing scaffolds for bone regeneration that have structural hierarchy as 
observed in bones is a difficult task considering the existing methods for scaffold fabrication. 
However, it can be possible to incorporate important features similar to bone extracellular matrix 
(ECM) in scaffolds using the existing fabrication methods. Regeneration of hard tissues such as 
bone necessitates the use of scaffolds having mechanical properties capable of presenting 
appropriate mechanical cues to the cells in the porous microenvironment of scaffolds and also 
adequate to support the regenerating bone or biomechanical loads at the defect site. Reinforcing 
polymeric materials with inorganic fillers to fabricate composite scaffolds has emerged as a 
useful strategy which imparts scaffolds with organic-inorganic nature similar to bone and can 
also satisfy the necessities of bone tissue engineering.  
The nature of inorganic fillers used for preparing polymer composite scaffolds can affect 
multiple aspects such as cell-scaffold interactions, subsequent tissue formation and mechanical 
properties of scaffolds. The known role of hydroxyapatite (HAP) in influencing biomechanical 
properties of bone and its characteristics such as biocompatibility, osteoconductivity, non-
immunogenecity [3-6] are some of the important reasons for its extensive use in scaffold 
preparation for bone tissue engineering. The use of calcium phosphate based fillers such as HAP 
has also been attributed to the possible role of calcium and phosphate ions released from them 
under physiological environment in influencing cellular behavior [7]. Trace elements such as 
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carbonate, sodium, magnesium, silicon, zinc etc. [4] present in bone besides apatite influence 
bone formation and mineralization processes [8, 9]. This has been the basis of studies where such 
trace elements were used for preparing substituted HAP and its effect was studied on osteoblasts 
[10, 11] and in vivo bioactivity [9, 12]. Studies involving bioactive glass composed of oxides of 
some these trace elements had an effect on attachment [13] and genetic expression  of osteoblasts 
[14, 15]. Silicon present in silicates has been also shown to affect differentiation and cell 
signaling routes of bone marrow stromal cells [16]. Although most studies involving HAP, 
substituted HAP and bioactive glass scaffolds emphasize their effect on cell behavior the low 
fracture toughness of these materials can limit their use for bone tissue engineering. Sodium 
montmorillonite (Na-MMT) clay, a layered silicate with ionic constituents, is known for its 
reinforcing capability in case of polymer-clay nanocomposites (PCNs) [17, 18] along with few 
studies showing its effect on cell behavior [19-22]. This suggests the utility of MMT clay as a 
filler for fabricating biodegradable composites that can be useful for bone tissue engineering. 
MMT clay is a 2:1 phyllosilicate with its each nanometer thick layer having one 
octahedral alumina sheet between two tetrahedral silica sheets [17, 18]. High aspect ratio of 
MMT results from nanometer thickness of its each layer. Favorable effect of nanoscale features 
on cell behavior and protein adsorption [23-25] implies potential of MMT to affect cell behavior. 
The exchangeability of interlayer ions in MMT clay with organic molecules and cations in 
addition to its ability to be dispersed in to individual layers has been responsible for its use in 
several studies for preparing PCNs [18]. These studies since the first reported use of MMT clay 
for preparing PCNs in 1990 by Toyota research group [26] have shown that MMT clay improves 
mechanical properties [17, 18, 27, 28] and also affects biodegradability [18], gas permeability 
[29-31] and flammability [32, 33] of PCNs. The strengthening effect of MMT clay observed in 
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case of PCNs has led to studies exploring the mechanisms for enhancement in mechanical 
properties of PCNs. “Altered Phase Model” for PCNs [34] developed in our group based on 
molecular dynamics and experimental studies premises that molecular interactions between the 
PCN constituents (polymer, modifier and clay) are responsible for formation of an “altered 
phase” around clay particles in PCNs, which has considerably different mechanical properties 
than the polymer.  Another simulation study involving evaluation of interaction energies between 
different components of PCN constituents elucidated the effect of molecular interactions on 
crystallinity and nanomechanical properties [35]. Our simulation studies also showed the effect 
of a modifier’s backbone chain length and its functional groups on clay d-spacing and 
nanomechanical properties of PCNs [36]. Besides the role of molecular interactions in enhanced 
mechanical properties of PCNs our simulation studies also indicate that designing PCNs at the 
molecular level can lead to better control of their physical properties across higher length scales.  
The strengthening effect of MMT clay in case of PCNs combined with its medicinal 
properties [37, 38], ability to be excreted from the body [37] and known pharmaceutical 
applications [39-44] seems to make its use promising for tissue engineering. Optimal use of 
inorganic fillers for fabricating composite scaffolds useful for their desired application requires 
an understanding of the influence of such composite scaffolds on cellular events favoring tissue 
formation. For bone tissue engineering, it can thus be useful to study the response of 
mesenchymal stem cells or osteoblasts to polymer-clay based composite substrates (films and 
scaffolds). Past few studies have shown enhancement in mechanical properties of PCNs based on 
polymers such as chitosan [45], polycaprolactone [46] and gelatin [47] that were considered as 
potential materials for tissue engineering. Cellular behavior on PCNs has been reported in few 
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studies mentioned earlier with one of them related to pharmaceutical applications. This 
emphasizes the scope for further studies focused on cell-material interactions in case of PCNs.  
Natural polymers known for promoting favorable cell responses are limited by their 
inadequate mechanical strength, batch-to-batch variation in properties and difficulties in 
controlling their degradation rate. Synthetic polymers though lacking the biomolecule sequences 
promoting desired cell responses as in case of natural polymers seem to have optimizable 
mechanical and degradation properties along with better processability. Polycaprolactone (PCL), 
a synthetic and aliphatic polyester, has re-emerged as a polymer with huge scope for tissue 
engineering applications. Good processability, compatibility with different polymers to form 
blends, broad molecular weight range, solubility in common organic solvents and its excellent 
potential for offering desired mechanical properties via its blends, copolymers, composites have 
contributed to this re-emergence of PCL in the biomedical field [48]. The versatility of PCL and 
the reinforcing ability of MMT clay may thus prove beneficial for fabricating composite 
scaffolds that can satisfy the complex bone tissue engineering requirements.  
Mesenchymal stem cells (MSCs) have emerged as a promising alternative cell source for 
tissue engineering applications and continue to be studied further due to several factors. 
Important among these are their ability to proliferate in an undifferentiated state while 
maintaining the ability to differentiate in to different cell lineages when provided with 
appropriate stimuli, relatively controllable differentiation compared to embryonic stem cells, 
accessibility and possibilities of allogeneic use due to their “immunosuppressive effects [49-
55].” The evolving understanding about the role of MSCs in wound healing [56] and their 
recruitment through peripheral blood to sites of bone injury [57] has extended the scope of their 
use in bone tissue engineering. Studying the behavior of MSCs in 3D scaffold microenvironment 
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resembling the in vivo environment can be helpful for understanding the complex mechanisms 
related to wound healing and tissue repair besides the cell-material interactions.  
MMT clay was modified in our previous work [58] with three unnatural amino acids 
known for their antibacterial activity and having a longer backbone chain length compared to 
natural amino acids. Effect of a modifier’s backbone chain length on mechanical properties [36] 
was considered while using these unnatural amino acids in addition to the intercalation potential 
of amino acids in clay interlayer as indicated by our previous simulation studies [59]. Based on 
its relatively better biocompatibility with human osteoblasts 5-aminovaleric acid modified MMT 
clay was chosen among the modified clays for preparing biopolymer polyelectrolyte 
(chitosan/polygalacturonic acid) composite scaffolds [60]. Osteoblast proliferation in case of 
biopolymer scaffolds containing modified clay was similar to those scaffolds containing HAP 
and these modified clay based scaffolds also satisfied basic requirements for tissue engineering. 
Biomimetic strategy was used in further studies to prepare a unique three-component nanoclay-
HAP hybrid (in situ HAPclay) by mineralizing HAP in modified MMT clay to improve 
osteoconductive properties of MMT clay [61]. Infrared spectroscopy studies indicated 
involvement of the intercalated modifier’s carboxylic groups in HAP mineralization through 
chelation and thus suggested a molecular level organic-inorganic association. Also, cluster 
formation by human osteoblasts observed on biopolymer (chitosan/polygalacturonic)/in situ 
HAPclay composite films indicated the osteogenic potential of in situ HAPclay. Similar behavior 
of osteoblasts leading to formation of bone nodules on biopolymer/HAP composites in the 
presence of cell culture medium without osteogenic supplements was seen in our previous 
studies [62, 63].  
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Based on our hypothesis that in situ HAPclay has potential to impart bone formation 
ability along with desirable mechanical properties to the resulting composites we studied the 
response of human MSCs to biopolymer/in situ HAPclay composite films and scaffolds. These 
MSCs formed bone nodules on composite films and mineralized extracellular matrix (ECM) in 
composite scaffolds in the absence of osteogenic supplements that indicated the mediatory effect 
of in situ HAPclay in MSC differentiation and bone nodule formation [22]. In this work, we 
extend our hypothesis about in situ HAPclay to a synthetic polymer composite system and 
attempt to evaluate it through studies involving PCL/in situ HAPclay composites. PCL was used 
in this work considering its immense prospects for tissue engineering due to its versatility and its 
lesser complexities compared to polymers obtained from natural sources. Besides the fabrication 
of PCL/in situ HAPclay composite films and scaffolds this work involves investigation of 
viability and differentiation of MSCs on these composites through appropriate assays. Atomic 
force microscopy (AFM) was used to characterize the surface of PCL composite films and study 
the morphology of mineralized ECM formed by MSCs on these films. Phase contrast microscopy 
was used to assay the formation of mineralized ECM formed by MSCs seeded on PCL 
composite films after Alizarin Red S staining. Scanning electron microscopy (SEM) was used to 
study scaffold microstructure and MSC infiltration in the PCL composite scaffolds. Attachment, 
spreading of MSCs on PCL/in situ HAPclay composites (films and scaffolds) and formation of 
mineralized ECM by MSCs on PCL composite films was also studied using SEM. 
Nanoindentation was used to evaluate the nanomechanical properties of the composite films. 
Photoacoustic FTIR (PA-FTIR) spectroscopy was used to study molecular level effect of 
accelerated in vitro degradation on PCL/in situ HAPclay composite scaffolds and the 
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morphological changes in these scaffolds resulting from such degradation were studied by SEM. 
Thus, the objectives of this work were as follows: 
1. Fabrication of PCL/in situ HAPclay composites (films and scaffolds) 
2. Studying MSC response (viability, differentiation, attachment and spreading, mineralized 
ECM formation) to the fabricated PCL/in situ HAPclay composites were the objectives of 
this study.  
3. Investigating scaffold microstructure and micron to sub-micron scale characterization of 
surface morphology of PCL/in situ HAPclay composite films.  
4. Sub-micron scale characterization of mineralized ECM formed by MSCs on PCL/in situ 
HAPclay composite films. 
5. Nanomechanical characterization of PCL/in situ HAPclay composite films 
6. Degradation studies of PCL/in situ HAPclay composite scaffolds. 
6.2. Materials and Methods 
6.2.1. Materials 
Sodium-montmorillonite (Na-MMT) clay used for preparing modified clay, Swy-2 
(Crook County, Wyoming), had a cation exchange capacity (CEC) of 76.4 mequiv./100 g and 
was sourced from the Clay Minerals Repository at the University of Missouri, Columbia. 5-
aminovaleric acid, polycaprolactone (PCL) (average Mn = 80,000) and 1, 4 dioxane (anhydrous, 
99.8 %) from Sigma Aldrich were used for experiments. Materials for preparing in situ HAPclay 
such as sodium phosphate (Na2HPO4) and calcium chloride (CaCl2) were obtained from J.T. 
Baker and EM Sciences respectively. Human MSCs from bone marrow (PT-2501, 
Lonza,Walkersville, MD) were cultured in cell culture medium made by adding MSCGMTM 
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SingleQuotsTM (PT-4105) to mesenchymal stem cell basal medium (MSCBMTM, PT-3238). 
These two components of cell culture medium were purchased as MSCGMTM (mesenchymal 
stem cell growth medium) BullekitTM from Lonza, Walkersville.  
6.2.2. Procedure for Preparation of Amino Acid Modified MMT Clay 
Na-MMT was modified with 5-aminovaleric acid (unnatural amino acid) according to the 
procedure described in our previous studies [22, 58, 60, 61]. In short, mixture obtained by adding 
5-aminovaleric acid solution (pH=1.8 & temperature = 60°C) prepared in DI water to Na-MMT 
clay suspension in DI water (pre-heated to 60°C) was stirred vigorously for an hour. The stirred 
mixture was then centrifuged for removal of DI water and washed further for removal of chloride 
ions followed by drying at 70°C, grinding and sieving to obtain a fine powder.  
6.2.3. Procedure for Preparing In Situ HAPclay 
In situ HAPclay was prepared according to procedure described in our earlier studies [22, 
61]. Modified MMT clay was dispersed and further stirred for 2 hours in Na2HPO4 solution (23.8 
mM) at room temperature to obtain modified MMT clay-Na2HPO4 suspension. CaCl2 solution 
(39.8 mM) was then added to this suspension and the resulting mixture (at pH=7.4) was stirred 
for 8 hours. Precipitates obtained were allowed to settle, centrifuged to remove water, dried at 
70°C and subsequently sieved after grinding to obtain a fine powder. 
6.2.4. Preparation of Polycaprolactone (PCL)/ In Situ HAPclay Films and Scaffolds 
Figure 6.1. represents a schematic for preparing PCL/in situ HAPclay films and scaffolds 
respectively.  For preparing composite films with different (10 wt % and 20 wt %) in situ 
HAPclay concentrations, PCL (0.09 grams/ml dioxane) was dissolved in 1, 4 dioxane at room 
temperature. Thus for preparing PCL films with 10 wt% in situ HAPclay, 3.6 grams PCL was  
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dissolved in 40 ml 1, 4 dioxane and a sonicated suspension of in situ HAPclay in 1, 4 dioxane 
(0.4 grams in 16 ml dioxane) was added to the PCL solution. The resulting solution was stirred  
for 2 hours and then transferred to glass Petri dishes. The composite solution in Petri dishes was 
subjected to drying for 72 hours at room temperature to get films. Samples having ~12.7 mm 
diameter were punched out from these dried films (~85 mm diameter) for further experiments. 
Similar procedure was followed for preparing PCL composite film containing 20 wt % in situ 
HAPclay by using appropriate proportion of constituents accordingly. PCL films without in situ 
HAPclay were also prepared similarly with the difference being absence of addition of in situ 
HAPclay suspension to the PCL solution.  
 
Figure 6.1. Representative schematic showing methods for preparation of polycaprolactone 
(PCL)/in situ HAPclay composite films and scaffolds 
For preparing scaffolds, the PCL/in situ HAPclay composite solution was frozen at -20°C 
in an iso-propyl alcohol bath overnight. Cylindrical shaped frozen samples of the composite 
solution were then carefully removed from polypropylene (PP) centrifuge tubes and further 
immersed in absolute ethanol (cooled to -20°C) for solvent extraction. Immersion in absolute 
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ethanol was continued for 4 days with absolute ethanol being refreshed every day. After 4 days 
the cylindrical shaped porous samples known as scaffolds were removed and dried at room 
temperature. PCL composite scaffolds with 10 wt % and 20 wt % in situ HAPclay were thus 
prepared using freeze extraction method.  
6.2.5. Scanning Electron Microscopy (SEM) studies 
SEM was used to study microstructure of fabricated PCL/in situ HAPclay composite 
scaffolds (~12 mm diameter and ~ 3 mm thickness) using JEOL JSM-6490LV scanning electron 
microscope. The same SEM instrument was also used for studying MSC adhesion to both 
PCL/in situ HAPclay composite scaffolds and films. For this purpose, PCL/in situ HAPclay 
composite scaffolds seeded with human MSCs (9.16 x 104 cells in each scaffold containing well) 
were removed from culture, washed with phosphate buffer saline (PBS), fixed using 
glutaraldehyde (2.5%), subsequently dehydrated using ethanol series (10 % v/v, 30 % v/v, 50 % 
v/v, 70 % v/v and 100 %) and then dried after 100 % ethanol was replaced with 
hexamethyldisilazane.  These scaffold samples were then used for SEM imaging after coating 
them with gold using sputter coater and mounting them on a SEM sample stub. Similarly, fixed 
and dried MSC seeded (7.36 x 104 cells in each sample containing well) PCL/in situ HAPclay 
composite film samples were imaged using SEM. Fabricated PCL/in situ HAPclay composite 
scaffolds did not require fixing and dehydration before imaging. SEM was also used to study the 
effect of accelerated degradation (described later) on the microstructure and surface morphology 
of PCL/in situ HAPclay composite scaffolds. 
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6.2.6. Cell Culture 
6.2.6.1. Cell Viability Using MTT Assay 
MSC viability was studied in the fabricated PCL composite scaffolds and also on the 
PCL composite films using MTT assay. Purple colored formazan obtained after reduction of 
MTT (3-(4, 5 dimethylthiazol-2)-2, 5-diphenyltetrazolium bromide) reagent by mitochondrial 
dehydrogenase enzyme in live cells is solubilized and intensity of this solubilized formazan read 
using a spectrophotometer indicates number of live cells. PCL/in situ HAPclay (10 wt %) 
composite film samples (~12.7 mm as mentioned earlier) in sterile 24-well polystyrene plates 
(Falcon®, Corning®) were UV sterilized and then immersed in 70 % alcohol overnight to ensure 
wetting of these hydrophobic polyester (PCL) based films [64-67].  The PCL composite film 
samples were then washed with PBS twice and further incubated in PBS (6 hours) for removal of 
alcohol. PBS was then removed and after 24 hours of subsequent incubation at 37°C, 5 % CO2 in 
cell culture medium human MSCs (3.96 x 104) were seeded in each well on these composite film 
samples (quadruplicates) and these seeded samples were incubated at 37°C, 5 % CO2  under 
humidified conditions for 10, 16 and 23 days. Media was refreshed after every two days. After 
incubation the MSC seeded PCL composite film samples were washed with PBS and transferred 
to unused wells of the 24-well plates. 75 µL MTT solution (5 mg/ml PBS) along with 500 µL 
serum-free DMEM was added further to each well. After subsequent incubation for 12 hours, 
remaining solution was aspirated from the wells and 500 µL DMSO was added to these wells. 
Microplate spectrophotometer (Bio Rad, Benchmark Plus) was then used to read the absorbance 
values of the supernatant (400 µL) at 570 nm of quadruplicate sample sets. PCL film samples 
containing 10 wt % in situ HAPclay and 20 wt % in situ HAPclay were assayed in two separate 
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experiments. 3.1 x 104 human MSCs were seeded in each well of 24-well polystyrene plates on 
PCL composite film samples (quadruplicates) containing 20 wt % in situ HAPclay.  
For performing MTT assay in case of PCL composite scaffolds containing 10 wt% in situ 
HAPclay, scaffold samples (quadruplicates) in sterile 24-well polystyrene plates (Falcon®, 
Corning®) were UV sterilized, immersed in 70 % alcohol overnight, subsequently washed with 
PBS twice and incubated in PBS (7 hours). Further, PBS was removed and after 24 hours of 
incubation in cell culture medium at 37°C, 5 % CO2, 5.66 x 10
4 cells human MSCs were seeded 
in each of the scaffold containing wells. Incubation of seeded scaffold samples was carried out at 
37°C, 5 % CO2 under humidified conditions for 10, 16 and 23 days. Seeded scaffold samples 
were then washed with PBS after incubation and transferred to unused wells of 24-well plates. 
This was followed by addition of 90 µL MTT (5 mg/ml PBS) along with 600 µL serum-free 
DMEM to each well. After further incubation for 12 hours, remaining solution was aspirated and 
600 µL DMSO was added to these wells. Absorbance readings of the supernatant (400 µL) were 
then obtained at 570 nm using a microplate spectrophotometer (Bio Rad, Benchmark Plus) for 
quadruplicate sample sets. Separate MTT assay experiment was also performed using the same 
procedure in case of PCL composite scaffolds containing 20 wt% in situ HAPclay with 4.7 x 104 
human MSCs seeded in each of the scaffold containing wells of 24-well polystyrene plates. 
Human MSCs up to passage 5 were used during MTT assay experiments and all other cell 
culture experiments conducted during this work.  
Presence of micron to sub-micron surface features in case of PCL and PCL composite 
films (discussed later under section 6.3.5.2) makes it difficult to estimate the surface area 
available for cell attachment and growth. The actual surface area available for cell attachment, 
growth can be different or more than the area calculated using external dimensions (e.g. 
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diameter, length, breadth) due to the presence of such micron to sub-micron scale features on 
PCL/PCL composite films. There is also a possibility that change in in situ HAPclay content 
(weight percentage) may lead to change in the surface area of the PCL composite films. This 
change caused due to relative change in the dimensions of the surface features may be an effect 
of in situ HAPclay on polymer crystallization during fabrication of PCL composite films and 
scaffolds. Similarly, it is difficult to estimate the surface area for cell attachment, growth in case 
of scaffolds due to different features associated with its microstructure such as pore shape, pore 
size, pore interconnectivity and topography of pore walls. PCL composite films and scaffolds 
with different weight percentage of in situ HAPclay were assayed in separate experiments due to 
possible differences in their surface areas and to make interpretation of experimental results less 
difficult. Since one of the important objectives of this work was to study the effect of addition of 
in situ HAPclay to PCL (by using PCL composite films and scaffolds) on MSC proliferation and 
differentiation, PCL/in situ HAPclay composite films/scaffolds were compared with PCL 
films/scaffolds without in situ HAPclay in these separate experiments. Also, since PCL 
composites with different weight percent composition of in situ HAPclay were being 
investigated as different systems in separate experiments, it was deemed that use of different cell 
numbers in these independent experiments was appropriate since the important objective was to 
study the effect of in situ HAPclay addition in PCL on MSC behavior (proliferation, 
differentiation). Although it may be possible to determine the surface area of films using AFM, 
Brunauer-Emmett-Teller (BET) methods and those of scaffolds possibly by BET method, further 
investigation may be needed to determine the suitability, consistency of these methods in case of 
scaffolds and films. Besides this, current experimental assay protocols developed for cells 
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cultured in standard polystyrene well plates may not address the difficulty in using samples 
having different surface areas with same external dimensions.  
6.2.6.2. Alizarin Red S Staining  
PCL/in situ HAPclay (10 wt %) film samples seeded with human MSCs were incubated 
at 37°C, 5 % CO2 under humidified conditions for 41 days and were then washed with PBS 
before fixing with 2.5 % glutaraldehyde overnight. PBS was further used to wash the fixed 
samples and this was followed by staining of the samples with Alizarin Red S dye (EMD 
Chemicals Inc., USA, 2 g/100 ml, deionized water and pH = 4.10-4.15). After washing the 
stained samples with cell culture grade water to remove excess dye, images were captured using 
a phase contrast microscope (Axiovert 40, Zeiss).   
6.2.6.3. Alkaline Phosphatase (ALP) Assay 
PCL composites containing in situ HAPclay (film samples and scaffolds) were subjected 
to similar sterilization, wetting, washing and immersion (in cell culture medium) steps as those in 
case of MTT assay prior to seeding them with human MSCs. 4 x 104  human MSCs were seeded 
in each well on the PCL composite film samples containing 10 wt % in situ HAPclay. In a 
separate experiment, same number of human MSCs were seeded in each well on PCL composite 
film samples containing 20 wt % in situ HAPclay. The cell-seeded film samples were further 
incubated at 37°C, 5 % CO2 under humidifed conditions for 10, 16 and 23 days. Media was 
refreshed after every two days. These samples were washed with PBS after incubation, 
transferred to unused wells of 24-well plates and 500 µL Triton X-100 (1 v/v % solution) was 
then added to each of the well containing the film samples. Cell lysates (250 µL) obtained after 
subjecting the immersed film samples to two freeze-thaw cycles (-70°C to 37°C) were 
transferred to new 24-well plates and incubated with p-nitrophenyl phosphate (250 µL) at room 
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temperature for 60 minutes. 3N NaOH (70 µL) was further added to the wells and absorbance 
readings were taken at 405 nm using a microplate spectrophotometer (Bio Rad, Benchmark Plus) 
for quadruplicate sample sets.  
In case of PCL composite scaffolds containing 10 wt % in situ HAPclay, 4.77 x 104 
human MSCs were seeded in each of the scaffold containing wells. PCL composite scaffolds 
containing 20 wt % in situ HAPclay were assayed in a separate experiment with 4 x 104 human 
MSCs seeded in each of the scaffold containing wells. The MSC seeded scaffold samples were 
incubated at 37°C, 5 % CO2 under humidified conditions for 10,16 and 23 days, further washed 
with PBS after incubation and then transferred to unused wells of 24-well plates. 850 µL Triton 
X-100 (1 v/v % solution) was added to each of the scaffold containing wells. Cell lysates (250 
µL) obtained after two cycles of freezing-thawing (-70°C to 37°C) of scaffold samples immersed 
in Triton X-100 were incubated in a new 24-well plate with p-nitrophenyl phosphate (250 µL) at 
room temperature for 60 minutes. Absorbance values were measured at 405 nm for quadruplicate 
sample sets after further addition of 3N NaOH (70 µL) to the wells.  
6.2.6.4. MSC Infiltration in PCL/In Situ HAPclay Composite Scaffolds 
PCL composite scaffolds (dimensions ~ 12 mm diameter and 12 mm thickness/height)  
containing 10 wt % in situ HAPclay were sterilized, wetted in alcohol, washed using PBS and 
incubated in cell culture media as mentioned earlier (section 2.6.1) before seeding them with 
human MSCs. 1 x 105 MSCs were seeded in each of the scaffold containing wells. MSC seeded 
scaffolds were further incubated under humidified conditions at 37°C, 5 % CO2 for 20 days. 
These MSC seeded scaffolds were then washed with PBS, fixed and dried using glutaraldehyde 
(2.5%), ethanol series and hexamethyldisilazane as mentioned earlier in section 2.5. After cutting 
217 
 
the fixed scaffolds at depths of 3.5 mm and 6 mm from the scaffold surfaces, upper surface 
regions of the remaining portions of the scaffolds were imaged using SEM.  
6.2.6.5. Two Stage Cell Seeding 
Two-stage cell seeding experiment was performed as a possible approach to increase 
tissue formation under in vitro conditions based on the experimental method reported in our 
previous work [22]. Potential of proteins present in the extracellular matrix (ECM) produced by 
the MSCs, complexities related to proliferation and differentiation of MSCs such as “growth 
arrest” during their differentiation [68] were considered while using this approach. Following 
sterilization, wetting, washing and incubation (in cell culture media) prior to cell seeding as 
mentioned earlier for PCL/in situ HAPclay composite film samples, 7.36 x 104 human MSCs 
were seeded in each well (of 24-well plate) on PCL composite film samples containing 10 wt % 
in situ HAPclay. After incubating these MSC seeded composite films for 24 days at 37°C, 5 % 
CO2, human MSCs (7.36 x 10
4) were again seeded on these films. Incubation of the PCL 
composite films thus seeded two times with human MSCs was continued further up to 41st  day. 
The composite film samples were then stained with Alizarin Red S dye and were also imaged 
using SEM and AFM (described later). Similarly, in a separate two-stage cell seeding experiment 
PCL films containing 20 wt % in situ HAPclay seeded with MSCs were incubated for 42 days 
and then imaged using SEM.  
6.2.7. Atomic Force Microscopy (AFM) studies 
AFM was used to study the sub-micron scale morphology of PCL/in situ HAPclay 
composite films and mineralized ECM formed by human MSCs on PCL/in situ HAPclay (10 wt 
%) composite films. MultimodeTM AFM equipped with Nanoscope IIIa controller and J-type 
piezo scanner (Veeco Metrology Group, Santa Barbara, CA) was used to perform AFM imaging 
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in TappingModeTM . Antimony (n) doped Si tips were used to image the samples under 
laboratory conditions. 
6.2.8. Nanoindentation 
Nanoindentation experiments were performed using a Hysitron Triboscope 
nanomechanical testing instrument (Minneapolis, MN) to measure nanomechanical properties of 
PCL/in situ HAPclay films. The nanomechanical testing instrument was used along with 
MultimodeTM AFM mentioned earlier to perform load-controlled nanoindentation tests. This 
instrument has a diamond Berkovich tip (100-200 nm diameter) operated by a three-plate 
capacitive transducer that is used to apply desired load on the sample. Load-displacement curves 
obtained by loading and unloading the sample were used to calculate the elastic modulus (E) and 
hardness (H) using the Oliver-Pharr method [69]. In this work, a 5-5-5 trapezoidal load function 
was used to perform load-controlled indentation tests at 1000 µN and 5000 µN loads. Elastic 
moduli and hardness values obtained from a total 31 indents made at different sites on the sample 
surface were used to calculate the average E and H values represented in Table 1.  
6.2.9. In Vitro Degradation Studies 
Accelerated degradation studies were performed on PCL composite scaffolds using 
sodium hydroxide solution (0.1 M). Scaffold samples (~12 mm diameter and ~ 3 mm thickness) 
were UV sterilized, immersed in 70 % alcohol overnight and then washed with PBS. The 
scaffold samples were then transferred to glass vials containing the degradation media (0.1 M 
NaOH ). Each scaffold sample was thus immersed in separate vials containing the degradation 
media with the caps of these vials tightened properly. These scaffold containing vials were 
maintained at 37°C during the degradation period with degradation media being refreshed after 
every 7 days. After each degradation period (time point), the scaffolds were removed from the 
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vials, washed carefully with deionized water and dried at room temperature. The percentage 
weight loss for the scaffold samples was calculated using the following formula: 
% weight loss = (wi-wd)/wi x 100 
wi = initial weight of scaffold before degradation 
wd = weight of degraded scaffold 
Data was obtained for quadruplicate sample sets after each time point in these experiments. 
6.2.10. Fourier Transform Infrared (FTIR) Spectroscopy Studies 
Photoacoustic FTIR (PA-FTIR) spectroscopy experiments were performed on PCL and 
PCL composite scaffolds containing in situ HAPclay. Degraded PCL/in situ HAPclay composite 
scaffold samples obtained during accelerated in vitro degradation studies were also characterized 
using PA-FTIR spectroscopy for comparative studies. PA-FTIR experiments were performed 
using ThermoNicolet Nexus 870 spectroscopy instrument accessorized with MTEC Model 300 
photoacoustic detector. Spectra were collected in the 4000-400 cm-1 range at a mirror velocity of 
0.15 cm/s.  
6.2.11. Porosity Evaluation 
Apparent density of the scaffolds was calculated by considering their mass and volume. 
Solid density of the scaffold material was determined using a pycnometer. Porosity of the PCL/in 
situ HAPclay composite scaffolds was then calculated using the following formula: 
% porosity = (1- ρa/ρs) 
ρa = apparent density of scaffold and ρs=solid density of scaffold material 
6.2.12. Mechanical Properties 
Compressive mechanical properties of scaffold samples (~ 13 mm diameter and 13 mm 
length) were determined using MTS 858 materials testing servo mechanical test frame (Materials 
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Testing Solutions, Eden Prairie, MN). Quadruplicate sample sets were used while performing 
during this experiment. Slope of the initial linear region of stress-strain curve was used for 
calculating the compressive elastic moduli of scaffold samples.   
6.2.13. Statistical Analysis 
Student’s t-test was performed using Minitab to analyze the data acquired during 
experiments. One-way ANOVA was used in case of comparison between more than two 
different samples. Data was considered significantly different when probability values were less 
than 0.05 (p < 0.05).   
6.3. Results and Discussion 
6.3.1. Scanning Electron Microscopy 
6.3.1.1 Scaffold Morphology 
SEM micrographs in Figure 6.2. (a-c) show that the PCL and PCL composite scaffolds 
containing in situ HAPclay prepared using freeze-extraction method have a porous 
microstructure. These scaffolds seem to have pore sizes in the 100 µm-300 µm range and also 
below 100 µm. Pore size is known to have an effect on cell migration and proliferation, diffusion 
of nutrients and oxygen, vascularization and bone formation [70]. Also, other morphological 
features (pore shape, internal geometry, macro and micro porosities, surface concavities) of the 
scaffold can affect bone formation [71-73] and also have an effect on the osteoinductivity of 
scaffolds [6]. Microporosities (pore size < 10 µm) along with few pores in the 10 µm-30 µm 
range can be seen in the walls of larger (100 µm-300µm range) pores [Figure 6.3. (a-c)]. Such 
micropores can result in increase of protein adsorption due to increase in surface area, assist in 
ion-exchange along with apatite formation via dissolution-reprecipitation on pore surfaces [74] 
and can be useful to allow effective nutrient-waste exchange [75]. These processes (protein 
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adsorption and apatite formation) are known to promote bone formation and also induce 
favorable response of bone forming cells through the roughened pore surface. The PCL 
composite scaffolds containing in situ HAPclay also show interspersed lamellar features [Figure 
6.3. (d, e)]. Presence of such features in PCL/in situ HAPclay composite scaffolds can thus 
possibly affect bone formation and may contribute to enhance their osteoinductivity in case of in 
vivo applications. 
 
Figure 6.2. SEM micrographs of PCL scaffolds [a)], PCL scaffolds containing 10 wt % in situ 
HAPclay [b)] and PCL scaffolds containing 20 wt % in situ HAPclay [c)] 
 
Consideration of the complexities of in vivo environment such as the 
inflammatory/foreign body response to implanted biomaterials while designing scaffolds can be 
useful to improve the in vivo performance of scaffolds. Macrophages involved in foreign body 
reaction to conventional biomaterials (solid implants) undergo “frustrated phagocytosis” and 
eventually the implanted biomaterial gets enclosed in a collagenous capsule [76]. Degrading 
substances released during this reaction affect the performance of the implanted biomaterial [77].  
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Figure 6.3. SEM micrographs showing micropores (<10 µm and 10 µm-30 µm range) in PCL 
scaffolds [a)], PCL scaffolds containing 10 wt % in situ HAPclay [b)], PCL scaffolds containing 
20 wt % in situ HAPclay [c)] and lamellar features in PCL scaffolds containing 10 wt % in situ 
HAPclay [d)], PCL scaffolds containing 20 wt % in situ HAPclay [e)] 
 
Studies over the past few years have suggested that porous scaffolds can be useful to 
evade the foreign body reaction in case of in vivo applications [78, 79]. It has been hypothesized 
that the pore size of scaffolds can be used to induce the M2 phenotypic expression of the 
macrophages. M2 phenotype of macrophages is considered to be immunosuppressive, anti-
inflammatory and has healing properties as opposed to the pro-inflammatory M1 phenotype [78]. 
Recent studies have reported scaffolds having pore size below 50 µm  capable of inducing M2 
phenotypic expression in macrophages [79, 80] and reducing the thickness of the collagenous 
capsule formed under in vivo conditions [81, 82]. Several studies have proposed pore size of 
100-500 µm for bone regeneration taking in to account factors such as cell attachment, 
proliferation and infiltration in scaffolds, capillary formation, nutrient diffusion and waste 
removal [70, 83, 84]. Importance of graded pore size in scaffolds to mimic the structural 
complexities of natural tissues was also emphasized in some of these studies [75, 85]. The two 
different pore size ranges seen in PCL/in situ HAPclay scaffolds seem to satisfy the criteria for 
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use in bone tissue engineering and were used for in vitro experiments in this work. Differences in 
pore size/pore size range required for bone regeneration and avoidance of adverse in vivo 
response makes synergizing tissue regeneration with in vivo immune response a difficult task 
and needs further investigation.  
6.3.1.2. Human MSC seeded PCL/In Situ HAPclay Composite Films and Scaffolds 
Figure 6.4. (a-l) shows SEM micrographs of PCL/in situ HAPclay composite films 
seeded with human MSCs. These images indicate attachment, spreading of MSCs on the 
composite films and formation of mineralized extracellular matrix (ECM) by MSCs on these 
composite films. The attached MSCs also seem to conform to substrate geometry and formation 
of cell layers by MSCs on the PCL composite films can also be observed in some of these SEM 
micrographs. These cell layers can be a result of membrane fusion events or formation of special 
types of intercellular adherens junctions such as “processus adhaerentes” or “recessus 
adhaerentes” between the MSCs [86]. A closer inspection of some of these SEM micrographs 
also gives an indication of intercellular communication in MSCs through cell protrusions such as 
lamellipodia (sheet-like) and a few filopodia (long & thin processes). The mineralized ECM 
formed by the MSCs appears to be composed of matrix vesicles. Matrix vesicles have been 
implicated in cell-dependent bone mineral formation mechanisms where such vesicles may either 
emerge from the cell plasma membrane [87] or may be transported from inside of the cell to the 
extracellular space [88]. Matrix vesicles observed in the SEM micrographs also appear to be 
associated with surface of the cell layers with a few of them seeming to be embedded in the cell 
layers. This suggests the delivery of these vesicles from the cells along the routes involved in 
bone mineral formation mentioned earlier. Moreover, cell layers formed due to intercellular 
associations or junctions observed in the SEM micrographs also suggests movement of 
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substances/particles across cell membranes. However, further detailed investigation using 
different types of available microscopy techniques is needed to confirm the transport of 
particles/substances across cell membranes. 
 
Figure 6.4. SEM micrographs of human MSCs cultured on PCL composite films containing 10 
wt % in situ HAPclay [a) -f)] after 41 days, PCL composite films containing 20 wt % in situ 
HAPclay [g) -l)] after 42 days indicating cell attachment, spreading and mineralized extracellular 
matrix (ECM) formation. Solid black arrows indicate sheet-like cell protrusions known as 
lamellipodia and dotted black arrows indicate long, thin cell processes known as filopodia. White 
arrows in image f) indicate mineralized ECM  
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SEM micrographs in Figure 6.5. (a-h) represent qualitative data from the two-stage cell 
seeding experiment involving MSCs. These micrographs show formation of MSC cell layers on 
the PCL/in situ HAPclay composites. The MSC cell layers also appear to exhibit some stacking 
(indicated by arrows) along with possibilities of membrane fusion and formation of cell junctions 
mentioned earlier. Formation of dense mineralized ECM is also observed in some of the 
micrographs which indicates differentiation of MSCs towards an osteogenic lineage. Besides 
this, “stacked cells” (possibly osteoprogenitor cells) consisting a layer of four to six cells 
surrounding a “prechondrogenic” core of cells and known to differentiate in to ostoeblasts are 
considered to be involved in initial stages of embryonic bone formation [89].  
 
Figure 6.5. SEM micrographs of human MSCs cultured on PCL composite films containing 10 
wt % in situ HAPclay [a) -d)] after 41 days, PCL composite films containing 20 wt % in situ 
HAPclay [e) -h)] after 42 days indicating stacking of cell layers and mineralized extracellular 
matrix (ECM) formation during two-stage cell seeding experiment. Different colored arrows in 
a), b) and h) indicate different cell layers 
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In case of two-stage cell seeding experiment, the observed stacking in cell layers may be 
an effect of experimental procedure where the cells seeded initially form the initial cell layer on 
the substrate and cells seeded second time form the following cell layers. Moreover, it may also 
be possible that the cells (MSCs) in the initial layer on the substrate may be at an advanced stage 
of differentiation compared to the cells in the successive layers and needs further studies. This 
implies the possible utility of two-stage cell seeding experiment in creating an in vitro 
environment similar to the one known to exist during embryonic stages of bone formation. MSCs 
were also able to attach to the PCL/in situ HAPclay composite scaffolds [Figure 6.6. (a-h)] and 
showed both spherical and flat morphology. Some of the SEM micrographs in Figure 6.6. also 
indicate MSCs having interdigitated membrane features possibly containing adhering junctions 
[86]. In a separate experiment to study the infiltration of MSCs in the PCL/in situ HAPclay 
composite scaffolds, it was observed that the MSCs were able to infiltrate the scaffolds at depths 
of 3.5 mm and 6 mm from the scaffold surface [Figure 6.7. (a-i)]. SEM micrographs in Figure 
6.7. (a-i) also indicate differences in morphology of the infiltrated MSCs and those attached to  
the scaffold surface. MSCs attached on the scaffold surface appear to have a flat morphology 
along with the interdigitated membrane features. MSCs that infiltrated the interior regions of the 
scaffold seem to have longer filopodia and also appear to be clustered while exhibiting relatively 
complex cellular configurations. Differences in microenvironment at the surface and in the 
interior regions of the PCL composite scaffolds may be one of the factors that can be attributed 
to the observed differences in morphology of the MSCs. Cell morphology is known to be 
affected by dynamic reorganization of cytoskeletal filaments and also related to cell signaling 
cascades, protein synthesis along with other vital cellular functions. Thus, the MSCs in the 
interior regions of the PCL composite scaffolds possibly experience different signaling cascades 
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compared to the MSCs at the scaffold surface with this further having an effect on their protein 
synthesis and other functions. 
 
Figure 6.6. SEM micrographs of human MSCs cultured on PCL composite scaffolds after 11 
days: PCL scaffolds containing 10 wt % in situ HAPclay [a),b)], PCL scaffolds containing 20 wt 
% in situ HAPclay [c),d)] and after 34 days: PCL scaffolds containing 10 wt % in situ HAPclay 
[e), f)], PCL scaffolds containing 20 wt % in situ HAPclay [g),h)]. Black arrows indicate cells 
that appear to have spherical morphology and flat morphology (either conforming to scaffold 
pore walls or bridging the pores). White arrows indicate regions of scaffold pore walls/material  
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Figure 6.7. SEM micrographs of human MSCs on scaffold surface [a) - c)], at 3.5 mm depth 
from scaffold surface [d) – f)] and at 6 mm depth from scaffold surface [g) – i)] in case of PCL 
scaffolds containing 10 wt % in situ HAPclay after 20 days of culture. Images d) - h) indicate 
MSC infiltration in PCL/in situ HAPclay scaffolds and also show that the infiltrated cells appear 
to be clustered and have relatively complex cellular configuration compared to the cells on 
scaffold surface 
 
6.3.2. Cell Viability 
MTT assay indicated the viability of human MSCs on PCL/in situ HAPclay composite 
films [Figure 6.8.] and scaffolds [Figure 6.9.]. Statistical similarity (insignificant differences) 
between the absorbance values (live cells) can be seen in case of PCL films containing 10 wt % 
in situ HAPclay and PCL films without in situ HAPclay. In case of PCL films containing 20 wt 
% in situ HAPclay and PCL films without in situ HAPclay, significant differences in absorbance 
values can be observed (after 10 days and 23 days). Insignificant differences can be seen 
between absorbance values for PCL scaffolds containing 10 wt % in situ HAPclay and PCL 
scaffolds without in situ HAPclay except for data obtained after 10 days culture. Significant 
differences between absorbance values are observed for PCL scaffolds containing 20 wt % in 
situ HAPclay and PCL scaffolds without in situ HAPclay. PCL composite scaffolds containing 
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20 wt % in situ HAPclay also show lower mean absorbance values compared to PCL scaffolds 
without clay at all data points. Studies have suggested that MSCs can go through complex 
cellular events such as “predifferentiation growth arrest,” “nonterminal” and “terminal” 
differentiation that are involved in their unified control process of proliferation and 
differentiation [68, 90]. Recently it has been reported that a considerable heterogeneity exists in 
the division capabilities of MSCs in a single passage constituted of multiple generations [91]. A 
smaller fraction of the original cell numbers is mostly responsible for the increase in cell 
numbers in a single passage and a large fraction of the original cells do not undergo cell division. 
It was also reported that a size heterogeneity exists between MSCs in a single passage where the 
larger cells do not divide or self-replicate. The numerous complexities associated with MSCs 
along with yet incomplete understanding about the interrelationship between their proliferation 
and differentiation makes it difficult to conclude about the effect of material (PCL/in situ 
HAPclay composites) on cell proliferation from MTT assay results.  
 
Figure 6.8. Comparative results from MTT assay [a)], ALP assay [b)] for PCL composite films 
containing 10 wt % in situ HAPclay and MTT assay [c)], ALP assay [d)] for PCL composite 
films containing 20 wt % in situ HAPclay 
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Figure 6.8. Comparative results from MTT assay [a)], ALP assay [b)] for PCL composite films 
containing 10 wt % in situ HAPclay and MTT assay [c)], ALP assay [d)] for PCL composite 
films containing 20 wt % in situ HAPclay (continued) 
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Figure 6.8. Comparative results from MTT assay [a)], ALP assay [b)] for PCL composite films 
containing 10 wt % in situ HAPclay and MTT assay [c)], ALP assay [d)] for PCL composite 
films containing 20 wt % in situ HAPclay (continued) 
 
 
 
 
Figure 6.9. Comparative results from MTT assay [a)], ALP assay [b)] for PCL composite 
scaffolds containing 10 wt % in situ HAPclay and MTT assay [c)], ALP assay [d)] for PCL 
composite scaffolds containing 20 wt % in situ HAPclay 
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Figure 6.9. Comparative results from MTT assay [a)], ALP assay [b)] for PCL composite 
scaffolds containing 10 wt % in situ HAPclay and MTT assay [c)], ALP assay [d)] for PCL 
composite scaffolds containing 20 wt % in situ HAPclay (continued) 
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Figure 6.9. Comparative results from MTT assay [a)], ALP assay [b)] for PCL composite 
scaffolds containing 10 wt % in situ HAPclay and MTT assay [c)], ALP assay [d)] for PCL 
composite scaffolds containing 20 wt % in situ HAPclay (continued) 
 
6.3.3. Cell Differentiation 
Alkaline phosphatase (ALP), a metalloenzyme present in plasma membrane, is known as 
biochemical marker of osteoblast phenotype and used to study the differentiation of MSCs 
towards osteogenic lineage. ALP assay indicated the differentiation of MSCs on PCL/in situ 
HAPclay films [Figure 6.8.] and scaffolds [Figure 6.9.]. ALP activity was not normalized to the 
total protein content. Due to the possibility of extracellular matrix (ECM) formation on PCL/in 
situ HAPclay films and scaffolds (also indicated by figures 6.4., 6.5 and 6.7) seeded with MSCs 
during cell culture, the proteins present in the ECM may get included while estimating the total 
protein content. There are uncertainties whether the current methods (such as RC DC assay) to 
estimate protein content specifically quantify the intracellular proteins or both intracellular and 
extracellular proteins. Inclusion of ECM proteins in the total protein content may affect the 
results since total intracellular protein content (proportional to cell numbers) is required for data 
normalization. Insignificant differences between absorbance values obtained from MTT assay 
234 
 
for PCL/in situ HAPclay (10 wt %) films and PCL films without in situ HAPclay at the same 
time points (e.g. 16 and 23 days) suggest that the ALP activity is unlikely to be significantly 
affected by cell numbers in case of PCL films containing 10 wt % in situ HAPclay. Increase in 
mean absorbance values was observed in case of these films after 10 days of culture but the 
differences in mean values were not statistically significant (p > 0.05). ALP activity was lower in 
case of PCL films containing 20 wt % in situ HAPclay compared to PCL films without in situ 
HAPclay and is more likely to be affected by the differences in absorbance values (cell 
numbers) obtained from MTT assay at this time point. Though lower ALP activity was observed 
in case of PCL/in situ HAPclay (20 wt %) films compared to the PCL films after 16 days culture, 
insignificant differences in absorbance values (cell numbers) at this time point obtained from 
MTT assay suggests that the ALP activity is more likely to be affected by other factors 
(explained later) rather than the cell numbers. Similar observation about ALP activity can also be 
made in case of PCL/in situ HAPclay scaffolds containing 10 wt % in situ HAPclay for 
comparative data obtained at time point of 23 days. Insignificant differences between ALP 
activity of PCL scaffolds with 20 wt % in situ HAPclay and PCL scaffolds (at days 16 and 23) 
with higher mean absorbance values (ALP activity) for PCL scaffolds. This can be attributed to a 
combination of statistically higher absorbance values (proportional to cell numbers) from MTT 
assay for PCL scaffolds and other factors affecting ALP activity.  
ALP known to be associated with cell membrane and matrix vesicles is considered to be 
involved in the initiation of mineralization by hydrolyzing organic phosphates to release 
inorganic phosphates at mineralization sites [92] and may also cause increase in local pH to 
precipitate apatite [93]. Decrease in ALP activity has been associated with mineralization due to 
its adsorption to the mineral being formed and loss of metal ions from its active site [94]. This 
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may be one of the factors for the comparatively lower ALP activity observed in case of PCL/in 
situ HAPclay films and scaffolds mentioned earlier. ALP is also considered as a marker for early 
stage of osteogenic differentiation and has higher expression in pre-osteoblasts that represent one 
of the transitional stages of differentiation of stem cells to osteoblasts capable of synthesizing 
extracellular matrix (ECM). Other factors affecting ALP activity can thus include the differences 
in differentiation stage of MSCs (e.g., ALP negative osteoprogenitor cells and ALP positive pre-
osteoblasts [95, 96] cultured on composites (scaffolds and films) with and without in situ 
HAPclay.  
6.3.4 Alizarin Red S Staining 
Alizarin Red S, a dye known to develop red color on forming a complex with calcium, 
was used to stain the PCL/in situ HAPclay (10 wt %) films seeded with MSCs. Figure 6.10. (b,c) 
indicates appearance of red color with some regions in these images showing relatively intense 
red color. Appearance of red color indicates presence of calcium and thereby formation of 
mineralized extracellular matrix (ECM) by the MSCs. The irregularly shaped regions (100-200 
µm) of relatively intense red color seen in the images may possibly be cell clusters/nodules with 
higher calcium concentration. Considering the presence of calcium in in situ HAPclay 
incorporated in the PCL composite film and for making the formation of mineralized ECM more 
evident in case of PCL composite films, unseeded PCL/in situ HAPclay (10 wt %) film was 
stained with Alizarin Red S. Red colored spots (~ 80 µm and below) seen in Figure 6.10. (a) 
indicate the presence of calcium in these films. On comparison with PCL/in situ HAPclay (10 wt 
%) films seeded with MSCs, it was observed that irregularly shaped regions (similar to one 
delineated in Figure 9.10. (b) with relatively intense red color are absent in case of unseeded 
PCL/in situ HAPclay (10 wt %) films. Besides this, red color seen in Figure 6.10.(b, c) for MSC 
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seeded PCL composite films appears to be well dispersed over the region of images compared to 
the relatively discrete red colored spots seen in case of image for unseeded PCL composite film. 
The relatively large and bright yellow colored regions interspersed among these red spots 
possibly indicate absence of calcium and such regions appear to be less in case of images for 
MSC seeded PCL composite films. The formation of mineralized ECM on MSC seeded PCL/in 
situ HAPclay (10 wt %) films also indicated differentiation of MSCs towards osteogenic lineage 
and possibly the last stage of osteoblast differentiation [97, 98]. Also, mineralized ECM 
formation indicated the osteoinductive and osteoconductive properties of PCL/in situ HAPclay 
composites due to the absence of osteogenic supplements in the cell culture medium used for 
experiments.  
 
Figure 6.10. Phase contrast images of a) Alizarin Red S stained PCL/in situ HAPclay (10 wt %) 
film, b) PCL/in situ HAPclay films seeded with human MSCs after Alizarin Red S staining 
(culture time 41 days) indicating mineralized extracellular matrix (ECM) formation. One of the 
irregularly shaped regions of intense red color in image b) delineated by dotted line may possibly 
be mineralized ECM in cell nodules/clusters having higher calcium concentration. Scale bar -200 
µm 
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6.3.5. Atomic Force Microscopy (AFM) 
6.3.5.1 Sub-micron Scale Structure of Mineralized ECM 
Lower levels of structural hierarchy arising from arrangement of hydroxyapatite (HAP) 
with self-assembled collagen at the nanoscale level and interaction between these two 
components (viz., HAP and collagen) across different scales contribute to the high mechanical 
properties of bone. Studying the sub-micron scale structure of engineered bone or mineralized 
ECM generated from cell-material interactions in vitro can be useful for comparative assessment 
of their nano/microstructural components with their natural bone counterparts. Figure 6.11. (a-f) 
shows 3D AFM height and phase images of mineralized ECM formed on PCL/in situ HAPclay 
(10 wt %) composite films by human MSCs (also discussed earlier under section 3.4). Alizarin 
Red S staining was performed prior to AFM imaging to confirm positive staining and thus 
mineralization of ECM formed by MSCs. Collagen fibrils having a width/diameter in the 70-100 
nm range are visible in the phase images [Figure 6.11. (b, d)] and also appear to have banded 
features similar to collagen fibrils in natural bone. These banded features represent gap (hole) 
and overlap zones resulting from characteristic “quarter-staggered” arrangement of collagen 
fibrils in natural bone. Identification of collagen by different microscopy techniques (e.g. 
transmission electron microscopy, AFM) via presence of banded features has been reported in 
several studies [99-104]. Besides appearing to be arranged parallel to each other, the collagen 
fibrils also seem to be in the process of forming fibers by associating with each other. The 
associated fibrils seem to have formed bundles having width approximately in 0.85-1.00 µm 
range [indicated by black dotted arrows in Figure 6.11. (a)]. The AFM images also indicate 
considerable mineralization and presence of irregularly shaped mineral particles having size 
approximately in 20-330 nm range.  
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Figure 6.11. AFM 3D height images/surface plots [a), c), e)] and phase images [b), d), f)] 
showing sub-micron scale structure of mineralized ECM formed by MSCs on PCL/in situ 
HAPclay (10 wt %) films. Dotted black arrows in image a) indicate formation of collagen fibril 
bundles. Banded features observed in images b), d), f) (more evident in image f) indicate 
presence of collagen (explanation under section 6.3.5.1). Black arrows in image c) and smaller 
white arrows in image d) indicate “fish scale” packing of mineral particles over collagen fibrils. 
Solid white lines with dotted arrow at the center (image d) indicate orientations of different 
groups of collagen fibrils. Dotted square in image d) represents the zoomed region shown in 
images e) and f)  
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The mineral particles appear to overlay the collagen fibrils in some regions and are 
oriented both parallel and perpendicular to the long axis of collagen fibrils. Also, the mineral 
particles appear to be fused with each other to form mineral layers/sheets. Figure 6.11. (c, d) 
indicates presence of “fish scale” packing [101] of mineral particles over the collagen fibrils 
(indicated by black arrows in 3D height image and white arrows in phase image). This type of 
packing [more evident in zoomed regions shown in Figure 6.11. (e) & Figure 6.11. (f)] involves 
mineral platelets arranged along the long axis of collagen fibrils with the z-axis of these mineral 
platelets perpendicular to the fibril axis. Figure 6.11.(b) further indicates presence of groups of 
mineral overlaid fibrils with fibrils in the same group parallel to each other but fibrils in different 
groups oriented in different directions (indicated by white solid lines with dotted arrow at the 
center). The dimensions of banded features showing repetitive patterns in collagen fibrils at a 
few subportions of the fibrils were found to be approximately 64-70 nm. Considerable 
mineralization as indicated by the AFM images caused most of the collagen fibrils to be overlaid 
by mineral particles that led to insufficient demarcation of the gap/overlap banded pattern in 
AFM images of collagen fibrils. This made it difficult to measure the size of the morphological 
features along the length of collagen fibrils. Dependence of AFM Tapping ModeTM imaging 
mode on factors such as sample topography, sample-tip interactions, surface stiffness and 
experimental parameters may have further contributed to this insufficient demarcation of 
gap/overlap regions in the collagen fibrils. Presence of variation in dimensions of banding 
pattern (values greater or less than the widely reported 67 nm)  observed in collagen fibrils can 
be attributed to several factors [105]. One of them is the difference in local mechanical stresses 
under in vitro (cell culture) and in vivo (in functional bone inside the body) conditions. Also, 
different cells participating in collagen fibrillogenesis via “fibropositors” may experience 
240 
 
different mechanical stresses that may further affect the dimensions of the banding pattern [105]. 
Additionally, cell-related factors such as expression levels of homotrimeric collagens and minor 
collagens (types V and XI) along with posttranslational modifications can further influence the 
dimensions of the banding pattern.   
6.3.5.2 Surface Morphology of PCL/In Situ HAPclay Composite Films 
Surface morphological features in the micron to sub-micron size range have been 
reported for their effect on cell adhesion, morphology, migration, proliferation, differentiation, 
contact guidance [106-108] and possible role in modulating foreign body response [109]. Figure 
6.12. (a-d) shows AFM images (rotated 3D surface plots) of PCL and PCL/in situ HAPclay (10 
wt %) films. Disordered morphological features in the micron to sub-micron scale were seen in 
case of PCL films without in situ HAPclay [Figure 6.12. (a, b)]. Shapes of these morphological 
features varied from elongated, globular to irregular. The size of most of these morphological 
features was in the sub-micron range (below 1µm-100 nm) with some of them being in the 
nanoscale range (< 100 nm). A few relatively larger, elongated features in 500 nm-1µm size 
range were also observed. Closer observation of the images showed some of these larger features 
to be composed of smaller globular morphological features. In case of PCL composite films 
containing 10 wt % in situ HAPclay surface morphological features had similar shapes to those 
observed in case of PCL films without in situ HAPclay [Figure 6.12.(c,d)]. In addition to the 
observation of some globular features in the 100 nm-200 nm, it was also seen that the elongated 
features of 1-2 µm size appeared to be formed by side-by-side arrangement of short, thick 
features of sub-micron size. Thus, a certain degree of order seems to exist in the substructure of 
the elongated features in case of PCL composite films. Such substructural arrangement of short, 
thick features was not observed in the elongated features present on surface of PCL films without 
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in situ HAPclay. Overall, the shorter dimension (width) of most of the elongated morphological 
features in case of PCL films with in situ HAPclay appeared to be larger (250 nm -1µm range) 
than those seen in case of PCL films (< 250 nm). Osteoinductive properties have been attributed 
to topography and geometry in previous studies involving biomaterials for bone formation [6]. 
The subtle differences between topographical features of PCL/in situ HAPclay composite films 
compared to PCL  films among various other factors may thus have contributed to the 
osteoinductivity (inferred  from SEM studies and Alizarin Red S staining) of PCL/in situ 
HAPclay composite films. Representative AFM phase images [Figure 6.13. (a, b)] of PCL and 
PCL/in situ HAPclay films indicate presence of lamellae known to form spherulites in 
semicrystalline polymers. These lamellae/lamellar features are polymer crystallites composed of 
folded polymer chains and are considered to radiate outward from the center of polymer 
spherulites. Existence of such lamellae in “flat-on” and “edge-on” orientations have been 
reported in case of polymer films prepared by solution casting and solvent evaporation [110, 
111]. The lamellae seen in the phase images seem to have a “flat-on” orientation both in case of 
PCL and PCL/in situ HAPclay (10 wt %) films. Also, these lamellae appear to be made of short 
and discrete features due to which their substructure seems to have a granular appearance. 
Lamellae in case of PCL films had widths in the nanoscale (< 100 nm) range and 100-150 nm 
range whereas in case of PCL/in situ HAPclay (10 wt %) films most of the lamellar widths were 
approximately in the 100-500 nm range. Polymer crystallization involving nucleation and 
subsequent growth of lamellae may proceed in a different manner at the complex polymer (PCL) 
/inorganic (in situ HAPclay) interfaces during preparation of PCL/in situ HAPclay (10 wt %) 
films compared to the neat PCL films. The relatively larger lamellar widths observed in case of 
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PCL/in situ HAPclay (10 wt %) films may thus be an effect of in situ HAPclay particles on the 
nucleation and subsequent growth of polymer lamellae.  
 
Figure 6.12. AFM images (rotated 3D surface plots) of PCL [a), b)] films, PCL composite films 
containing 10 wt % in situ HAPclay [c), d)]. PCL films appear to have morphological features of 
different shapes (elongated, globular, and irregular) in the sub-micron range and nanoscale 
range. PCL composite films also had similar morphological features in 100-200 nm range and 1-
2 µm range. The elongated features in case of PCL composite films seem to consist of sub-
micron sized features arranged side-by-side 
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Figure 6.13. AFM phase images of PCL [a)], PCL composite films containing 10 wt % in situ 
HAPclay [b)]. Lamellar features observed in these phase images are polymer crystallites 
composed of folded polymer chains and appear to have a “flat-on” orientation. Widths of 
lamellar features in case of PCL films were in the nanoscale range and 100-150 nm range. 
Lamellar widths in case of PCL composite films were in 100-500 nm range  
6.3.6. Nanomechanical Properties of PCL/In Situ HAPclay Composite Films 
Table 6.1. shows comparative nanomechanical properties (average values of elastic 
moduli and hardness) of PCL composite films containing in situ HAPclay. It was observed that 
the average elastic moduli and hardness were significantly higher in case of PCL composites 
containing in situ HAPclay compared to PCL. At 1000 µN, the average elastic modulus 
increased by ~ 592 % and ~ 223 % in case of PCL films containing 10 wt % and 20 wt % in situ 
HAPclay respectively. Similarly, increase in average hardness at this load was ~ 798 % and ~ 
290 % in case of PCL films containing 10 wt % and 20 wt % in situ HAPclay respectively. At a 
higher load of 5000 µN, similar trend of increase in nanomechanical properties was observed. 
For PCL films containing 10 wt % in situ HAPclay (at 5000 µN), the average elastic modulus 
increased by ~ 370 % and the average hardness increased by ~ 587 %. In case of PCL films 
containing 20 wt % in situ HAPclay (at 5000 µN), the average elastic modulus and hardness 
values increased by ~ 106 % and ~ 97 % respectively. Better dispersion of in situ HAPclay in 
PCL films containing 10 wt % in situ HAPclay may be one of the reasons for relatively higher 
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nanomechanical properties observed in case of PCL films containing 10 wt % in situ HAPclay 
compared to PCL films containing 20 wt% in situ HAPclay. Higher nanomechanical properties 
of the PCL/in situ HAPclay composite films compared to PCL can be attributed to several 
factors such as interfacial interactions between PCL and in situ HAPclay, size and distribution of 
in situ HAPclay particles along with the mechanical properties of PCL. The relative decrease in 
nanomechanical properties at higher load (5000 µN) compared to lower load (1000 µN) may be 
due to the failure of interfaces in the bulk of the film samples. Such decrease in nanomechanical 
properties of modified hydroxyapatite (HAP) at higher loads has been reported in one of our 
previous studies [112]. Cellular processes such as proliferation, migration and differentiation are 
known to be influenced by mechanical properties of the underlying substrate through complex 
mechanisms involving conversion of mechanical cues to biochemical signals [113, 114]. 
Considering the increase in nanomechanical properties of PCL films with the addition of in situ 
HAPclay, it may be possible that in situ HAPclay thus plays a role in influencing the behavior of 
human MSCs. 
Table 6.1. Nanomechanical Properties of Polycaprolactone (PCL)/In Situ HAPclay composites 
 
Sample Maximum 
Load (µN) 
Elastic Modulus 
(GPa) 
Hardness 
(GPa) 
Polycaprolactone (PCL) without in 
situ HAPclay 
1000 0.406±0.115 0.0421 
5000 0.362±0.096 0.0328 
PCL/10 wt % in situ HAPclay 1000 2.808±0.641 0.377 
5000 1.702±0.251 0.220 
PCL/20 wt % in situ HAPclay 1000 1.310±0.413 0.164 
5000 0.745±0.113 0.0635 
 
6.3.7. In Vitro Degradation of PCL/In Situ HAPclay Scaffolds 
In vitro accelerated hydrolytic degradation of PCL/in situ HAPclay composite scaffolds 
was studied under alkaline conditions (0.1 M NaOH). Studies have shown that non-enzymatic 
hydrolysis of ester linkages in PCL constitutes the first stage of its in vivo degradation followed 
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by a second stage involving intracellular degradation of decreased molecular weight, 
hydrolytically cleaved PCL [48, 115]. Use of alkaline conditions during degradation studies 
helps to increase the hydrolytic degradation rate of PCL and thus simultaneously simulates the 
initial in vivo stage of PCL degradation. Possibilities of reversible hydrolytic degradation under 
acidic conditions [116], effect of temperature on polymer morphology during thermal 
degradation and lack of degrading enzymes under normal physiological conditions [117] were 
some of the other factors responsible for the preference of alkaline conditions for degradation 
studies. Figure 6.14. indicates increase in in vitro degradation of PCL and PCL/in situ HAPclay 
scaffolds over a period of 18 days. Mean weight percent loss values of PCL scaffolds containing 
in situ HAPclay were observed to be higher compared to PCL scaffolds without in situ HAPclay 
over the degradation period. Statistically significant difference in weight percent loss values was 
observed between PCL and PCL scaffolds containing 20 wt % in situ HAPclay after 14 days. 
Similarly, significant difference in weight percent loss values was also observed between PCL 
and PCL scaffolds containing 10 wt % in situ HAPclay after 18 days. Changes in rate of weight 
loss percentage were observed for scaffolds over the degradation period indicated by the 
changing slopes of lines connecting the data points (Figure 9.14. inset). PCL scaffolds without in 
situ HAPclay appear to have lost weight only after 7 days unlike PCL scaffolds with in situ 
HAPclay that appear to show weight loss before 7 days from the start of the experiment. It was 
also observed that the rate of weight loss percentage was more in case of PCL scaffolds without 
in situ HAPclay from 7 to 18 days compared to the rate of weight loss percentage observed in 
case of PCL scaffolds containing in situ HAPclay over the same time period. Rate of percentage 
weight loss was more in case of PCL scaffolds containing 10 wt % in situ HAPclay during time 
intervals of 0-7 days, 14-18 days and lower during 7-14 days time interval compared to the PCL 
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scaffolds containing 20 wt % in situ HAPclay. Weight loss during degradation of aliphatic 
polyesters such as PCL has been reported to occur when oligomeric species resulting from 
degradation become adequately small (also implying molecular weight decrease to a certain 
extent) to diffuse in to the surroundings from the bulk [115]. Also, weight loss may not be 
observed despite cleavage of ester bonds resulting in progressive decrease of molecular weight 
during the initial stage of degradation. Therefore in case of PCL scaffolds without in situ 
HAPclay though weight loss was not observed till 7 days, hydrolysis of ester linkages may have 
possibly started before 7 days (also supported by observations made from FTIR data described 
later). Weight loss observed in case of PCL scaffolds containing in situ HAPclay before 7 days 
can be a result of processes such as ester bond (polymer chain) cleavage, diffusion of oligomers 
formed by polymer chain cleavage in to the surroundings and erosion of in situ HAPclay 
particles. This also implies possibility of relatively faster reduction in molecular weight of PCL 
chains to an extent adequate for the diffusion of oligomers in case of PCL/in situ HAPclay 
composite scaffolds compared to PCL scaffolds without in situ HAPclay. Higher weight loss 
seen in case of PCL scaffolds containing in situ HAPclay compared to the PCL scaffolds without 
in situ HAPclay can be attributed to several factors. Our previous studies have shown that 
addition of organomodified clays decreases the crystallinity of PCNs and regions with disrupted 
crystallinity exist around the organomodified clay particles [35, 118]. Since the crystalline 
regions in semi-crystalline polymers are more resistant to water (degradation media) ingress than 
the amorphous regions, it may be possible that water ingress was comparatively higher in PCL 
scaffolds containing in situ HAPclay due to hypothesized presence of regions of disrupted 
crystallinity around the in situ HAPclay particles. Also, calcium phosphate based particles (e.g. 
tricalcium phosphate) incorporated in PCL based scaffolds have been reported for their effect on 
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the arrangement of polymer chains that further affects polymer chain hydrolysis. Also, these 
particles enhance water ingress since they act as “defects” in the polymer and serve as 
“conductors,” “channels” assisting in water diffusion [119]. This indicates possibility of similar 
effect of in situ HAPclay particles on the surrounding polymer (PCL) and transport of water 
molecules during degradation of PCL/in situ HAPclay scaffolds. Taking in to account the 
mobility of PCL chains at 37°C (temperature used during degradation studies) due to its low Tg 
(-60°C) and ability to recrystallize [119], the in situ HAPclay particles may impede 
recrystallization of PCL chains in PCL/in situ HAPclay composite scaffolds that further affects 
their crystallinity and thereby their degradation.  PCL scaffolds and PCL/in situ HAPclay 
composite scaffolds may also differ in porosity, pore size, pore interconnectivity that affect water 
(media) access and thus the degradation (extent of hydrolysis).  
 
Figure 6.14. Comparative percentage weight loss of PCL composite scaffolds containing in situ 
HAPclay from in vitro degradation experiment under accelerated conditions 
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Comparative photoacoustic FTIR (PA-FTIR) spectra of in vitro degraded PCL and PCL 
scaffolds with in situ HAPclay are shown in Figure 6.15. and Table 6.2. shows the relevant band 
assignments. FTIR spectra for scaffolds within the 1860-1530 cm-1 wavenumber region show  
presence of bands close to/at 1558 cm-1 ( 7 days) and 1565 cm-1 (14 and 18 days) in case of in 
vitro degraded scaffold samples. This band not seen in case of undegraded scaffolds can be 
attributed to the asymmetric stretching of carboxylate groups formed due to the hydrolysis of 
ester bonds in PCL. It was also observed that in case of PCL scaffolds without in situ HAPclay, 
this band due to the stretching of carboxylate groups was present after 7 days of in vitro 
degradation though no weight loss was observed after 7 days (discussed earlier). This indicated 
that the process of PCL chain hydrolysis may have started prior to 7th day during in vitro 
degradation and the oligomeric species formed were unable to diffuse in to the surroundings. 
Moreover, the intensity of this band representing carboxylate stretching appeared to increase 
with degradation time (7-18 days). Bands observed close to/at 1741 cm-1 and 1725 cm-1 in FTIR 
spectra of scaffolds (both degraded and undegraded) correspond to carbonyl stretching bands 
associated with amorphous and crystalline phases in PCL. Differences in widths and heights of 
these bands can be observed between overlaid FTIR spectra of undegraded and degraded 
scaffold samples [shown in Figure 6.15. (b, e, f)]. This implies changes in crystallinity of the 
scaffold samples during the degradation process due to the possible rearrangement of PCL chains 
having considerable mobility at 37°C.  Similar differences were observed in widths and heights 
of bands close to/at 1295 cm-1 and 1194 cm-1 in overlaid FTIR spectra of scaffolds [Figure 6.15. 
(c, f, i)]. Bands close to/at 1295 cm-1 arise due to C-O and C-C stretching in the crystalline phase 
of PCL and those close to/at 1194 cm-1  have been reported for their sensitivity to orientation 
[120]. This further suggests rearrangement of PCL chains in the scaffolds during the degradation 
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process. FTIR spectra of PCL scaffolds containing 10 wt % in situ HAPclay within 795-420 cm-1 
region [Figure 6.15. (j, k)] indicate minor changes (shape, intensity, width) in the band formed 
by the overlap of phosphate vibrations (close to/at 607 cm-1, 565 cm-1) and out of plane bending 
vibrations of carbonyl groups in PCL. Shoulder band at 473 cm-1 in undegraded PCL/in situ 
HAPclay (10 wt %) scaffold sample appears to show shifts over the degradation period with the 
highest shift (6 cm-1) observed for scaffolds after 14 days degradation. Although difficulty exists 
in assigning this shoulder band since it can arise from either Si-O-Si bending vibration in MMT 
clay or from phosphate vibration in HAP, it can be presumed to be arising from molecular 
vibrations in in situ HAPclay having MMT clay and HAP both as its components. Similar shifts 
in this shoulder band were also seen in case of PCL/in situ HAPclay (20 wt %) scaffolds and it 
appeared to be absent in spectra of scaffold samples subjected to 18 days of in vitro degradation. 
The reasons for this apparent absence of the band are yet incompletely understood.   
 
Figure 6.15. Comparative photoacoustic FTIR spectra of PCL scaffolds [a) – c)], PCL scaffolds 
with 10 wt % in situ HAPclay [d) – f), j)], PCL scaffolds with 20 wt % in situ HAPclay [g) – i), 
k)] over 18 days of in vitro degradation under accelerated conditions. Vertical lines a and b 
represent positions 1295 cm-1 and 1194 cm-1 in FTIR spectra 
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Figure 6.15. Comparative photoacoustic FTIR spectra of PCL scaffolds [a) – c)], PCL scaffolds 
with 10 wt % in situ HAPclay [d) – f), j)], PCL scaffolds with 20 wt % in situ HAPclay [g) – i), 
k)] over 18 days of in vitro degradation under accelerated conditions. Vertical lines a and b 
represent positions 1295 cm-1 and 1194 cm-1 in FTIR spectra (continued) 
Figure 6.16. (m-r) shows SEM images of scaffolds after 14 days and 18 days of in vitro 
degradation. Although weight loss was observed in case of all scaffolds at these time points, the 
overall structure of these scaffolds appeared to remain intact and were retrievable. The effect of 
in vitro degradation is more evident in Figure 6.16. (a-l) representing SEM images of scaffold 
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surfaces over the degradation time. Filamentous features (~ 1-3 µm length and below 500 nm 
width) were observed on surfaces of the degraded scaffolds. These features seen only in case of  
degraded scaffolds appeared to sprout from the degraded scaffold surfaces either in bunches or 
individually. The degraded scaffold surfaces thus appeared to be rougher compared to the 
undegraded scaffold surfaces having a relatively smooth texture. In case of undegraded PCL 
scaffolds containing in situ HAPclay, the scaffold surfaces seemed to have bumps probably due 
to presence of in situ HAPclay particles close the scaffold surface and minuscule defects 
appeared to surround these in situ HAPclay particles. Such defects have been previously reported 
due to the presence of tricalcium phosphate particles in synthetic polymer matrix and are 
considered to assist in water ingress in the scaffolds [119].  Also, intactness of the overall 
structure of the scaffolds over the degradation period and changes observed in scaffold surface 
morphology due to degradation indicate that the scaffolds may have undergone a surface 
degradation pathway. 
Table 6.2. FTIR band assignments for PCL/In Situ HAPclay composite scaffolds 
 
Band position (cm-1) Band assignment Reference 
1559-1566 Asymmetric COO- stretching [116, 121] 
1581-1583 Symmetric COO- stretching [122, 123] 
1707-1710 Hydrogen bonded carbonyl groups in PCL [124] 
1723-1725 C=O stretching related to crystalline regions in PCL [120] 
1739-1741 C=O stretching related to amorphous regions in PCL [120] 
1295 C-O and C-C stretching in crystalline phase [120, 125] 
1194 OC-O stretching [125] 
605-608 ν4 phosphate vibration [126] 
559-565 ν4 phosphate vibration [126] 
581-586 out of plane bending of carbonyl groups from PCL [127] 
469, 479 ν2 phosphate vibration from HAP/ Si-OSi deformation [126] 
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Figure 6.16. SEM micrographs of scaffolds from in vitro degradation experiments: PCL 
scaffolds – 0 days [a)], 14 days [b), m)], 18 days [c), d), n)], PCL scaffolds containing 10 wt % 
in situ HAPclay - 0 days [e)], 14 days [f), o)], 18 days [g), h), p)] and PCL scaffolds containing 
20 wt % in situ HAPclay - 0 days [i)], 14 days [j), q)], 18 days [k), l), r)]. Arrows in image d) 
show filamentous features (~1-3 µm length, < 500 nm diameter) sprouted from degraded 
scaffold surfaces 
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Figure 6.16. SEM micrographs of scaffolds from in vitro degradation experiments: PCL 
scaffolds – 0 days [a)], 14 days [b), m)], 18 days [c), d), n)], PCL scaffolds containing 10 wt % 
in situ HAPclay - 0 days [e)], 14 days [f), o)], 18 days [g), h), p)] and PCL scaffolds containing 
20 wt % in situ HAPclay - 0 days [i)], 14 days [j), q)], 18 days [k), l), r)]. Arrows in image d) 
show filamentous features (~1-3 µm length, < 500 nm diameter) sprouted from degraded 
scaffold surfaces (continued) 
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6.3.8. Scaffold Porosity 
Mean values of percentage porosity evaluated for PCL and PCL/in situ HAPclay (10 wt 
%) scaffolds were 88.83 % and 86.06 % respectively (Figure 6.17.). The difference between the 
percentage porosity values was found to be statistically significant. Porosity of scaffolds has 
been reported for its effect on biological processes such as cell migration, vascularization, tissue 
formation along with nutrient transport, degradation and mechanical properties of the scaffold. 
Percentage porosity above 85 percent for PCL/in situ HAPclay scaffolds further indicates the 
suitability of these scaffolds for bone tissue engineering applications.    
 
Figure 6.17. Porosity of PCL/In Situ HAPclay composite scaffolds 
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6.3.9. Compressive Mechanical Properties 
Figure 16.18 shows comparative plot of elastic moduli of PCL scaffolds without in situ 
HAPclay and PCL/in situ HAPclay (10 wt %) composite scaffolds. PCL scaffolds containing in 
situ HAPclay (10 wt %) showed ~ 94 % increase in elastic modulus compared to the PCL 
scaffolds without in situ HAPclay (table 6.3.). Mechanical properties of scaffolds can be affected 
by factors such as porosity, pore size, interconnections between the scaffold pores apart from the 
interfacial interactions between the components used to fabricate scaffolds (e.g. PCL and in situ 
HAPclay in this case). The interdependency of these factors makes it difficult to attribute the 
change in mechanical properties of scaffolds to one of these factors. Mechanical properties 
including elastic modulus values of PCL composite scaffolds containing in situ HAPclay higher 
(>) than 10 wt % in situ HAPclay can depend on dispersion of in situ HAPclay in PCL and the 
extent of change in the polymer nucleation process, freezing kinetics during scaffold fabrication. 
Representative stress-strain curve for PCL composite scaffolds containing 10 wt % in situ 
HAPclay comprising of elastic region (a), plateau region (b) and densification (c) regions is 
shown in figure 16B. Presence of such regions have been reported to be observed in case of 
stress-strain curves of porous (cellular) materials [128]. Similar stress-strain curve is also 
observed for PCL scaffolds. The elastic region of stress-strain curve for PCL composite scaffolds 
containing 10 wt % in situ HAPclay appears to have a relatively steeper slope that indicates a 
higher elastic modulus compared to PCL scaffolds without in situ HAPclay. 
Table 6.3. Compressive mechanical properties of PCL/In Situ HAPclay composite scaffolds 
Sample Elastic Modulus 
(MPa) 
Standard deviation 
(MPa) 
% increase 
Polycaprolactone (PCL) 1.285 0.212 - 
PCL with 10 wt % in situ 
HAPclay 
 
2.495 0.146 94.16 
258 
 
 
 
 
 
 
Figure 6.18. Compressive mechanical properties: A) compressive elastic moduli of PCL/in situ 
HAPclay (10 wt %) composite scaffolds, B) Representative stress-strain curves obtained for PCL 
and PCL/in situ HAPclay scaffolds- elastic region (a), plateau region (b) and densification region 
(c), Curves 1 and 2 represent stress-strain curves for PCL/in situ HAPclay (10 wt%) composite 
scaffolds and PCL scaffolds respectively 
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6.4. Conclusions 
In situ HAPclay prepared based on biomineralization process and containing 
organomodified MMT clay associated with HAP was used to fabricate synthetic 
polycaprolactone (PCL) composite films and scaffolds. Incorporation of in situ HAPclay 
imparted osteoinductive and osteoconductive properties to PCL/in situ HAPclay films evidenced 
by formation of mineralized ECM by MSCs on these films in the absence of osteogenic 
supplements. Significant improvement in nanomechanical properties and subtle effects on sub-
micron scale surface morphology were observed due to addition of in situ HAPclay in case of 
PCL/in situ HAPclay composite films. PCL/in situ HAPclay scaffolds showed a microstructure 
suitable for bone bone regeneration and their interior seemed to provide appropriate 
microenvironment for MSC attachment and their spatial organization. Cell culture assays 
indicated that PCL/in situ HAPclay composites (both scaffolds and films) provided suitable 
environment for MSC viability and influenced MSC differentiation. Increased degradation 
of PCL/in situ HAPclay composite scaffolds observed during accelerated in vitro degradation 
experiments suggested a role of in situ HAPclay in influencing degradation of slow degrading 
PCL (or polyester based) scaffolds. Also, considering these effects of in situ HAPclay on PCL/in 
situ HAPclay composites (films and scaffolds) extending from nanoscale to microscale suggests 
the potential of scaffold systems containing in situ HAPclay to satisfy multiple requirements of 
bone tissue engineering and also the ability of in situ HAPclay to impart multifunctional 
properties to resulting composites. AFM imaging experiments revealed that mineralized ECM 
formed by MSCs on PCL/in situ HAPclay composite films consisted of components of 
hierarchical organization known to exist in natural bone. These components (collagen and 
mineral) showed similarities with their natural bone counterparts with respect to their structure, 
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dimensions and arrangement. Formation of dense mineralized ECM and stacking of MSCs was 
observed on PCL/in situ HAPclay films during two-stage cell seeding experiment indicating its 
potential as a strategy to enhance tissue (bone) formation under in vitro conditions through 
cellular events similar to those observed in vivo during bone formation.    
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CHAPTER 7. CELL DEPENDENT BONE MINERAL FORMATION ON 
TISSUE ENGINEERING COMPOSITES CONTAINING NANOCLAYS 
WITH BIOMINERALIZED HYDROXYAPATITE 
This chapter presents a brief overview of bone mineral formation mechanisms and studies 
related to cell dependent bone mineral formation on polycaprolactone (PCL) composites 
containing nanoclays with biomineralized hydroxyapatite (in situ HAPclay). Observations made 
from scanning electron microscopy (SEM) studies on PCL composite composites containing in 
situ HAPclay seeded with human mesenchymal stem cells (MSCs) and results obtained from 
SEM-EDS (energy dispersive spectroscopy) experiments performed on these cell seeded 
composites constitute a major part of this chapter. 
7.1. Introduction 
Mineralization is considered an important process due to its fundamental relationship to 
human health, development and its proposed role in different types of bone diseases. The role of 
collagen and the associated non-collagenous proteins in extracellular mineralization of bone has 
been widely reported in literature. Understanding mechanisms responsible for bone mineral 
formation continue to be a part of several studies till date and it has been difficult to reach 
consensus on a specific mechanism being responsible for mineralization in bone. There seems to 
be a renewed interest in studies related to mineralization processes involving cells [1]. A major 
focus of such studies has been the role of matrix vesicles in bone mineral formation. 
Observations made during recent studies [1, 2] suggest relation between intracellular processes 
and bone mineral formation.  
Matrix vesicles are “membrane-invested” particles released by “budding” and “pinching” 
of plasma membranes of cells such as osteoblasts, chondrocytes and odontoblasts [3, 4]. Their 
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diameter can vary from 30 nm to one micron or more [3] and have been reported to be located at 
the sites of initial mineralization (or where mineralization will commence) in the extracellular 
matrix (ECM). In case of bone, matrix vesicles are positioned in the developing osteoid under 
osteoblast surfaces. Matrix vesicles are composed of “vesicle sap” enclosed by a membrane and 
are considered as sites of initial appearance of bone mineral crystals. These crystals are closely 
associated with the inner layer of the vesicular membrane. Also, these crystalline mineral 
particles appear after the vesicles are released in the ECM and are further immobilized in 
collagenous matrix of the ECM [3]. Crystals in the matrix vesicles break the vesicular membrane 
and are known to guide crystal growth known to form mineral spherules. Bone mineralization 
involving matrix vesicles is considered biphasic. First stage involves formation of mineral 
crystals in matrix vesicles followed by breaking of vesicular membrane. Subsequently, the 
mineral crystals are exposed to extracellular fluid consisting of ions (calcium and phosphate), pH 
conditions of the extracellular fluid and molecules (e.g. proteoglycans, non-collagenous proteins) 
in the extracellular environment that are considered to affect mineral crystal growth. Initial stage 
of mineral formation is controlled by enzymes, proteins and phospholipid membrane of the 
matrix vesicle. Since all these factors affecting initial mineral formation originate from the cells 
that give rise to matrix vesicles, the initial stage of mineral formation is considered to be under 
cellular control.   
The uncertainty over presence of mineral in the vesicles emerging from the cells in to the 
ECM has been discussed in several studies related to mineralization. The presence of amorphous 
calcium phosphate in intracellular matrix vesicles and the transport of such calcium phosphate 
containing vesicles from intracellular to extracellular space was suggested through experimental 
investigation involving electron microscopy, electron energy loss spectroscopy (EELS) in one of 
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the recent studies [1]. This study suggested involvement of simultaneously occurring 
processes/routes during bone mineralization. Similarly, presence of amorphous phosphate in 
intracellular vesicles and the involvement of these vesicles in bone mineralization was suggested 
in another study involving use of electron microscopy techniques. [2]. Most studies related to 
bone mineral formation have been performed using samples prepared using mineralized nodules 
formed by inducing cells with osteogenic supplements, tissue sections and tissue fragments. In 
this work, human mesenchymal stem cells (MSCs) seeded on a synthetic substrate composed of 
polycaprolactone (PCL) incorporated with in situ HAPclay (nanoclay with biomineralized 
hydroxyapatite) showed attachment and were also able to form mineralized ECM (discussed in 
Chapter 9). This synthetic substrate designed for bone regeneration applications was able to 
stimulate the human MSCs to form mineralized ECM without the use of osteogenic supplements 
or any externally applied stimuli. In this study, we hypothesize that bone mineral formation 
mechanism on an engineered substrate such as PCL/in situ HAPclay substrate (film) is similar to 
mineral formation mechanism proposed in case of natural bone. This similarity pertains to 
composition and transport of matrix vesicles involved in mineral formation in natural bone. 
Investigating the mineralized ECM and studying the morphology, composition, transport 
(delivery) of matrix vesicles present in the mineralized ECM were the objectives of this study. 
SEM imaging was used to perform qualitative studies related to cell dependent mineralization on 
these MSC seeded PCL/in situ HAPclay synthetic substrates and SEM-EDS (energy dispersive 
spectroscopy) was used to study the composition of matrix vesicles. Through these studies we 
attempt to understand the suitability of synthetic polymer composites containing in situ HAPclay 
for providing an environment assisting cellular processes involved in bone mineral formation.  
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7.2. Materials and Methods 
7.2.1. Materials 
Sodium-montmorillonite (Na-MMT) clay, Swy-2 (Crook County, Wyoming), having a 
cation exchange capacity (CEC) of 76.4 mequiv./100 g and sourced from the Clay Minerals 
Repository at the University of Missouri, Columbia was used to prepare modified MMT clay. 5-
aminovaleric acid for modifying MMT clay, polycaprolactone (PCL) (average Mn = 80,000) and 
1,4 dioxane (anhydrous, 99.8 %) for scaffold preparation were obtained from Sigma Aldrich. 
Sodium phosphate (Na2HPO4) and calcium chloride (CaCl2) required for preparing in situ 
HAPclay were obtained from J.T. Baker and EM Sciences respectively. Human MSCs from bone 
marrow (PT-2501, Lonza,Walkersville, MD.) were cultured in cell culture medium made by 
adding MSCGMTM SingleQuotsTM (PT-4105) to mesenchymal stem cell basal medium 
(MSCBMTM, PT-3238). These two components of cell culture medium available as MSCGMTM 
(mesenchymal stem cell growth medium) BullekitTM were purchased from Lonza, Walkersville, 
MD. 
7.2.2. Preparation of Modified MMT Clay and In Situ HAPclay 
Na-MMT was modified with 5-aminovaleric acid (unnatural amino acid) according to the 
procedure described in our previous studies [5-8]. Briefly, 5-aminovaleric acid solution (pH=1.8 
& temperature = 60°C) prepared in DI water was added to Na-MMT clay suspension in DI water 
(pre-heated to 60°C) and the resultant mixture was stirred vigorously for an hour. The stirred 
mixture was centrifuged for removal of DI water, washed further for removal of chloride ions, 
subsequently dried at 70°C followed by grinding and sieving to obtain a fine powder.  
In situ HAPclay was prepared according to procedure described in our earlier studies [7, 
8]. A suspension of modified MMT clay in Na2HPO4 solution was prepared by dispersing 
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modified MMT clay in Na2HPO4 solution and further stirring it for 2 hours. CaCl2 solution (39.8 
mM) was further added to this suspension and the resulting mixture (at pH=7.4) was stirred for 8 
hours. Precipitates formed were allowed to settle, centrifuged to remove water, dried at 70°C and 
then sieved after grinding to obtain a fine powder. 
7.2.3. Preparation of Polycaprolactone (PCL)/In Situ HAPclay Films (Substrates) 
PCL (0.09 grams/ml dioxane) was dissolved in 1, 4 dioxane at room temperature. For 
preparing PCL composite films containing 10 wt % in situ HAPclay, PCL (3.6 grams) was 
initially dissolved in 40 ml 1, 4 dioxane to obtain PCL solution. Further, a sonicated suspension 
of in situ HAPclay (0.4 grams in 16 ml dioxane) was added to the PCL solution. The resulting 
solution was stirred for 2 hours, further transferred to glass Petri dishes and then dried for 72 
hours to obtain PCL/in situ HAPclay (10 wt %) composite films. Samples of ~12.7 mm diameter 
were punched out from these dried films (~85 mm diameter) for cell culture experiments. 
7.2.4. Cell Culture 
PCL/in situ HAPclay composite film samples (~12.7 mm diameter) in 24-well plates 
were UV sterilized and further immersed in 70 % alcohol overnight to wet these hydrophobic 
polyester (PCL) based film samples [9-12].  The wetted PCL composite film samples were 
washed with PBS twice and then incubated in PBS (6 hours) for removal of alcohol. PBS was 
then removed and after 24 hours of subsequent incubation at 37°C, 5 % CO2 in cell culture 
medium 7.36 x 104 cells human MSCs were seeded in each well on the PCL/in situ HAPclay 
composite film samples. The cell seeded samples were incubated at 37°C, 5 % CO2 under 
humidified conditions for 41 days. 
A separate two-stage cell seeding experiment was performed using PCL/in situ HAPclay 
composite films. After sterilization, wetting, washing and incubation (in cell culture media), 7.36 
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x 104 human MSCs were seeded in each well (of 24-well plate) on PCL/10 wt% in situ HAPclay 
composite film samples. Following incubation of these MSC seeded composite films for 24 days 
at 37°C, 5 % CO2, human MSCs (7.36 x 10
4) were again seeded on these films. PCL composite 
films thus seeded two times with human MSCs were incubated further up to 41st day. MSCs up 
to passage 5 were used for all cell culture experiments. 
7.2.5. Scanning Electron Microscopy (SEM) and SEM-EDS (Energy Dispersive 
Spectroscopy) 
SEM was used to perform imaging on MSC seeded PCL/in situ HAPclay films. For this 
purpose, JEOL JSM-6490LV scanning electron microscope was used. After removing the MSC 
seeded film samples from culture, these samples were washed with phosphate buffer saline 
(PBS), fixed using glutaraldehyde (2.5%), subsequently dehydrated using ethanol series (10 % 
v/v, 30 % v/v, 50 % v/v, 70 % v/v and 100 %) and then dried after 100 % ethanol was replaced 
with hexamethyldisilazane. SEM imaging was then performed on the dried samples after coating 
them with gold and mounting them on a SEM sample stub. SEM-EDS experiments were also 
performed on these MSC seeded film samples after fixing, dehydration in ethanol series and 
drying. In SEM-EDS, a sample is bombarded with electrons (or electron beam) that causes 
emission of X-rays of characteristic energies to be emitted from the spots where the electron 
beam bombards the sample. An energy dispersive spectrometer consisting of a detector detects 
the X-rays having different energies. X-ray spectrum is then generated with y-axis showing the 
number of counts (corresponding to number of X-rays detected and processed by the detector) 
and x-axis showing the energy levels of these counts. Since each element has a unique atomic 
structure and characteristic X-ray energy, an X-ray spectrum consisting of elemental peaks is 
generated and is useful to know elemental composition of a sample. Number of counts 
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corresponding to these peaks are used to calculate the ratios of elements present in a sample. 
JEOL JSM-6490LV scanning electron microscope equipped with an energy dispersive 
spectrometer was used in this study. X-ray spectra were obtained from different spots 
corresponding to matrix vesicles formed at various locations on MSC seeded PCL composite 
films. These spectra were then used to determine the Ca and P composition (atom %) for 
different spots and Ca/P ratio for each of these spots was subsequently calculated. Number of 
points were then grouped according to the range of Ca/P ratio as shown in tables 7.1. and 7.2. 
7.3. Results and Discussion 
Figures 7.1. and 7.2. show SEM images of PCL/in situ HAPclay films seeded with 
human MSCs after 41 days of cell culture. SEM images obtained from two-stage cell seeding 
experiment are shown in Figure 7.2. In addition to the attachment of human MSCs, these images 
also indicate formation of mineralized ECM by the seeded MSCs. Magnified regions of images 
e), g), i), k) in Figure 7.1. outlined by green squares are represented by images f), h), j), l) in the 
same figure. These images indicate that the mineralized regions consist of smaller structures 
having spherical features. These spherical structures known as matrix vesicles appear to have 
different sizes. The size of most of these vesicles was in the sub-micron to below ten 
micrometers range. Some of these images also indicate that the vesicles fuse or aggregate to form 
complex structures having size above ten micrometers. SEM images in Figure 7.2. obtained from 
two-stage cell seeding experiment (described under section 7.2.4.) also indicate formation of 
matrix vesicles and these vesicles show similarity in size, organization with those shown in 
Figure 7.1. The vesicles appear to be closely associated with cellular protrusions (lamellipodia, 
filopodia) and thus seem to be emerging from the attached cells to the extracellular environment 
as observed in images c) and d) in Figure 7.1. The size of these vesicles emerging from the cells 
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was in 0.5 micrometer to 0.7 micrometer range, which is closer to the size of the vesicles 
reported in other studies [2, 3].  
 
 
Figure 7.1. SEM images (a-r) of PCL/in situ HAPclay (10 wt %) films seeded with human 
MSCs showing presence of matrix vesicles after 41 days of culture. Images b, d, f, h, j, l 
represent magnified regions of images a, c, e, g, i, k (outlined by green squares) and indicate 
presence of structures with spherical features (also known as matrix vesicles) with size in the 
sub-micron to below ten micrometers range. Images c, d show vesicles to be associated with 
cellular protrusions. (Detailed explanation given under 7.3. Results and Discussion) 
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MSCs showing presence of matrix vesicles after 41 days of culture. Images b, e, f, h, j, l 
represent magnified regions of images a, c, e, g, i, k (outlined by green squares) and indicate 
presence of structures with spherical features (also known as matrix vesicles) with size in the 
sub-micron to below ten micrometers range. Images c, d show vesicles to be associated with 
cellular protrusions. (Detailed explanation given under 7.3. Results and Discussion) (continued) 
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Figure 7.2. SEM images (a-h) of PCL/in situ HAPclay (10 wt %) films seeded twice with human 
MSCs during two-stage cell seeding experiment showing presence of matrix vesicles. Image h 
represents magnified region of image g. Structures with spherical features (also known as matrix 
vesicles) shown in these images have size in the sub-micron to below ten micrometers range. 
(Detailed explanation given under 7.3. Results and Discussion) 
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Figure 7.2. SEM images (a-h) of PCL/in situ HAPclay (10 wt %) films seeded twice with human 
MSCs during two-stage cell seeding experiment showing presence of matrix vesicles. Image h 
represents magnified region of image g. Structures with spherical features (also known as matrix 
vesicles) shown in these images have size in the sub-micron to below ten micrometers range. 
(Detailed explanation given under 7.3. Results and Discussion) (continued) 
 
A closer observation of images shown in Figures 7.1. and 7.2. indicates the vesicles to be 
either embedded within the cells or closely associated with the surface of the cells. It can be 
possible that these vesicles are present under the surface of cells. Such vesicles are seen in 
images b), m) - r) in Figure 7.1. and images a) – e) in figure 7.2. The size of some of the vesicles 
observed in these images was closer to one micrometer and below that suggests that these can be 
intracellular vesicles. Similar observations were made in another study where cryo-SEM was 
used to study mouse bones and vesicles closer to one micrometer size were suggested to be 
intracellular vesicles containing bone mineral [2].  
SEM-EDS experiments were also performed to detect the presence of calcium and 
phosphorus in the matrix vesicles formed on MSC seeded PCL/in situ HAPclay films. Figure 
7.3. shows images indicating different sites/points (represented by numbers) on these samples 
used for obtaining EDS data. Similarly, images indicating data points are also shown in Figure 
7.4. for SEM-EDS performed on samples seeded twice with MSCs (during two-stage cell 
seeding experiment). Tables 7.1. and 7.2. represent calcium to phosphorus (Ca/P) ratio obtained 
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from SEM-EDS experiments. Data presented in these tables is for points selected on matrix 
vesicles while performing SEM-EDS experiments. Localized elemental data (calcium and 
phosphorus percentage) was obtained from these points.  
 
 
 
Figure 7.3. SEM images (a-l) obtained during SEM-EDS experiment indicating different points 
used for obtaining SEM-EDS data for matrix vesicles formed on MSC seeded PCL/in situ 
HAPclay (10 wt %) films. Blue and yellow points shown in left hand side images represent the 
spots from which localized elemental data (calcium and phosphorus percentage) was obtained 
during SEM-EDS experiments. Images on the right hand side [b), d), f), h), j), l)] are shown for 
better visualization of the features seen in images a), c), e), g), i), k) 
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Figure 7.3. SEM images (a-l) obtained during SEM-EDS experiment indicating different points 
used for obtaining SEM-EDS data for matrix vesicles formed on MSC seeded PCL/in situ 
HAPclay (10 wt %) films. Blue and yellow points shown in left hand side images represent the 
spots from which localized elemental data (calcium and phosphorus percentage) was obtained 
during SEM-EDS experiments. Images on the right hand side [b), d), f), h), j), l)] are shown for 
better visualization of the features seen in images a), c), e), g), i), k) (continued) 
 
Previous studies involving SEM-EDS analysis of matrix vesicles have implicitly 
suggested presence of calcium phosphate based minerals in matrix vesicles based on calcium and 
phosphorous detected during SEM-EDS experiments [1, 2]. Presence of calcium and phosphorus 
detected by SEM-EDS in this study is thus suggestive of calcium phosphate in the matrix 
vesicles. Hydroxyapatite (HAP) containing calcium and phosphorus constitutes approximately 
60 weight percent of bone. Stoichiometric HAP with chemical formula Ca10(PO4)6(OH)2 has 
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Ca/P ratio of 1.67. However, in case of natural bone it is known that Ca/P ratio can be non-
stoichiometric due to substitution of calcium, phosphate or hydroxyl ions by ions such as 
carbonate, zinc and silicon. The non-stoichiometric ratios have also been associated with bone 
maturity, bone site and bone disease [13, 14]. The Ca/P ratios obtained from SEM-EDS 
experiments vary from less than 1 to 1.8. Most of these ratios are non-stoichiometric (< 1.67 for 
stoichiometric hydroxyapatite). Studies have related Ca/P ratios of mineral containing matrix 
vesicles to polyphosphates present in matrix vesicles that increase the local concentration of 
phosphates in the vesicles that can be responsible for Ca/P ratios lower than 1.67 [2, 15]. Ca/P 
ratios lower than one have also been associated with new bone formation in these studies 
indicating the effect of polyphosphates on Ca/P ratios.  
 
 
Figure 7.4. SEM images (a-j) obtained during SEM-EDS experiment indicating different points 
used for obtaining SEM-EDS data for matrix vesicles formed on MSC seeded PCL/in situ 
HAPclay (10 wt %) films during two-stage cell seeding experiment. Blue and yellow points 
represent the spots from which localized elemental data (calcium and phosphorus percentage) 
was obtained during SEM-EDS experiments. Images on the right hand side [b), d), f), h), j)] are 
shown for better visualization of the features seen in images a), c), e), g), i) 
286 
 
 
 
 
Figure 7.4. SEM images (a-j) obtained during SEM-EDS experiment indicating different points 
used for obtaining SEM-EDS data for matrix vesicles formed on MSC seeded PCL/in situ 
HAPclay (10 wt %) films during two-stage cell seeding experiment. Blue and yellow points 
represent the spots from which localized elemental data (calcium and phosphorus percentage) 
was obtained during SEM-EDS experiments. Images on the right hand side [b), d), f), h), j)] are 
shown for better visualization of the features seen in images a), c), e), g), i) (continued) 
 
7.4. Conclusions 
SEM imaging experiments performed on PCL/in situ HAPclay composite films seeded 
with human MSCs indicated formation of matrix vesicles. These vesicles appeared to be 
emerging from the cells attached to the PCL/in situ HAPclay composite films and also to be 
deposited in the extracellular space. SEM images also indicated presence of vesicles embedded 
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in the cells or under the surface of cells. This further suggested the presence of intracellular 
vesicles. Data obtained from SEM-EDS experiments showed presence of calcium and phosphate 
in the vesicles. Ca/P ratios calculated using EDS data showed values ranging from below 1 to 
those closer to the stoichiometric value of 1.67. These values suggested an ongoing process of  
mineralization and new bone formation. Also, these studies show that PCL/in situ HAPclay 
composites besides being osteinductive are also capable of providing a favorable micro-
environment for cell dependent processes involved in bone mineral formation.  
Table 7.1. Calcium to phosphorus (Ca/P) ratios for matrix vesicles obtained from SEM-EDS 
experiments performed on matrix vesicles formed on MSC seeded PCL/in situ HAPclay (10 wt 
%) composite films 
 
Ca/P ratio Number of Points 
0.7 – 0.8 0 
0.8 – 0.9 2 
0.9 – 1.0 2 
1.0 – 1.1 1 
1.1 – 1.2 4 
1.2 – 1.3 3 
1.3 – 1.4 8 
1.4 – 1.5 4 
1.5 – 1.6 6 
1.6 – 1.7 0 
1.7 – 1.8 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
288 
 
Table 7.2. Calcium to phosphorus (Ca/P) ratios for matrix vesicles obtained from SEM-EDS 
experiments performed on matrix vesicles formed on PCL/in situ HAPclay (10 wt %) films 
during two-stage cell seeding experiment 
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CHAPTER 8. CONCLUSIONS 
Use of modified sodium montmorillonite (Na-MMT) clay for designing polymeric 
scaffolds useful for bone regeneration is a major focus of this work. Bone regeneration strategies 
based on tissue engineering principles that involve use of scaffolds are driven by multiple 
challenges associated with these scaffolds. Scaffolds need to be capable of eliciting favorable 
cell response and also provide enough mechanical support until the regenerating tissue can 
support itself or becomes capable of restoring function at the defect site. Requirements of 
osteoinductivity and osteoconductivity along with adequate mechanical properties enhances the 
complexity of designing scaffolds for bone regeneration. Na-MMT clay was used in this work 
considering its widely reported reinforcing ability in case of polymer-clay nanocomposites 
(PCNs). Two different types of polymer, both natural and synthetic, were used for designing 
polymeric scaffolds containing modified Na-MMT clay and investigated further for bone tissue 
engineering applications.  
A molecular level materials design strategy was used in which Na-MMT clay was 
modified with three different unnatural amino acids. Unnatural amino acids were used 
considering the bicompatibility requirements for tissue engineering, longer backbone chain of 
these amino acids and their previously reported use for pharmaceutical applications. X-ray 
diffraction (XRD) experiments indicated that the unnatural amino acids were able to intercalate 
Na-MMT clay. Fourier Transform Infrared (FTIR) spectroscopy studies on these modified 
nanoclays suggested non-bonded molecular level interactions between the intercalated amino 
acids and Na-MMT clay. Previous molecular dynamics simulation studies of PCNs in our group 
had revealed that such non-bonded interactions between the constituents (modifier, clay and 
polymer) of PCNs have a significant effect on the mechanical properties of PCNs. This further 
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indicated the potential of Na-MMT clay modified with unnatural amino acids to influence the 
mechanical properties and their use for preparing PCNs. Cell culture experiments performed 
using the unnatural amino acid modified nanoclays indicated their biocompatibility with bone 
forming cells (osteoblasts).  
Na-MMT clay modified with 5-aminovaleric acid was used to fabricate natural polymer 
based composite scaffolds. For this purpose, 5-aminovaleric modified nanoclay was incorporated 
in a polyelectrolyte complex formed between natural polymers such as chitosan (Chi) and 
polygalacturonic acid (PgA). The ChiPgA biopolymer based composite scaffolds containing 5-
aminovaleric acid modified nanoclay satisfied the basic requirements of tissue engineering and 
showed bicompatibility with osteoblasts (bone cells). Similarities were also observed in 
proliferation of osteoblasts between ChiPgA scaffolds containing modified Na-MMT clay and 
ChiPgA scaffolds containing hydroxyapatite (HAP). HAP is known for its favorable cell 
response and similarity of modified clay containing scaffolds with HAP containing scaffolds 
with respect to cell proliferation indicated the potential of modified Na-MMT clay to elicit 
favorable cell response for tissue engineering applications.  
Considering the requirements of osteoconductivity and osteoinductivity along with 
mechanical properties for scaffolds, HAP was mineralized in modified Na-MMT clay based on 
the process of biomineralization in bone. The nanoclay-HAP hybrid (in situ HAPclay) thus 
prepared was used to fabricate ChiPgA composites. FTIR studies indicated the role of functional 
groups of the intercalated modifier in nucleation of HAP along with molecular interactions 
between modified Na-MMT clay and mineralized HAP. Formation of osteoblast clusters 
considered to be an important event in bone formation was observed on ChiPgA/in situ HAPclay 
composites that suggested the osteoconductive properties of these composites. 
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Human mesenchymal stem cells (MSCs) were able to form mineralized ECM in 
ChiPgA/in situ HAPclay composite scaffolds and formed mineralized extracellular matrix 
(ECM) on ChiPgA/in situ HAPclay composite films. Formation of mineralized ECM and 
nodules in the absence of osteogenic supplements demonstrated the osteoinductive and 
osteoconductive potential of ChiPgA/in situ HAPclay composite systems. This also implied the 
ability of in situ HAPclay to impart osteoinductivity, osteoconductivity to the resulting polymer 
composites. During these studies, it was also observed that the order of mixing of in situ 
HAPclay with Chi and PgA had an effect on the microstructure of the fabricated scaffolds and 
also the response of human MSCs to the ChiPgA/in situ HAPclay composite films. ChiPgA/in 
situ HAPclay scaffolds also supported the viability and differentiation of MSCs. 
Two-stage cell seeding experiment involving human MSCs was introduced as a strategy 
to enhance amount of bone tissue formation under in vitro conditions and approaching the 
difficulties related to repair of large tissue defects. Complexities related to MSC proliferation and 
differentiation, ability of ECM proteins to assist cell proliferation and differentiation were 
considered while performing two-stage cell seeding experiment involving MSCs. Qualitative 
data obtained from this experiment showed formation of relatively dense ECM and larger size 
nodules on the ChiPgA/in situ HAPclay composites.  
Polycaprolactone (PCL), a synthetic polymer, was used to prepare PCL/in situ HAPclay 
composites (scaffolds and films) and these composites were investigated for their use in stem cell 
based bone regeneration. In situ HAPclay appeared to affect the microstructure of PCL 
composite scaffolds and these scaffolds showed pore size range considered useful for bone 
regeneration. Human MSCs seeded on PCL/in situ HAPclay films were able to form mineralized 
ECM in absence of osteogenic supplements and appeared to form cell layers on these composites 
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during two-stage cell seeding experiment. Formation of such cell layers indicated possible 
similarities with cellular events known to take place during embryonic stages of bone formation. 
ECM formation by MSCs in absence of osteogenic supplements indicated the osteoinductive and 
osteoconductive properties of PCL composites. MSCs were also able to infiltrate the interior of 
the PCL composite scaffolds and also appeared to be remain viable, differentiate in these 
scaffolds. Atomic force microscopy (AFM) imaging of mineralized ECM formed on PCL 
composites showed presence of collagen and mineral. Collagen and mineral are important 
constituents of hierarchical organization in bone and in case of in vitro generated ECM formed 
on PCL/in situ HAPclay composites these components showed similarities in their organization, 
dimensions with their natural bone counterparts. Addition of in situ HAPclay led to significant 
increase (~ 100 to 595 %) in nanomechanical properties of PCL composites and increase in 
degradation of PCL/in situ HAPclay composite scaffolds under accelerated conditions. The 
observed effects of in situ HAPclay on PCL/in situ HAPclay composites extending from 
nanoscale to micron scale suggests the potential of scaffold systems containing in situ HAPclay 
to meet the multiple requirements of bone tissue engineering.  
Scanning electron microscopy (SEM) experiments showed vesicles emerging from the 
cells attached to the PCL/in situ HAPclay composites and being deposited in the extracellular 
space. SEM-EDS showed presence of calcium and phosphorous in these vesicles that suggested 
presence of calcium phosphate in these vesicles. PCL/in situ HAPclay thus also seemed to 
provide favorable environment for cellular processes involved in bone mineral formation.  
In situ HAPclay was incorporated in two different polymer systems (natural and 
synthetic) to prepare polymeric composites for bone tissue engineering applications in this work. 
These polymer composite systems showed osteinductive and osteoinductive behavior that 
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emphasizes the ability of in situ HAPclay to impart osteinductivity, osteoconductivity to polymer 
composite scaffold systems. Along with the potential of in situ HAPclay to influence the 
mechanical properties of composites for bone tissue engineering, this work also puts forth the 
utility of Na-MMT clay as a promising cell-instructive material.  
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CHAPTER 9. FUTURE WORK 
Polymeric composites (scaffolds and films) containing unnatural amino acid modified 
nanoclay and in situ HAPclay were fabricated for bone tissue engineering applications in this 
work. Investigations performed during this work showed that nanoclays can be useful for 
designing scaffolds with biomimetic environment for bone regeneration. Based on the 
understanding gained about biomaterials and their interactions with relevant cells for bone 
regeneration during this work, following suggestions can be made for future research: 
1. As a step towards clinical application of the fabricated polymer composite scaffolds, it 
can be useful to investigate the response of immune/inflammatory cells to the fabricated 
scaffolds. Understanding gained from such investigation can lead to better design of 
scaffolds for avoiding foreign body reaction and increase the possibilities of their 
transition towards clinical applications.  
2. Human mesenchymal stem cells (MSCs) were used in this work. These cells are known 
for their immunosuppressive effects. Polymer composite scaffolds fabricated in this work 
can be seeded with MSCs and used for understanding the interaction between MSCs and 
the cells of immune system. 
3. Comparative studies can be performed between scaffolds having diversity in their 
structure at the sub-micron to microscale and scaffolds having a uniform structure at a 
similar scale with respect to their interactions with cells.  
4. Tissue or bone defects can be of irregular shapes. Scaffolds in tissue engineering need to 
conform to the shape of these defects. Studies related to load transfer through such 
irregularly shaped scaffolds can lead to better design of scaffolds for in vivo bone 
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formation and improve understanding about the effect of mechanical loads on bone 
regeneration and remodeling. 
 
 
 
 
